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ABSTRACT 
Today’s high failure rate in ophthalmic clinical trials can be largely explained by two 
major shortcomings: (i) the animals routinely studied (rabbits, mice, rats) are not representative 
of the affected population due to apparent anatomical and physiological differences with 
humans; and (ii) studies conducted in healthy eyes do not account for physiological disturbances 
in ocular homeostasis present in diseased eyes. Unlike traditional laboratory animals, diseases in 
dogs better reflect the complex genetic, environmental, and physiological variation present in 
humans; however, the translational potential of canine research is currently limited by scarce 
information on normative data specific to dogs, and the limited means to mimic ocular disease in 
a reliable and non-invasive manner in this species. 
The work conducted in the dissertation provides a deeper understanding of the canine 
ocular surface in health and disease states, investigating laboratory Beagle dogs and canine 
patients of varied breeds and cephalic conformations. Tear fluid was collected from canine eyes 
in successive experiments – primarily via Schirmer tear strips but also capillary glass tubes and 
absorbent sponges – and subsequent bioanalytical tools included fluorophotometry (tear film 
fluorescence), infrared spectroscopy (total protein content), immunoassays (serum albumin, 
cytokines, chemokines) and liquid chromatography-mass spectrometry (corticosteroids). Data 
analysis combined conventional statistical tests with nonlinear mixed-effects mathematical 
modeling to improve the robustness of the predictions.  
The main research outcomes of the dissertation work are the following: (i) Normative 
data were established for canine tear film dynamics, including tear volume (65.3 µL), basal tear 
turnover rate (12.2%/min) and reflex tear turnover rate (50%/min). In both clinical and research 
settings, successive lacrimal tests should be spaced by ≥ 10 min in dogs to provide sufficient 
x 
time for the tear film to replenish. (ii) The volumetric capacity of the canine palpebral fissure 
was 31.3 µL, approximating the volume of a single eyedrop. Kinetic studies confirmed that a 
single drop is sufficient for topical administration in dogs, any excess being lost predominantly 
by blinking and spillage over the periocular skin. (iii) Topical histamine solutions of 1, 10, and 
375 mg/mL induced mild, moderate, and severe conjunctivitis in dogs, respectively. The 
resulting disruption of the blood-tear barrier promoted leakage of plasma compounds (eg., 
albumin) into the tear film, a finding confirmed in dogs with naturally acquired ocular diseases. 
This ‘large animal’ model was robust, non-invasive, and self-resolving, providing a unique 
opportunity to investigate the ocular surface in health and disease. (iv) Acute conjunctivitis 
increased tear quantity and decreases tear stability, although ocular surface homeostasis was 
rapidly restored. (v) Corticosteroid levels in the tear film did not change significantly between 
healthy vs. diseased eyes following oral prednisone administration, although findings may differ 
for drugs with other physicochemical properties. (vi) Albumin in tears lowered the ocular 
bioavailability of topically administered drugs, as shown for tropicamide and (to a lesser extent) 
latanoprost in dogs.  
The thesis concludes with a comprehensive review of key ocular parameters in humans, 
dogs, and traditional laboratory species (rabbits, mice, rats), detailing species differences in 
ocular surface anatomy, physiology, tear film dynamics and tear film composition, and 
highlighting the benefits of integrating dogs into preclinical studies given striking resemblances 
between the canine and human eyes (One Health approach). 
1 
CHAPTER 1.    GENERAL INTRODUCTION  
Companion animals such as the dog constitute an underutilized resource for translational 
research in biomedical sciences.1 Unlike traditional laboratory animals (eg., rabbits, mice, rats), 
naturally-occurring diseases in dogs better reflect the complex genetic, environmental, and 
physiological background present in humans; therefore, integrating canine subjects into 
preclinical studies can accelerate and improve the framework in which research is translated to 
the human clinic, and ultimately generate discoveries that will benefit the health of humans and 
animals. This ‘One Health’ approach is rapidly growing in several medical fields (eg., oncology, 
neurology, stem cells),2-4 yet the literature in comparative ophthalmology is very limited to date. 
Dogs are routinely examined by veterinarians for the diagnosis and management of 
diverse ocular pathologies, exploiting the expertise of general practitioners and veterinary 
specialists across the world. Importantly, numerous canine ocular disorders share striking 
phenotypical resemblances with their human clinical analogues – as exemplified by 
keratoconjunctivitis sicca (‘dry eye’)5 – and could therefore serve as spontaneous animal models 
of ocular diseases. To date, the paucity of canine research for translational purposes is generally 
explained by perceived limitations such as ethical and economic considerations, lack of 
transgenic dogs, and limited molecular tools compared to laboratory species.1,6,7 In the authors’ 
opinion, more scientifically relevant hindrances to the use of canines in ophthalmology research 
include limited data on the physiology of the ocular surface in dogs, and the lack of non-invasive 
experimental model to mimic disease pathophysiology in this species. Unfortunately, direct 
extrapolation from other animals is not possible given notable species differences in ocular 
anatomy and physiology.8,9 
2 
The first two chapters of this dissertation describe fundamental work to better understand 
the physiology of the canine ocular surface, establishing normative data for key parameters such 
as tear volume, tear turnover rate, volumetric capacity of the palpebral fissure, and tear film 
kinetics following topical eyedrop administration. The next two chapters describe the 
development of a robust in vivo model of conjunctivitis in dogs, a translational large animal 
model that provides a unique opportunity for scientists to investigate the ocular surface in health 
and disease states. Practical applications of the model are reported in the last two chapters of the 
thesis, highlighting the clinical significance of blood-tear barrier breakdown on ocular 
pharmacology and drug bioavailability. Finally, the last chapter of this manuscript provides a 
comprehensive review of the ocular surface in humans and selected animals, describing major 
pitfalls that tremendously limit the translational potential of conventional laboratory animals 
(rabbits, mice, rats) in ophthalmic research. This chapter further highlights the benefits of 
leveraging information from canine pharmacokinetic, efficacy and safety preclinical studies 
given striking resemblances between the canine and human eyes. 
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CHAPTER 2.    FLUOROPHOTOMETRIC ASSESSMENT OF TEAR 
VOLUME AND TURNOVER RATE IN HEALTHY DOGS AND CATS  
Lionel Sebbag,1,2 Rachel A. Allbaugh,1 Rita F. Wehrman,1 Lisa K. Uhl,1  
Gil Ben-Shlomo,1 Thomas Chen,3 Jonathan P. Mochel2 
1 Department of Veterinary Clinical Sciences, Iowa State University, College of 
Veterinary Medicine, IA, USA; 2 Department of Biomedical Sciences, SMART Pharmacology, 
Iowa State University, College of Veterinary Medicine, IA, USA; 3 Department of Small Animal 
Clinical Sciences, The University of Tennessee, College of Veterinary Medicine, TN, USA. 
Modified from a manuscript published in the Journal of Ocular Pharmacology and 
Therapeutics 
 
Abstract 
Purpose: The study establishes normative data of tear volume (TV) and tear turnover 
rate (TTR) in healthy dogs and cats, two species commonly used for translational research in 
ophthalmology. Methods: Thirty six dogs and 24 cats were enrolled, encompassing a variety of 
breeds with diverse skull conformations (brachycephalic, mesocephalic, dolichocephalic). Two 
µL of 10% fluorescein were instilled onto the upper bulbar conjunctiva of both eyes, followed by 
tear collection with 2-µL capillary tubes at 0, 2, 4, 6, 10, 15 and 20 minutes. Fluorescein 
concentrations were measured with a computerized scanning ocular fluorophotometer. The TV 
and TTR were estimated based upon nonlinear mixed-effects analysis of fluorescein decay 
curves. Results: In dogs, median (interquartile range) TV, basal TTR and reflex TTR were 65.3 
μL (42.3-87.9), 12.2%/min (3.7-22.1) and 50.0%/min (25.9-172.3), respectively. In cats, median 
(interquartile range) TV, basal TTR and reflex TTR were 32.1 μL (29.5-39.9), 10.9%/min (3.0-
23.7) and 50.0%/min (28.4-89.4), respectively. Body weight (r=0.44) and age (r=0.30) were 
5 
positively correlated (P≤0.019) with TV in dogs. Age was negatively correlated (P≤0.018) with 
TTR in dogs (r=-0.33) and cats (r=-0.24). However, TV and TTR were not associated with skull 
conformation in either species. Conclusions: Dogs have greater TV than cats but similar basal 
and reflex TTR. Tear parameters were impacted by body weight and age, but not skull 
conformation. In both clinical and research settings, successive lacrimal tests should be spaced 
by ≥10min to provide sufficient time for the tear film to replenish, as basal TTR is approximately 
11-12%/min in both species. 
 
Introduction 
Tear fluid dynamics, or the balance between tear secretion, distribution, absorption, 
evaporation and drainage, are critical for the maintenance of ocular surface health.1 Tear volume 
(TV) and tear turnover rate (TTR) are parameters that provide insight into these complex 
dynamics, and as such are valuable for numerous clinical and research applications: (i) TTR 
helps differentiate between aqueous-deficient dry eye and evaporative dry eye in human 
patients;2 (ii) TTR impacts the quantity of various tear components such as electrolytes and 
proteins;3-5 and (iii) determination of TV in horses highlights a large dilution effect of tear fluid 
on exogenously applied drugs, whereby over half of the drug concentration is diluted 
immediately upon topical instillation onto equine eyes.6  
Dogs and cats, in addition to being the most common companion animals worldwide, are 
commonly used as animal models for translational ocular surface research, as exemplified by 
canine keratoconjunctivitis sicca7 and feline epithelial wound healing.7,8 However, information 
about tear fluid dynamics is lacking in these species, despite numerous reports in humans1,2,9 and 
various animals such as rabbits,10 horses6 and cows.11 Evaluation of tear dynamics in dogs and 
cats is likely confounded by their diversity in facial conformations. Indeed, brachycephaly 
6 
(foreshortening of the facial skeleton) can impact tear drainage in dogs12 and in cats,13 and the 
associated lagophthalmos of some brachycephalic animals can impact tear distribution and 
evaporation. 
The present study establishes normative data of TV and TTR in dogs and cats using 
fluorophotometry, a method considered to be the gold standard in assessing tear dynamics.6,9 A 
secondary objective is to determine the impact of cephalic conformation and other variables (age, 
body weight, Schirmer values) on canine and feline tear dynamics. 
 
Materials and Methods 
Animals 
Thirty-six dogs (n = 72 eyes) and 24 cats (n = 48 eyes) were enrolled in the study. Prior 
to study participation, a consent form was signed by owners and each subject was confirmed to 
be ophthalmoscopically healthy by slit-lamp examination, indirect ophthalmoscopy, rebound 
tonometry (TonoVet, Icare Finland Oy, Espoo, Finland)  and normal Schirmer test values (≥ 15 
mm/min in dogs, ≥ 9 mm/min in cats).7,14 A soft measuring tape was used to measure the skull 
width (widest interzygomatic distance), skull length (dorsal tip of the nose to occipital 
protuberance) and muzzle length (dorsal tip of the nose to the stop). These values were used to 
calculate the cephalic index (CI = skull width / skull length) and the craniofacial ratio (CFR = 
muzzle length / skull length) in each animal.15-17 The CI was used to characterize canine subjects 
as brachycephalic (n = 10), mesocephalic (n = 16) or dolichocephalic (n = 10), as described by 
Evans and De Lahunta.15 Since similar numerical features are lacking in cats, the CI was still 
utilized for data analysis but feline subjects were classified as brachycephalic (n = 9; e.g. Persian, 
Himalayan, Exotic Shorthair) or non-brachycephalic (n = 15; e.g. Domestic Shorthair, Bengal) 
based on previous studies.13,17 The study was approved by the Institutional Animal Care and Use 
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Committee of Iowa State University, and was conducted in accordance with the Association for 
Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and vision 
research. 
 
Fluorophotometry 
Fluorophotometry was performed as previously described with minor modifications.6 
Briefly, 2µL of 10% sodium fluorescein (Akorn Inc., Buffalo Grove, IL) was instilled onto the 
dorsal bulbar conjunctiva of each eye using a pipette, with care not to touch the ocular surface. 
Immediately following 3 manual eyelid blinks (0 min), a 2-µL capillary glass tube (Drummond 
Scientific Co., Broomhall, PA) was placed in contact with the inferior tear lake for ≤ 2 seconds 
to collect a tear sample. Eyes were then allowed to blink naturally, and tear samples were 
collected in a similar fashion at 2, 4, 6, 10, 15 and 20 minutes. A maximum of 2 seconds was 
selected for tear collection as a compromise to obtain sufficient tear fluid for analysis while 
minimizing the risk of inadvertently touching the ocular surface and causing reflex tearing. This 
duration, however, was often insufficient to completely fill the 2-µL capillary tubes with tears. 
Thus, following each collection, the length of fluid contained within the capillary tube was 
measured to the nearest mm using a ruler, a value extrapolated to the volume of tears collected 
given that the 2-µL tube is 32 mm in length. The content of each capillary tube was expelled into 
a 2-mL Eppendorf tube pre-filled with 1mL of phosphate-buffered saline (Gibco® PBS, pH 7.2, 
Thermo Fisher Scientific, Rockford, IL). An additional 1mL of PBS was added to each tube, 
followed by vortex mixing for 30 seconds and transfer to a glass cuvette. Fluorescein 
concentration was measured in each sample with a computerized scanning ocular 
fluorophotometer (Fluorotron MasterTM, Coherent Radiation, Palo Alto, CA). All tear sample 
collection and experiments were performed in the morning (from 8 am to 12 pm) to reduce the 
8 
potential impact of circadian rhythm on TTR.18 All subjects were confirmed to be free of corneal 
epithelial defects using a cobalt blue light evaluation at completion of the last tear collection. Of 
note, both eyes of each animal received the same amount of fluorescein at baseline, except for 
six beagle dogs in whom one random eye received 2 µL of 10% fluorescein6 while the other eye 
received 1 µL of 1% fluorescein19 - an experiment conducted to assess the effect of fluorescein 
dosing on tear dynamics.  
 
Data analysis 
Since the fluorophotometer output is nonlinear at high fluorescein concentrations, a 
calibration curve was established for the Fluorotron MasterTM by analyzing a dilution series of 
known fluorescein concentrations in triplicate (1 to 10,000 ng/mL).20,21 Fluorescein 
concentrations in tear samples were corrected based on the resulting calibration equation (y = -
4E-05x2 + 0.9567x + 20.581). 
Fluorescein data of each animal were inputted to Monolix® version 2018R2 (Lixoft, 
Orsay, France). Selected data points were censored in Monolix® when a peak of fluorescence 
could not be identified on the fluorophotometer reading, or if the tear fluorescein concentration 
did not make physiologic sense (e.g. higher fluorescein at 2 min compared to baseline).6 Overall, 
<10% (93/944) of all data points were left-censored.  
Mathematical models of fluorescein disposition time-course were written as non-linear mixed 
effects (NLME) models as previously described and detailed in Appendix A.22-25 Data collection 
from the left and the right eye practically constitutes a repeat sample from the same individual. 
To account for this repeat sampling procedure, biological data collected from the right and left 
eye of each study subject were modeled using a within-dog variability term in the statistical 
model structure. Inclusion of covariate relationships with the model parameters TV and TTR 
9 
(age, body weight, sex, skull type, cephalic index, craniofacial ratio, STT value, and amount of 
fluorescein instilled onto the ocular surface) was assessed for statistical significance using a 
Pearson correlation test (for continuous variables) or Fisher’s exact test (for categorical 
variables) at a P < 0.05 threshold. Data modeling best fitted a biphasic decay curve, as 
previously reported,1,19,26,27 allowing for the calculation of the following parameters (Figure 1): 
(i) Tear volume (TV), calculated from the monophasic decay of fluorescence in the first 
regression line after instillation of fluorescein;1,26 (ii) Reflex TTR (rTTR), calculated from the 
slope of the first regression line;27 (iii) Basal TTR (bTTR), calculated from the slope of the 
second regression line.1,19,26,27 Basal TTR represents tear drainage during non-stimulated 
physiologic conditions, while reflex TTR represents the faster drainage that occurs as a response 
to noxious stimulation or irritative conditions (e.g. foreign body, corneal abrasion, eyedrop 
administration). Data supporting the validity and robustness of the model are shown in Figure 2 
and Appendix A. Lastly, theoretical TV was calculated based on tear film thickness measured in 
a subset of dogs (Appendix B).6,28,29 
 
Results 
All eyes (n = 72 in dogs, n = 48 in cats) were deemed healthy on ophthalmic examination 
and were utilized for data analysis. Using the model, TV and TTR for the general canine and 
feline population were calculated, and results are presented as median and interquartile range 
(25th-75th percentile) in Table 1.  Several correlations were found between individual 
characteristics and tear film parameters (Table 2). In particular, body weight (r = 0.44, P < 
0.001; Figure 3) and age (r = 0.30, P = 0.019) were positively correlated with TV in dogs, and a 
negative correlation was found between age and TTR in dogs (r = - 0.33, P = 0.007) and cats (r = 
-0.24, P = 0.018). Further, a positive correlation was detected between the dose (amount of 
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fluorescein instilled onto the ocular surface) and the calculated TV in dogs (P < 0.001). Of note, 
a post-hoc sample size calculation (SigmaPlot version 14.0, Systat Software, Point Richmond, 
CA) showed that n = 360 dogs and n = 130 cats would be required to detect statistical differences 
in TV and TTR among animals with diverse skull conformations, assuming a power of 80% and 
an alpha of 0.05. 
 
Discussion 
The present study establishes the tear film dynamics in healthy dogs and cats, accounting 
for the diversity of skull conformation occurring in these companion animals. Dogs and cats 
have a few advantages over current preclinical models of ocular surface disease: their ocular 
anatomy better resembles humans than rabbits or laboratory rodents,30 and both species develop 
spontaneous diseases that share strong similarities with human pathologies (e.g. dry eye disease, 
herpes keratitis).7,31 In pharmacology, for instance, extrapolation of findings from rabbits to 
humans is compromised by significant differences in precorneal residence time of drugs between 
these two species.32 In fact, the tear flow in rabbits is much slower than in humans,1,10 a 
difference likely explained by variability in tear film stability, mucin composition, and blink 
rate.20,33,34 Such differences would be minimized when working with companion animals, since it 
takes approximately the same amount of time for the tear fluid to replenish in humans as in dogs 
and cats (5-10 min); indeed, basal TTR in dogs (12.2%/min) and cats (10.9%/min) better mimics 
the human’s ocular surface physiology (10-20%/min).1 On the other hand, the TV is different 
among these species: TV in dogs (65.3 µL) and cats (32.1 µL) is larger than in humans (7.0-12.4 
µL),9,27 a finding that could explain why Schirmer testing is recommended for 1 min in 
companion animals vs. 5 min in people. Compared to humans, dogs and cats have a larger 
corneal surface to lubricate (average corneal diameter in humans is 11.7 mm vs. 16.7 mm and 
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16.5 mm for dogs and cats, respectively),35-37 and they possess an additional secretory tissue 
(gland of the third eyelid) to supplement the main lacrimal gland with aqueous tear production. 
Differences in tear film thickness (3.4 µm in humans29 vs. 15.1 µm in dogs [Appendix B]) could 
also explain the larger canine TV. Such differences in lacrimal volume have important practical 
implications. When compared to humans, dogs and cats have a greater initial dilution of a drug 
administered onto their ocular surface. Conversely, they offer easier collection of sufficient tear 
fluid for analytical purposes; in fact, up to 106 µL and 43 µL can be easily collected within 1 
min using ophthalmic sponges in dogs and cats, respectively.38 
Fluorophotometry is often considered superior to other tear assessment methods, such as 
fluorescein clearance test or lacrimal scintigraphy,1,39 to study tear film dynamics. However, one 
must be cognizant of the initial amount of fluorescein used in fluorophotometry studies as it can 
impact the calculated tear dynamics parameters,18,27 a finding verified in the present study. Here, 
we combined this analytical method with detailed modeling of the data to improve the robustness 
of our findings. Unlike previous studies in which t = 5 min is empirically selected as the 
transition between reflex and basal tearing,1,9,19,26 mathematical modeling appreciates the 
nuances of fluorescein decay between eyes and subjects, while incorporating individual 
characteristics (such as age and body weight) into the final analysis. Another value of the NLME 
approach is the ability to model both eyes simultaneously, thereby taking into account within-
subject (between eyes) variability (WSV) in the tear fluid dynamics. This is particularly relevant 
as this variability was estimated to be fairly high, such that modeling of the data without 
factoring in WSV could lead to significant model misfits. 
Further, we purposely enrolled animals with a variety of cephalic conformations to be 
representative of the diverse breeds examined by veterinarians and researchers. Brachycephalic 
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animals could theoretically have reduced TTR due to functional punctal occlusion caused by 
medial entropion and/or altered anatomy of the nasolacrimal duct associated with the skull 
conformation.13 The lack of statistical impact of cephalic conformation on TTR is likely due to 
strict inclusion criteria (normal subjects without obvious pathological changes) and an overall 
relatively low sample size. Recruiting brachycephalic animals with healthy ocular surface was 
indeed rather challenging, particularly in cats. A few significant correlations were detected 
between individual characteristics and tear dynamics parameters. Notably, lacrimal volume gets 
larger with increasing body weight in dogs (Figure 3), a finding previously documented in 
juvenile,40 but not adult dogs.41 Moreover, TTR decreases with age in both dogs and cats. In 
humans, aging reduces eyelid kinematics (blinking amplitude and peak velocity),42 a physiologic 
change that could result in a less efficient pump mechanism to drain the tear fluid through the 
nasolacrimal duct; the same may be true in companion animals. 
In both clinical and research settings, we recommend waiting 10 min between successive 
lacrimal tests. Indeed, 10 min would be required to fully replenish the canine or feline tear film if 
the initial lacrimal test did not cause ocular irritation (e.g. strip meniscometry), as the basal TTR 
is approximately 11-12%/min in both species. However, 5 minutes may be sufficient if the 
diagnostic test is causing reflex tearing (e.g. Schirmer test) given that the initial TTR is very fast 
(rTTR = 50%/min). From a pharmacological standpoint, the concentration of drug instilled onto 
the ocular surface is immediately diluted by 3-fold in dogs and 2-fold in cats upon mixing with 
the tear film, assuming an average drop size of 35 µL.39 The precorneal residence time of this 
drug is expected to be < 10 min as TTR following eye drop administration is presumably faster 
than under physiologic conditions.32 Further, fluorophotometry data from healthy animals can be 
compared to clinical cases with ocular surface disease, helping to differentiate between 
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symptomatic and asymptomatic patients  (TTR is significantly lower in symptomatic patients)43 
– particularly in cats for whom clinical signs of aqueous tear deficiency are not as overt as in 
dogs44 – and between aqueous-deficient and evaporative dry eye (TTR is significantly lower in 
aqueous deficiency),45 a distinction well established in human patients but poorly characterized 
in veterinary medicine.  
The main limitation of our study is the relatively low sample size, which could explain 
the lack of significant effect of the skull type (brachycephalic, mesocephalic, dolichocephalic) on 
tear film dynamics. Further, in situ assessment of tear fluorescence — as described in most 
investigations on human subjects9,19,21,27 — was not possible in our study, as dogs and cats would 
not tolerate the 20-min protocol without heavy sedation or general anesthesia, which in turn 
would affect tear film dynamics. Thus, tear fluid had to be collected with capillary tubes prior to 
analysis and this could have added another source of variability in the fluorophotometry 
measurements. The volume of fluid collected was calculated in each sample, but the exact 
duration of tear collection was not standardized among subjects. Since collection duration did not 
exceed 2 seconds to avoid reflex tearing, the potential impact of sampling duration on 
fluorophotometry data is deemed negligible in the present study; however, this parameter should 
be recorded in future studies should longer collection duration be necessary (i.e. higher risk of 
inadvertent reflex tearing).  
In conclusion, the normative data established in the present study has several implications 
for both clinicians and researchers. In particular, successive lacrimal tests should be spaced by ≥ 
10 min to provide sufficient time for the tear film to replenish, as basal TTR is approximately 11-
12 %/min in both species. In both species, tear film parameters were impacted by body weight 
and age, but not skull conformation. 
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Tables and Figures 
 
Table 1. Normative data of tear volume and tear turnover rate in dogs and cats, presented as 
median and interquartile range (25th-75th percentile). The relative standard errors (RSE) of 
parameters estimates from the model are listed for each species. For comparison, the human tear 
film parameters are presented in the right column.  
 
 Dog (n = 72 eyes) RSE (%) 
Cat 
(n = 48 eyes) RSE (%) 
Human1,9,27 
(n = 31-74 eyes) 
Tear volume (µL) 65.3 (42.3-87.9) 7.5 
32.1 
(29.5-39.9) 20.3 7.0-12.4 
Basal tear turnover rate 
(%/min) 
12.2 
(3.7-22.1) 5.4 
10.9 
(3.0-23.7) 13.7 10-20 
Reflex tear turnover rate 
(%/min) 
50.0 
(25.9-172.3) 5.4 
50.0 
(28.4-89.4) 13.7 31.5-100 
 
 
Table 2. Correlations between tear parameters and co-variates, using the Pearson test for 
continuous variables (age, body weight, STT, CI, CFR) and the Fisher’s exact test for categorical 
variables (gender, dose, skull type). STT = Schirmer tear test; CI = Cephalic index; CFR = 
Craniofacial ratio. Pearson’s correlation coefficients (r) are noted for continuous variables. N/A 
= Not assessed; — No correlation found. 
 Age Body weight Gender STT Dose 
Skull 
type CI CFR 
Dog 
TV r = 0.30 (P = 0.019) 
r = 0.44 
(P < 0.001) — — P < 0.001 — — — 
TTR r = -0.33 (P = 0.007) — P = 0.005 — — — — — 
Cat 
TV — — — r = 0.72 (P < 0.001) N/A — — — 
TTR r = -0.24 (P = 0.018) — — — N/A — — — 
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Figure 1. Representative fluorescein decay curve in tear fluid of a dog or a cat, allowing for 
calculation of tear volume and tear turnover rate (reflex and basal) using parameters calculated 
with non-linear mixed effects model. C0 represents the fluorescein concentration in tear fluid at t 
= 0 min, extrapolated from the fluorescein decay curve. NaFl = sodium fluorescein; TTR = tear 
turnover rate.
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Figure 2. Comparison of predicted tear fluorescence over time (purple curve) to observed data (blue points) for a random sample of 
dogs (A) and cats (B). Censored data are shown as vertical red bars. 
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Figure 3. A positive association was found between canine body weight and tear volume 
(Pearson correlation test). Estimated tear volumes are described in the table for body weights 
ranging from 1 to 65 kg. 
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Abstract 
The study aimed to determine the impact of drop size on tear film pharmacokinetics, and 
assess important physiological parameters associated with ocular drug delivery in dogs. Two 
separate experiments were conducted in 8 healthy Beagle dogs: (i) Instillation of 1 drop (35 µL) 
or 2 drops (70 µL) of 1% fluorescein solution in each eye, followed by tear collections with 
capillary tubes from 0 to 180 min; (ii) Instillation of 10 to 100 µL of 0.1% fluorescein in each 
eye, followed by external photography with blue excitation filter (to capture periocular spillage 
of fluorescein) and tear collections from 1 to 20 min (to capture tear turnover rate; TTR). 
Fluorescein concentrations were measured in tear samples with a fluorophotometer. The TTR 
was estimated based upon nonlinear mixed-effects analysis of fluorescein decay curves. Tear 
film pharmacokinetics were not superior with instillation of 2 drops vs. 1 drop based on tear film 
concentrations, residual tear fluorescence, and area under the fluorescein-time curves (P ≥ 
0.163). Reflex TTR varied from 20.2-30.5 %/min and did not differ significantly (P = 0.935) 
among volumes instilled (10-100 µL). The volumetric capacity of the canine palpebral fissure 
(31.3 ± 8.9 µL) was positively correlated with the palpebral fissure length (P = 0.023). Excess 
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solution was spilled over the periocular skin in a volume-dependent manner, predominantly in 
the lower eyelid, medial canthus and lateral canthus. In sum, a single drop is sufficient for topical 
administration in dogs. Any excess is lost predominantly by spillage over the periocular skin, as 
well as accelerated nasolacrimal drainage. 
 
Introduction 
Topical administration is the route of choice for treating diseases that affect the anterior 
segment of the eye.1,2 This route is simple, convenient, noninvasive, and allows for the use of 
relatively high drug concentrations at the target tissue while minimizing systemic exposure.1,2 
One of the main challenges associated with topical administration, however, remains the poor 
bioavailability of therapeutic drugs to the inner tissues of the eye given rapid precorneal loss 
from reflex blinking and efficient nasolacrimal drainage.3-5 Optimization of eyedrop delivery can 
enhance therapeutic benefits for the patient,2,6 regardless of the underlying pathology (e.g. dry 
eye, infectious keratitis, glaucoma), yet little consensus exists on fundamental concepts such as 
the number of eyedrops to apply. The label of ophthalmic products often recommends to ‘apply 
one to two drops’ (e.g. Optixcare®, Lotemax®), while diverse publications in veterinary and 
human ophthalmology describe the use of either ‘1 drop’,7,8 ‘1 to 2 drops’,9,10 or ‘2 drops’.11,12 
The volume of solution instilled through topical administration is known to influence the 
precorneal residence time, a key parameter in ocular pharmacology.5,13 A prolonged contact time 
between the solution and the ocular surface is often desired, as it enhances drug bioavailability 
and permits longer intervals between instillations.6 In humans, best practices for ocular delivery 
often recommend a single drop of commercial preparations (~ 35 µL) per dosing session,2,5,6 as 
the maximum volume that the human palpebral fissure can hold without overflowing is estimated 
at 25-30 µL.1,14 Any excess is rapidly lost via nasolacrimal drainage and spillage over the 
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eyelashes and periocular skin;6,15 therefore, a second drop does not provide any therapeutic 
advantage in humans and may in fact be counterproductive by increasing systemic absorption 
and the risk of associated adverse effects. In rabbits, a single drop is also sufficient as the 
lacrimal drainage rate is proportional to the volume of solution instilled (up to 50 µL), hence tear 
film drug concentrations decrease less rapidly with lower instilled volumes.13,16 In fact, the 
smaller the instilled volume, the greater the fraction of applied dose that is absorbed inside the 
rabbit’s eye.13,16 Similar findings may be true in dogs, albeit direct extrapolation between species 
is not possible given important differences in ocular anatomy and physiology. In particular, the 
canine tear volume (65.3 µL)17 is nearly 9-fold larger than humans (7.0 µL)14 and rabbits (7.5 
µL),13 while the canine tear turnover rate is comparable to humans (12.2 %/min vs. 10-20 %/min, 
respectively)17,18 but faster than rabbits (7.1 %/min).13  
The primary objective of this study was to determine the influence of volume instilled via 
topical administration (i.e. 1 vs. 2 drops) on tear film kinetics of fluorescein in dogs. Given the 
aforementioned species differences in tear film dynamics, we originally hypothesized that the 
kinetic profile would be superior following instillation of 2 drops in canine eyes, a hypothesis 
that was proven to be wrong. Hence, to explain why a single eyedrop is deemed sufficient in 
dogs, a secondary objective was to determine the maximal volume that the canine palpebral 
fissure can hold, as well as the drainage rate relative to diverse volumes (10 to 100 µL) instilled 
onto the canine ocular surface. The present work focuses on canine-specific ocular physiology, 
providing valuable information to veterinary practitioners, pet owners, and scientists working 
with dogs as a translational animal model for ocular surface diseases. 
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Materials and Methods 
Animals 
Eight Beagle dogs (4 neutered male, 4 spayed female) were included in the study, all 
confirmed to be healthy based on physical and ophthalmic examinations performed by a board-
certified veterinary ophthalmologist (LS), including Schirmer tear test-1 (Eye Care Product 
Manufacturing, LLC, Tucson, AZ, USA), rebound tonometry (TonoVet, Icare Finland Oy, 
Espoo, Finland), slit-lamp biomicroscopy (SL-17; Kowa Company, Ltd., Tokyo, Japan) and 
indirect ophthalmoscopy (Keeler Vantage; Keeler Instruments, Inc., Broomall, PA, USA). All 
dogs were 3.0 – 3.5 years old and weighed 7.5 – 10 kg. The study was approved by the 
Institutional Animal Care and Use Committee of Iowa State University (IACUC #18-398), and 
was conducted in accordance with the Association for Research in Vision and Ophthalmology 
statement for the use of animals in ophthalmic and vision research. 
 
Tear film fluorescein following instillation of 1 vs. 2 drops 
A 1% fluorescein concentration was obtained by mixing 10% fluorescein solution (Akorn 
Inc., Lake Forest, IL, USA) with 1.4% polyvinyl alcohol lubricating eye drops (Artificial Tears, 
Rugby, Rockville Center, NY, USA). On Day 1, one eye in each dog was randomly selected 
(Excel software) to receive 35 µL (1 drop) of 1% fluorescein solution while the contralateral eye 
received 70 µL (2 drops) of the same solution, using a pipette (Eppendorf Reference® 2, 10-100 
µL) for accuracy. On Day 2 (24 hours later), the order of eyes was reversed and the experiment 
was repeated. Of note, the volume chosen for a single drop (35 µL) approximates the average 
drop size of commercial ophthalmic preparations used in veterinary and human medicine (35-39 
µL),19,20 and is routinely described in previous scientific publications.4,8,21,22 Following topical 
instillation, tear fluid was collected in each eye with a 2-µL capillary glass tube (Drummond 
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Scientific Co., Broomhall, PA, USA) at the following time points: 0 min (i.e. immediately after 
instillation and spontaneous blinking), 1 min, 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 60 
min, 90 min, 120 min, and 180 min. The capillary tube was placed against the inferior tear lake 
for ≤ 2 seconds, a duration sufficient to collect tear fluid by capillary action while minimizing 
the risk of inadvertent ocular irritation and reflex tearing. Given the rapid collection time (< 2 
sec), the lack of blinking during collection (eyelids manually opened) and the relatively large 
tear volume in dogs (~65 µL)(Sebbag et al., 2019), the authors believe that it is unlikely for 
reflex tearing, if any, to affect tear fluorescein concentrations in a significant manner. The length 
of fluid contained within each capillary tube was measured to the nearest millimeter using a 
ruler, a value used to calculate the volume of fluid collected (as 32 mm equate to 2 µL). The 
collected fluid was then expelled into a 2-mL Eppendorf tube that contained 500 µL of 
phosphate buffered saline (Gibco® PBS, pH 7.2, Thermo Fisher Scientific, Rockford, IL, USA), 
vortexed for 30 seconds, and transferred to a cuvette for analysis. Fluorescein concentrations 
were measured (in ng/mL) with a computerized scanning ocular fluorophotometer (Fluorotron 
MasterTM, Coherent Radiation, Palo Alto, CA, USA) as previously described,17 with the 
exception that tear fluid was diluted with 0.5 mL of PBS herein (instead of 2 mL) to improve the 
sensitivity of fluorescein detection (data not shown); the cuvette was slightly raised in the 
device’s cuvette holder to account for the lower total volume. 
 
Volumetric capacity of the palpebral fissure 
A 0.1% fluorescein concentration was obtained by mixing 10% fluorescein solution with 
1.4% polyvinyl alcohol lubricating eye drops. Each eye received the following volumes of 0.1% 
fluorescein solution via pipette administration, the order being selected at random (Excel 
software, Microsoft Corp., Redmond, WA, USA) in each dog: 10 µL, 20 µL, 30 µL, 40 µL, 50 
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µL, 60 µL, 70 µL, 80 µL, 90 µL, and 100 µL. To minimize any carry-over effect from one 
session to another, the eyes and periocular skin were thoroughly rinsed with eye wash (Ocusoft® 
Eye Wash, OcuSOFT Inc., Richmond, TX, USA) at completion of each experiment, and a 1-hour 
break was provided between repeated instillations in each eye to allow ample time for the 
physiological tear film dynamics to be restored.17 At each session, within 10 seconds of topical 
instillation and spontaneous blinking, an external photograph was taken with a Nikon D90 
camera to capture each eye and associated periocular skin. To enhance detection of fluorescence, 
the camera was equipped with a screw-on Tiffen Wratten 15 deep yellow filter (Tiffen 
Manufacturing, Hauppauge, NY, USA) as well as an external flash (Nikon Speedlight SB-700) 
covered with a blue excitation filter (SJ-4 blue color). Of note, this photographic method better 
highlighted 0.1% than 1% fluorescein, hence the choice of 0.1% solution for this experiment. 
 
Tear turnover rate at various instilled volumes 
In the experiment described above, following external photography (taken ~10 seconds 
after 0.1% fluorescein instillation), tear fluid was collected with 2-µL capillary glass tubes at the 
following time points in each eye: 1 min, 2 min, 4 min, 6 min, 10 min, 15 min, and 20 min.17 
Tear film fluorescein concentrations were measured in all samples (see above for details) and 
recorded in ng/mL. 
 
Data analysis 
Fluorophotometry – First, a fluorescein calibration curve was established by analyzing a 
dilution series of known fluorescein concentrations in triplicate (1 to 10,000 ng/mL). Fluorescein 
concentrations in tear samples were corrected based on the resulting calibration equation (y = 
19.3 + 0.9 x – 3E-05 x2).17 Fluorescein data of each animal were inputted to Monolix® version 
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2019R1 (Lixoft, Orsay, France), and tear turnover rate (TTR) was derived from a non-linear 
mixed effects model as previously described.17 Selected data points were censored in Monolix 
when a peak of fluorescence could not be identified on the fluorophotometer reading, or if the 
tear fluorescein concentration did not make physiologic sense (e.g. higher fluorescein at 2 min 
compared with baseline).17 Overall, 11/640 (1.7%) of all data points were left censored. 
External photography – The volumetric capacity of the palpebral fissure was calculated in each 
eye as the average between the lowest instilled volume that led to periocular spillage of 
fluorescein solution, and the highest instilled volume for which all fluorescence remained on the 
ocular surface. For instance, a volumetric capacity of 35 µL was calculated for an eye that had 
spillage first noted at 40 µL of instilled solution, but no spillage noted at 30 µL (Figure 1). 
When present, the location of spillage was recorded (i.e. lower eyelid, upper eyelid, medial 
canthus, lateral canthus), and the area of fluorescence that extended beyond the eyelids margins 
was delineated with the ‘freehand selection’ tool in ImageJ 1.52a software (National Institutes of 
Health, Bethesda, MD, USA). The area of fluorescein spillage was recorded in mm2 (Figure 2) 
using a length bar specific to each eye (i.e. palpebral fissure length measured in mm with 
calipers).  
Statistical analysis – Normality of data was assessed with the Shapiro-Wilk test. A mixed model 
for repeated measures (MMRM) was fitted to the data using the R software version 3.6.0. In the 
model, fluorescein concentration was the response variable, the group (1 or 2 drops), time (0 to 
180 min) and group-by-time interaction were treated as fixed effects, and the animal and animal-
by-group interaction were treated as random effects, using animal as block. After the model was 
fit, the fixed effects were tested, and comparisons between 1 vs. 2 drops were made for the 
following outcomes: (i) fluorescein concentration in tears at each time point, and (ii) percent of 
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fluorescein remaining at each time point, using the baseline data of 1 drop for both groups in 
order to account for the different volumes instilled in both eyes. The R software was also used to 
calculate the area under the concentration-time curve (AUC), a parameter that was compared 
between groups (1 vs. 2 drops) using the paired t-test. Differences among volume instilled in 
fluorescein periocular spillage and tear turnover rate were assessed with a one-way ANOVA, 
while the relationship between the volumetric capacity and the palpebral fissure length was 
assessed with the Pearson’s correlation test. Statistical analyses were performed with SigmaPlot 
14.0 (Systat software, Point Richmond, CA), and P values < 0.05 were considered significant. 
 
Results 
Data were normally distributed (P > 0.05), therefore results are presented as mean ± standard 
deviation (range). 
 
Volumetric capacity of the canine palpebral fissure 
Mean ± SD (range) volumetric capacity of the canine palpebral fissure was 31.3 ± 8.9 µL 
(15-45 µL). A moderate positive correlation (r = 0.57, P = 0.023) was found between the length 
(in mm) and the volumetric capacity (in µL) of the palpebral fissure (Figure 3). Further, mean 
palpebral fissure length and volumetric capacity were slightly larger in male dogs (22.5 mm and 
35 µL) compared to female dogs (22 mm and 27.5 µL), although these differences were not 
statistically significant (P ≥ 0.090).  
 
Periocular spillage of instilled solution 
The lower eyelid represented the most common location (92%, Figure 1B, Figure 2, and 
Figure 4A) covered by fluorescein spillage from the ocular surface, followed by the medial 
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canthus (73%, Figure 4B), the lateral canthus (68%, Figure 4C) and the upper eyelid (32%, 
Figure 4E-F). Instillation of large volumes often resulted in excessive periocular spillage that 
covered multiple skin locations, although the amount and distribution of spillage varied within 
and between dogs; for instance, instillation of 100 µL of fluorescein onto the left eye of 3 
different dogs resulted in either mild (Figure 4D) or pronounced (Figure 4E-F) periocular 
spillage. Overall, the area of periocular spillage increased as the volume of instilled solution 
increased (Figure 5), with statistical differences noted between 90-100 µL vs. 50-60 µL (P = 
0.002), 90-100 µL vs. 30-40 µL (P < 0.001), and 70-80 µL vs. 30-40 µL (P = 0.003). 
 
Tear turnover rate  
Parameters estimation was performed using the stochastic approximation expectation 
maximization algorithm for nonlinear mixed-effects models implemented in the Monolix Suite, 
as previously described for analysis of canine pharmacokinetic data.23,24 Standard goodness-of-fit 
diagnostics were used to assess the validity of the model, including visual predictive checks, 
individual predictions vs. observations, individual weighted residuals plotted against tear 
fluorescein concentrations, and simulations of fluorescein vs. time disposition from 500 Monte 
Carlo simulations (Appendix C). Using the final mathematical model, a visual inspection of 
individual fluorescein decay curves showed a tendency for a ‘steeper’ initial slope (i.e. a faster 
tear drainage) with increasing volumes of instilled fluorescein, as seen in a representative animal 
that received 10-100 µL of topical solution (Figure 6). However, the average rTTR (20.2-30.5 
%/min) did not vary significantly among groups (P = 0.935), nor did the bTTR (1.1-1.4 %/min, 
P = 0.988) observed a few minutes following fluorescein instillation (Table 1). 
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Tear film fluorescein concentrations following 1 vs. 2 drops 
Tear film fluorescein concentrations in eyes receiving 1 vs. 2 drops are depicted in 
Figure 7. Immediately following instillation of fluorescein (t = 0 min), tear film concentrations 
were significantly higher (P = 0.046) in eyes receiving 2 drops (2345 ± 237 µg/mL) compared to 
1 drop (2104 ± 403 µg/mL). However, no statistical differences in fluorescein concentrations 
were noted at t = 1 min (P = 0.163) or any subsequent time points (P ≥ 0.293). In fact, the overall 
exposure of the ocular surface to fluorescein (AUC of fluorescein concentration-time curve) was 
slightly higher in eyes receiving 1 drop (30,513 ± 21530 µg*min/mL) compared to 2 drops 
(28,975 ± 17,410 µg*min/mL). However, this difference was not statistically significant (P = 
0.742), and the overall effect of volume instilled on tear film fluorescein was non-significant (P 
= 0.619) when taking ‘time’ into account in the model. 
The percentage of solution retained on the ocular surface following 1 vs. 2 drops is summarized 
in Figure 8. At t = 1 min, the percent retained was higher in eyes receiving 2 drops (90.6 ± 16.7 
%) compared to 1 drop (81.8 ± 8.2 %), a difference that approached statistical significance (P = 
0.071). However, no significant differences were noted for any other time point (P ≥ 0.220), or 
in the overall effect of volume instilled on the percentage of solution retained (P = 0.731) when 
the variable ‘time’ was taken into account. 
 
Discussion 
The present study supports the use of a single eyedrop in Beagle dogs, whether used 
therapeutically in canine patients with ocular disease, or experimentally in canine models of 
translational research.25,26 A second drop achieved higher tear film concentrations immediately 
after topical administration (t = 0 min), a finding that is partly explained by a lower dilution 
effect for 2 drops (1.9-fold) than 1 drop (2.9-fold) from the tear fluid present on the canine ocular 
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surface (~65 µL).17 However, the benefit of instilling two drops was short-lived (<1 min) and 
unlikely to be clinically important., although the present study focuses on fluorescein and cannot 
be directly extrapolated to ophthalmic drugs such as antibiotics, corticosteroids or anti-glaucoma 
medications. A second drop is wasted from an economic perspective, and can potentially 
exacerbate local and/or systemic adverse effects by overflow on the periocular skin and drainage 
through the nasolacrimal duct, respectively. The latter was not evaluated herein as fluorescein is 
non-biologically active, albeit previous studies have shown that overwhelming the lacrimal 
system can increase the amount of drug that reaches the blood via the naso-buccal mucosa.27 In 
sum, the kinetic profile of fluorescein in tears was not superior with 2 drops vs. 1 drop, a finding 
that is often explained by an accelerated lacrimal drainage with increasing volume in both 
rabbits13 and humans.3 However, this explanation is not valid in dogs as the rate of lacrimal 
drainage did not change significantly in our canine subjects despite a 10-fold increase in instilled 
volume (10 to 100 µL); rather, the present study shows that excessive periocular spillage is the 
main culprit limiting the benefit of using 2 topical drops in canine ophthalmology. The amount 
of solution that overflowed on the periocular skin was greater with larger volumes of instilled 
solution, and primarily affected the lower eyelid, medial canthus and lateral canthus. Such 
spillage can participate to local adverse effects, such as Malassezia sp. overgrowth in dogs 
receiving topical medications,28 or skin hyperpigmentation and lengthening of eyelashes in 
humans receiving topical prostaglandin analogues.29  
The volumetric capacity of the canine palpebral fissure is 31.3 µL. This value is 
somewhat similar to the volumetric capacity in humans (25-30 µL),1,14 and approximates the 
average volume of a single eyedrop of commercial preparations (~35 µL).19,20 As such, a single 
eyedrop is deemed sufficient in dogs and humans because their ocular surface is unable to 
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accommodate volumes larger than ~ 30 µL, yet therapy with a single drop is relatively inefficient 
in both species given the short precorneal residence time and low ocular bioavailability.30 
Several strategies can be implemented to enhance the benefits of eyedrop administration, 
including: (i) Eyelid closure and/or nasolacrimal punctal occlusion for several minutes following 
topical instillation;6,31,32 (ii) Higher drug concentration – Walters et al. showed that topical 1.5% 
levofloxacin in humans achieved tear concentrations that were 3-10 times higher than those seen 
with 0.3% ofloxacin at multiple time points over 24 hours;11 (iii) Higher solution viscosity and/or 
use of mucoadhesive polymers;15,33 (iv) Administration of a second drop ≥ 1 min apart from the 
first drop – Herring et al. showed that administration of 2 drops (1-min apart) of 0.5% 
proparacaine in dogs achieved significantly greater and longer anesthetic effect compared to eyes 
that received a single drop;34 and (v) Use of volumes smaller than the average commercial drop 
size.16,35  
Strategies to improve ocular drug delivery should ideally be investigated in each species 
separately, as direct extrapolation between species is hindered by differences in ocular anatomy 
and physiological parameters such as blink and tear turnover rates.13,14,17,36 Rabbits, for instance, 
have a much slower blink rate (3-6 blinks/h)37,38 and a slower tear drainage (7 %/min)13 
compared to humans (17 blinks/min and 10-20 %/min, respectively),18,39 as well as a different 
expression of mucins on the ocular surface that could affect the retention of mucoadhesive 
polymers.40 These differences explain why an instilled eyedrop is partially lost (20-30%) due to 
reflex blinking and periocular spillage in humans, but not in rabbits,15,37 or why a solution’s 
viscosity has a great impact on precorneal retention and drug ocular bioavailability in humans, 
but not in rabbits.15,41 In a study from over 4 decades ago, it was recognized that “considerable 
reservations may be felt about comparing results from rabbits with those from humans because 
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of the differences between the physiology of tear flow and mixing and general anatomy”, yet 
“the rabbit is the principal experimental animal in ophthalmology, so comparisons are needed”.42 
Since then, rabbits continued to be the ‘species of choice’ for ophthalmic studies given their 
availability and easy handling, yet the present study shows that dogs likely represent a more 
relevant model for translational research. Indeed, dogs and humans share many similarities that 
are relevant to ophthalmic drug delivery, although important differences exist (e.g. tear 
volume)17 that should be accounted for in comparative studies. The similarities include the blink 
rate (14.2 vs. 17 blinks/min),39,43 basal TTR (12.2 %/min vs. 10-20 %/min),17,18 reflex TTR 
following eyedrop instillation (20-30 %/min vs. 30 %/min, respectively),44 volumetric capacity 
of the palpebral fissure (31.3 µL vs. 25-30 µL),1,14 and periocular spillage of excess solution. The 
aforementioned similarities justify the use of dogs as a translational model in ophthalmic 
research, especially given the presence of spontaneous canine diseases that closely resemble 
human conditions including keratoconjunctivitis sicca,45,46 herpetic keratitis47 and neurotrophic 
keratopathy.48  
The main limitation of the study is the use of dogs from a single breed (Beagles), all 
being ophthalmoscopically healthy and relatively young (3-3.5 years). The tear film 
pharmacokinetics of 2 drops may be different in a larger canine breed, presumably due to 
differences in volumetric capacity and/or tear drainage, as shown in German Shepherd dogs 
using the fluorescein clearance test.20 Similarly, the ocular surface of older dogs may 
accommodate a larger volume due to laxity in the eyelids, and the instilled solution may be 
retained for longer durations due to reductions in tear volume, reflex tearing, and tear turnover 
rate.49,50 In addition, the present findings do not fully represent the physiology of eyes with 
ocular surface disease, in which chemosis can reduce the volumetric capacity of the palpebral 
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fissure,51 inflammation can affect tear drainage52 and ocular absorption,53 and excessive tearing 
from ocular irritation can further dilute the administered solution.54 In particular, patients with 
inflamed nasolacrimal duct (dacryocystitis) may actually benefit from instillation of a second 
drop, as greater nasolacrimal drainage would theoretically be beneficial in such cases. A second 
limitation of the study is related to the use of sodium fluorescein as a marker for tear film 
kinetics. Fluorescein was shown to overestimate tear turnover in human subjects, as a portion of 
instilled fluorescein can be lost by conjunctival permeation and not nasolacrimal drainage.55 
However, a common alternative described by other investigators (i.e. gamma scintigraphy)56 is 
not applicable to dogs, in whom the general anesthesia required to hold still for the procedure 
would negatively impact the tear film dynamics. 
The present study on drop size and tear film pharmacokinetics can be summarized as 
follows. Instillation of 2 drops provided tear film fluorescein concentrations that were higher 
than 1 drop at baseline, due to lower dilution effect from tears, although the benefits were short-
lived (<1 min) and not clinically important. The kinetic profile of fluorescein in tear film was not 
superior in eyes receiving 2 drops vs. 1 drop, as determined by the residual tear fluorescence at 
various time points, and the overall exposure of the ocular surface (AUC) to the solution 
instilled. Therefore, a single standard size drop is sufficient for topical administration in dogs, a 
finding supported by the volumetric capacity of the canine palpebral fissure (31.3 µL). Any 
excess is lost predominantly by spillage over the periocular skin, as well as accelerated 
nasolacrimal drainage. 
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Tables and Figures 
 
Table 1. Mean ± standard deviation of reflex tear turnover rate (rTTR) and basal tear turnover 
rate (bTTR) in 8 Beagle dogs following topical instillation of 10-100 µL of 0.1% fluorescein 
solution in each eye. P values depict the results of one-way ANOVA testing. 
 
Volume 
(µL) 10 20 30 40 50 60 70 80 90 100 
P-
value  
rTTR  
(%/min) 
20.6  
±  
14.5 
20.2  
±  
11.4 
22.7  
±  
17.1 
24.3  
±  
12.0 
30.3  
± 
23.3 
22.3  
± 
13.0 
24.6  
± 
13.2 
24.6  
± 
18.4 
30.5  
± 
22.1 
22.2  
± 
11.6 
0.935 
bTTR  
(%/min) 
1.4  
±  
0.4 
1.3  
±  
0.4 
1.3  
±  
0.5 
1.1  
±  
0.5 
1.2  
±  
0.6 
1.2  
±  
0.6 
1.1  
±  
0.6 
1.2  
±  
0.5 
1.1  
±  
0.6 
1.2  
±  
0.6 
0.988 
 
 
 
 
Figure 1. Photographs of the right eye and eyelids in a representative Beagle dog. The 
volumetric capacity of the palpebral fissure was calculated as 35 µL in this eye, based on the 
lack or presence of periocular spillage of 0.1% fluorescein with instillation of either 30 µL (A) or 
40 µL (B), respectively.  
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Figure 2. Photograph of the right eye and eyelids following topical instillation of 90 µL of 0.1% 
fluorescein in a representative Beagle dog. The area of periocular spillage was delineated with 
ImageJ software (version 1.52a, National Institute of Health), and recorded in mm2 based on a 
length bar (10 mm) specific to each eye. 
 
 
 
Figure 3. A positive association was found between the length and the volumetric capacity of the 
palpebral fissure (Pearson’s correlation test). 
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Figure 4. Representative ocular images following instillation of 60 µL (A), 80 µL (B), 40 µL 
(C), or 100 µL (D-F) of 0.1% fluorescein solution in different Beagle dogs. Notice the periocular 
spillage that predominantly affects the lower eyelid (A), medial canthus (B), lateral canthus (C), 
or multiple locations including the upper eyelid (D-F). 
 
 
Figure 5. Bar chart depicting the mean area (+SD) of periocular spillage of 0.1% fluorescein 
solution, instilled at various volumes (10-100 µL) in 8 Beagle dogs (n = 16 eyes).  
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Figure 6. Comparison of predicted tear fluorescence over time (purple curve) with observed data 
(blue points) following topical instillation of 0.1% fluorescein solution (10 to 100 µL) in a 
representative Beagle dog. Censored data are shown as vertical red bars.  
 
 
Figure 7. Scatter plot depicting the mean + SD of tear film fluorescence over time in canine eyes 
receiving either 1 drop (35 µL; red circles) or 2 drops (70 µL; blue triangles) of 1% fluorescein 
solution. Differences in tear fluorescence were noted at t = 0 min (P = 0.046) but no other time 
points (P ≥ 0.163). 
45 
 
 
Figure 8. Bar chart depicting the mean + SD of residual tear film fluorescence at each time point 
in canine eyes receiving either 1 drop (35 µL; plain red bars) or 2 drops (70 µL; hatched white 
bars) of 1% fluorescein solution. For standardization, the residual fluorescence in both groups 
was compared to the tear fluorescence obtained at t = 0 min in eyes receiving a single drop of 
fluorescein. No statistical differences were noted between both groups at any time point (P ≥ 
0.220). 
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Abstract 
Conjunctival inflammation disturbs the blood–tear barrier and thus affects the tear film 
stability and composition. We aimed to develop a non-invasive and reliable method to induce 
conjunctivitis in dogs, a large animal model for translational work on ocular surface disease in 
humans. Six beagle dogs underwent a randomized, vehicle-controlled, balanced crossover trial—
on six separate days, one eye received topical artificial tears (vehicle), while the other eye 
received one of six concentrations of histamine solution (0.005–500 mg/ml). At sequential times 
after eyedrop administration, a conjunctivitis score was given to each eye based on the degree of 
palpebral and bulbar conjunctival hyperemia and chemosis, ocular pruritus, and discharge. Total 
protein content (TPC) and serum albumin were quantified in tear fluid at baseline and 20 min. 
Additionally, 13 dogs presenting for various ophthalmic diseases with associated conjunctivitis 
were examined. Experimentally induced conjunctivitis developed rapidly (<1 min) following 
topical histamine administration and lasted for 1–3 h (four lowest doses) to 6–8 h (two highest 
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doses). The severity of conjunctivitis was dose-dependent. Histamine was overall well tolerated, 
although transient blepharitis, aqueous flare, and ocular hypertension occurred in a few dogs 
receiving histamine ≥375 mg/ml. TPC and serum albumin levels increased in tears of eyes 
receiving histamine ≥1.0 mg/ml, being significantly higher than vehicle and baseline in eyes 
receiving histamine ≥375 mg/ml. Lacrimal albumin levels were also increased in 13 dogs with 
naturally acquired conjunctivitis, up 2.7–14.9 fold compared to contralateral healthy eyes. 
Histamine-induced conjunctivitis represents a robust model for translational work on the ocular 
surface given the low cost, non-invasiveness, self- resolving nature, ability to adjust the duration 
and severity of the disease, and shared features with naturally occurring ocular diseases. 
Histamine solutions of 1, 10, and 375 mg/ml induce mild, moderate, and severe conjunctivitis in 
dogs, respectively. Leakage of serum albumin in tear fluid of eyes with conjunctivitis suggests a 
breakdown of the blood–tear barrier. 
 
Introduction 
Conjunctivitis, or inflammation of the vascularized mucous membrane lining the inside 
of  the  eyelids,  anterior sclera, and (when present) the nictitating membrane, is a common 
ocular surface disease in both humans and veterinary patients.1,2 In addition to well- recognized 
etiologies (e.g., infectious, allergic, toxic/irritative, immune-mediated), conjunctivitis frequently   
develops as a bystander to most adnexal and ocular diseases, such as blepharitis, keratitis, 
uveitis, and glaucoma.1,2 Regardless of the cause, conjunctivitis is debilitating to patients due to 
ocular discomfort, redness, and discharge, as well as the potential development of conjunctival 
scarring, fornix foreshortening, or symblepharon in severe or untreated cases. Further, 
conjunctivitis compromises the tear film homeostasis and thereby contributes indirectly to ocular 
surface damage. Changes in tear composition result from a loss of secretory function and 
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numbers of mucin secreting goblet cells,3 but can also be linked to the disruption of the blood–
tear barrier — a critical yet poorly understood mechanism.4 Indeed, conjunctivitis increases 
vascular permeability and results in leakage of plasma compounds into the tear film, as 
exemplified by human patients with conjunctivitis and dry eye who were noted to have 
significantly greater serum albumin in tears compared to healthycontrols,5-8 and dogs with 
spontaneous keratoconjunctivitis sicca for whom the clinical signs of conjunctivitis were 
positively correlated with tear levels of serum proteins.9  
Despite the prevalence of conjunctivitis, there is limited knowledge about the disease 
impact on the ocular surface in clinical patients. Are tear film composition and quality affected 
by conjunctivitis-induced breakdown of the blood–tear barrier? Is there an impact on the 
pharmacokinetic profile of drugs on the ocular surface? Do medications administered 
systemically reach the tear film compartment at higher concentrations? Such knowledge can be 
gained from experimentally induced models of conjunctivitis in animals, such as intraperitoneal 
injection   of ovalbumin in guinea pigs10 and topical administration of dust mite allergens in 
dogs.11 However, a delayed response occurs with ovalbumin (6 h from antigen exposure to 
conjunctival pathology), and dust mite allergens only cause conjunctivitis in individuals already 
sensitized to this antigen. In contrast, the use of topical histamine is promising as it causes 
conjunctivitis in a nonspecific and rapid manner12 and the compound is a potent inflammatory 
mediator that is associated with various disorders such as allergy, inflammation, autoimmune 
conditions, and possibly cancer.13 Takahashi and colleagues used topical histamine in guinea 
pigs and quantified the extravasation of Evans Blue to demonstrate vascular permeability in the 
conjunctiva.12 The authors focused on a single dose of histamine and did not assess the safety of 
the drug, disease severity, or disease duration. In the present study, the model of histamine-
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induced conjunctivitis was fine-tuned and perfected: we investigated a diverse range of histamine 
concentrations, performed serial ophthalmic and physical examinations to assess safety, and 
described in detail the clinical and biochemical changes observed at each dose. The dog is a 
preclinical species of choice for modeling human ocular diseases as the canine ocular anatomy is 
more similar to humans than routine laboratory species;14 dogs share similar environmental 
stressors with people, and spontaneously occurring ocular surface diseases are common in this 
species. We are confident that this translatable in vivo model of conjunctivitis will guide future 
studies to gain a deeper understanding of the disease, elucidating the impact of conjunctivitis on 
drug pharmacokinetics, tear film dynamics, metabolomics, and proteomics, among others. 
 
Materials and Methods 
Experimentally Induced Conjunctivitis in Dogs 
Animals 
Six beagle dogs (1.5–2.0 years, 7.7–10.1 kg) were used in the study. The gender and 
neuter status was the same for all subjects (female spayed), as sex hormones are known to be key 
regulators of vascular tone in various organs, including the eye.15 All dogs were confirmed to be 
healthy based on complete physical and ophthalmic examinations, including slit-lamp 
biomicroscopy (SL-17; Kowa Company, Ltd., Tokyo, Japan), indirect funduscopy (Keeler 
Vantage; Keeler Instruments, Inc., Broomall, PA, USA), rebound tonometry (TonoVet; Icare 
Finland Oy, Espoo, Finland), Schirmer tear test-1 (STT-1; Eye Care Product Manufacturing 
LLC, Tucson, AZ, USA), and fluorescein staining (Flu-Glo, Akorn, Inc., Buffalo Grove, IL, 
USA). The dogs were group-housed in kennels with ambient temperature maintained at 18–24°C 
and lights automatically turned on/off at 06:00/18:00. The study was approved by the 
Institutional Animal Care and Use Committee of Iowa State University (log # 2-18-8704-K) and 
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adhered to the Association for Research in Vision and Ophthalmology (ARVO) statement for the 
Use of Animals in Ophthalmic and Vision Research. 
 
Topical Histamine and Vehicle Solutions 
Histamine ophthalmic solutions were formulated by mixing histamine powder (Histamine 
dihydrochloride, FCC grade, Arcos® organics, Geel, Belgium) in 1.4% polyvinyl alcohol 
lubricating eye drops (Artificial tears solution, Rugby, Rockville Center, NY, USA) using a 
sterile manner under a laminar flow hood. The pH of each solution was tested with a pH meter 
(B-212 Twin compact pH, Horiba, Kyoto, Japan) and adjusted to 6.5 by adding 1% sodium 
hydroxide (prepared from granules mixed with sterile water), one drop at a time until the target 
pH was reached. The following 12 concentrations of histamine solution were compounded into 
15-ml sterile eyedropper bottles (Steri- dropper®, Medi-Dose®, Ivyland, PA, USA) by the 
pharmacist at Iowa State University’s Lloyd Veterinary Medical Center: 0.001, 0.005, 0.01, 
0.0375, 0.1, 0.5, 1.0, 10, 100, 375, 500, and 1,000 mg/ml. The vehicle solution consisted of 
artificial tears solution adjusted to pH of 6.5 with a minute amount of 1% sodium hydroxide (< 5 
drops in 15-ml bottle). Histamine and vehicle solutions were used within 24 h of preparation and 
kept in the dark at room temperature (18–24°C) before use and in between experiments. 
 
Experimental Design 
Pilot Study to Assess Tolerability and Appropriate Histamine Concentrations 
A pilot study was conducted to assess the tolerability of histamine solutions in dogs (local 
and systemic) and the most appropriate concentrations to select for the crossover trial. Each of 
the 12 eyes (n = 6 dogs) was randomly allocated to one of the 12 histamine concentrations 
(Excel, Microsoft, Redmond, WA, USA). A single drop of histamine solution was instilled onto 
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the ocular surface, followed by slit-lamp biomicroscopy and conjunctivitis scoring at 1, 3, 5, 7, 
10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 300, 360, and 420 min. Additionally, the 
following ocular and physical parameters were recorded at 1, 10, 20, 30, 60, 120, and 240 min 
post-histamine administration: intraocular pressure, aqueous flare grading, body temperature, 
heart rate, respiratory rate, respiratory efforts, capillary refill time, and indirect blood pressure 
(Doppler model 811-B, Parks Medical Electronics, Las Vegas, NV, USA). 
Balanced Crossover Vehicle-Controlled Trial 
Six histamine solutions were selected for the crossover trial based on good tolerability 
and diversity of conjunctivitis scoring (pilot study, data not shown). The six histamine solutions 
are listed as follows: H1 = 0.005 mg/ml, H2 = 0.1 mg/ml, H3 = 1.0 mg/ml, H4 = 10 mg/ml, H5 = 
375 mg/ml, and H6 = 500 mg/ml. For each dog, one eye received histamine solution (random 
selection by coin-toss) while the other eye received vehicle solution, and this order was kept 
consistent throughout the study. Each dog received all six histamine solutions over six 
consecutive days, using one solution per day (once in the morning) in a balanced crossover trial 
(Appendix D, Figure 1). In each dog, ocular and physical parameters were recorded at selected 
times (similar to pilot study), while tear collection and conjunctivitis scoring were performed as 
outlined below: 
• Tear collection: At baseline and at 20 min post-eyedrop administration, tear fluid was 
collected from both eyes and total protein content (TPC) was analyzed as previously described.16 
Briefly, a standardized Schirmer strip was inserted into the ventrolateral conjunctival fornix until 
the 20-mm mark was reached. Each wetted Schirmer strip was placed into a 0.2-ml tube (pre-
punctured at its bottom with an 18-gauge needle), secured into a 2-ml tube with adhesive tape, 
and centrifuged at 3,884 × g for 2 min (Mini Centrifuge, VWR International, Radnor, PA, USA). 
After estimating the volume of extracted tear fluid with a pipette, each tear sample was diluted 
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1:3 with phosphate- buffered saline (PBS 1X, Gibco™, Thermo Fisher Scientific, Inc., Waltham, 
WA, USA). TPC was calculated with Direct Detect™ infrared spectrometer and expressed in 
mg/ml after adjusting for the threefold dilution of each sample. Subsequently, the residual tear 
fluid was diluted fourfold with diluent provided with the albumin ELISA kit (Serum albumin 
ELISA kit, Life Span Biosciences, Inc., Seattle, WA, USA). Serum albumin and various 
cytokines/chemokines/growth factors (Canine Procarta Plex™ 11-plex immunoassay, Cat No 
EPX11A-50511-901, Thermo Fischer Scientific, Waltham, MA, USA) were quantified in each 
tear sample following the manufacturer’s protocol. 
• Conjunctivitis score: At baseline and at selected times post- eyedrop administration (similar to 
pilot study), one examiner (LS) who was masked to which eye received histamine or vehicle 
solution performed slit-lamp biomicroscopy of both eyes to determine a conjunctivitis score at 
each time point. The conjunctivitis score was calculated as the sum of the following categories, 
each graded on a three- to four-point scale (Appendix D, Table 1): hyperemia, chemosis and 
follicles of the palpebral and bulbar conjunctiva, conjunctival discharge, and ocular pruritus.17,18  
 
Naturally Acquired Conjunctivitis in Dogs 
Thirteen dogs presenting to Iowa State University’s Lloyd Veterinary Medical Center 
(ISU-LVMC) for clinical ophthalmic disease with associated conjunctivitis were enrolled. A 
verbal informed consent was obtained from all owners, which was sufficient for the hospital’s 
ethics committee given that Schirmer tear test is part of routine clinical care. Dogs were 
examined by a board-certified veterinary ophthalmologist (LS or RA) for diagnosis and 
treatment of various ocular complaints including corneal ulceration, uveitis, and glaucoma. 
Details of the dogs (breed, sex, age) and their clinical diagnosis are presented in Table 1. Tear 
collection and albumin analysis were performed in both eyes of each dog as described above. 
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Data Analysis 
Normality of the data was assessed with the Shapiro-Wilk test. The one-way ANOVA and Tukey 
post hoc test was used to compare the six histamine doses for i) duration of conjunctivitis, 
determined as the time for conjunctivitis score to return  to zero, and ii) severity of conjunctivitis, 
determined by the area under the curve of conjunctivitis score from 0 to 180 min. Within each 
histamine dose, the one-way repeated measures ANOVA and Bonferroni post hoc test was used 
to assess differences in conjunctivitis scores between time points. The Student t-test was used to 
evaluate differences between vehicle and histamine-treated eyes for TPC and albumin levels, 
both at baseline and at 20 min following eyedrop administration. Further, a ratio was calculated 
for TPC and albumin levels for each histamine dose as follows: (Concentration histamine 20 
min/histamine baseline)/(Concentration vehicle 20 min/ vehicle baseline). This ratio describes 
the percentage change in protein levels between baseline and 20 min post-induction of 
conjunctivitis, taking into account the variability inherent to the tear collection method itself by 
adding the vehicle-treated eyes as the denominator.16 The one-way ANOVA and Tukey post hoc 
test was used to assess differences in protein ratios and levels of cytokines/chemokines/growth 
factors in tears of different groups. In dogs with naturally acquired conjunctivitis, differences in 
lacrimal concentrations of albumin between affected and unaffected eyes were analyzed with the 
Mann–Whitney test. Statistical analysis was performed using SigmaPlot version 14.0 (Systat 
Software, Point Richmond, CA), and values P < 0.05 were considered statistically significant. 
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Results 
Experimentally Induced Conjunctivitis in Dogs 
Clinical Features of Conjunctivitis 
All eyes receiving the vehicle solution were scored at zero for all time points. In eyes 
receiving histamine, the ocular surface was examined from different angles to evaluate the 
canine conjunctiva in a comprehensive manner, including a view from the front (Figure 1A), 
side (Figure 1B), top (Figure 1C), and globe retropulsion with lower lid retraction (Figure 1D), 
which facilitated assessment of the palpebral conjunctiva and nictitating membrane. Figure 2 
shows representative photographs and conjunctivitis scoring of a canine eye at 30 min following 
H4 administration (10 mg/ml histamine solution), while Figure 3 demonstrates the development 
and progression of conjunctivitis from 0 to 420 min in a canine eye receiving H5 (375 mg/ml 
histamine solution). Data were normally distributed such that results are presented as mean ± 
standard deviation (range). Conjunctivitis developed rapidly (<1 min) for all doses (Figure 4A). 
Of note, not a single eye developed conjunctival follicles. Details of conjunctivitis scoring for 
each subsection (palpebral chemosis, bulbar hyperemia, etc.) is described in Appendix D (Table 
2). 
The duration of conjunctivitis was statistically different among histamine doses (P < 
0.001), ranging from 61 ± 37 min (25–120 min) for H1, 110 ± 36 min (90–180 min) for H2, 115 ± 
52 min (60–180 min) for H3, 190 ± 45 min (120–240 min) for H4, 390 ± 33 min (360–420 min) 
for H5, and 400 ± 31 min (360–420 min) for H6. All pairwise comparisons were statistically 
significant (P ≤ 0.029) except for H1–H3 (P = 0.201) and H5–H6 (P = 0.998). 
The severity of conjunctivitis was significantly different among histamine doses (P < 
0.001), with an AUC0–180min (in score x min)  ranging  from  59.2  ± 36.8  (21.5–119)  for  H1, 
200.2 ± 53.9 (107.5–254.5) for H2, 277.2 ± 128.3 (144.5–495.5) for H3, 522.3 ± 131.8 (358–735) 
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for H4, 1,168.5 ± 266.4 (892.5–1,585) for H5, and 1,186.5 ± 242.4 (914–1,443.5) for H6. All 
pairwise comparisons were statistically significant (P ≤ 0.037) except for H5–H6 (P = 1.000) and 
H2–H3 (P = 0.794; Figure 4B). 
A post hoc power analysis showed that n = 5 dogs were sufficient to detect a difference in 
total clinical scores of 2.2 (as observed clinically in eyes with mild vs. moderate vs. severe 
conjunctivitis), a standard deviation of 0.9, a power of 80%, and an α value of 0.05. 
 
Tolerance 
Locally, histamine administration was very well tolerated in dogs except for transient 
adverse effects noted with H5 and H6: i) Blepharitis, manifested by mild blepharedema and 
erythema (Figure 5A), was noted in 1/6 dogs receiving H5 and 2/6 dogs receiving H6, 
developing within 10–30 min of histamine administration and self-resolving within 3 h. ii) 
Aqueous flare, subtle in intensity (trace to 1+), was noted in 2/6 dogs receiving H5 and 6/6 dogs 
receiving H6, developing within 25–90 min and self-resolving within 1–3 h. Aqueous flare  was  
commonly  accompanied  by  miosis  (Figure 5B). iii) Ocular hypertension, defined as IOP > 25  
mmHg,19 was noted in 1/6 dogs receiving H5 at 30 min (IOP = 32 mmHg), although it was not 
statistically greater than baseline IOP (P = 0.529) and it self-resolved within 10 min. Ocular 
hypertension was also noted in 3/6 dogs receiving H6  in which IOP was significantly higher at 
30 min (23.8 ± 5.5 mmHg; P = 0.011) and 60 min (23.2 ± 2.6 mmHg; P = 0.029) compared to 
baseline (16.8 ± 2.6 mmHg). Importantly, no fluorescein stain uptake or corneal changes were 
noted for any histamine dose. 
Systemically, all the vital parameters monitored were stable and not a single dog 
receiving H1 to H6 developed systolic hypotension (<90 mmHg). However, the systolic blood 
pressure dropped from 130 to 88 mmHg in a single dog receiving 1,000 mg/ml histamine during 
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the pilot phase, and the dog exhibited transient depression and weakness until blood pressure 
returned to baseline 10 min later. 
 
Total Protein Content and Serum Albumin Levels in Tears 
At baseline, lacrimal TPC varied from 3.0 to 29.0 mg/ml (8.8 ± 4.0 mg/ml) and no 
differences were noted between vehicle and histamine-treated eyes for any dose (P ≥ 0.365). 
Twenty minutes following eyedrop administration, lacrimal TPC varied from 2.3 to 36.3 mg/ml 
(9.9 ± 5.6 mg/ml) and was statistically greater in histamine vs. vehicle-treated eyes for H5 (P = 
0.009) and H6  (P = 0.021) but no other doses (P ≥ 0.310, Figure 6A). Mean ± SD (range) 
changes in TPC were 171 ± 112% (6–271%) and 170 ± 181% (13–499%) for H5 and H6, 
respectively, values that were significantly greater than H1 and H2 (P ≤ 0.036, Figure 6B). 
At baseline, albumin levels in tears varied from 0.015 to 1.431 mg/ml (0.413 ± 0.455 
mg/ml) and no differences were noted between vehicle and histamine eyes for any dose (P ≥ 
0.394). Twenty minutes following eyedrop administration, albumin levels varied from 0.019 to 
9.595 mg/ml (1.158 ± 2.098 mg/ml) and were statistically greater in histamine vs. vehicle-treated 
eyes for H5 (P = 0.021) and H6 (P = 0.029) but no other doses (P ≥ 0.106; Figure 6C). Mean ± 
SD (range) changes in albumin levels were 2,348 ± 1,454% (314–4,348%) and 4,031 ± 4,679% 
(583–12,689%) for H5 and H6, respectively, values that were significantly greater than H1 and H2 
(P ≤ 0.016; Figure 6D). 
 
Canine Chemokines/Cytokines/Growth Factors in Tears 
The levels of interferon-gamma (IFNγ), interleukin-2 (IL-2), and beta nerve growth 
factor (NGF-β) were below limits of quantification in all tear samples. Tear concentrations of 
other chemokines/cytokines/growth factors, described as mean ± standard deviation (range), 
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were as follows (Figure 7): 4.5 ± 19.4 pg/ml (0–147.6  pg/ml) for interleukin-6 (IL-6), 2,647.8 ± 
5,680.4 pg/ml (0–25,640.2 pg/ml) for interleukin-8 (IL-8), 17.8 ± 16.3 pg/ml (0–86.8 pg/ml) for 
interleuekin-10 (IL-10), 30.6 ± 104.0 pg/ml (0–807.3 pg/ml) for interleukin-12 (IL-12), 532.5 ± 
510.6 pg/ml (0–2,650.8 pg/ml) for vascular endothelial growth factor A (VEGF A), 0.80 ± 2.9 
pg/ml (0–20.9 pg/ml) for tumor necrosis factor alpha (TNFα), 1.3 ± 4.3 pg/ml  (0–24.8 pg/ml) 
for  stem  cell factor  (SCF), and 5.4 ± 13.1 pg/ml (0–80.2 pg/ml) for chemokine monocyte 
chemoattractant protein-1 (MCP-1). Statistical differences among groups (vehicle histamine 
solutions) were noted for IL-8 (Figure 7B), IL-10 (Figure 7C), IL-12 (Figure 7D), and VEGF A 
(Figure 7E). 
 
Naturally Acquired Conjunctivitis in Dogs 
Ocular disease was unilateral in all dogs, and spontaneous conjunctivitis was noted upon 
examination of all affected eyes (Figures 8–10). Lacrimal concentrations of albumin ranged 
from 1.1 to 17.95 mg/ml in affected eyes, representing a significant change by 2.67–14.86 fold 
(P < 0.001) compared to lacrimal concentrations noted in contralateral unaffected eyes (0.13–
3.06 mg/ml). Re-examination of two dogs following therapy of the underlying ocular disease 
(cases #12–13; Table 1, Figure 10) showed reduction in lacrimal albumin concentrations 
concomitant with a reduction in the conjunctivitis score (Table 1). 
 
Discussion 
The present study establishes a robust in vivo model of conjunctivitis in dogs, a 
translational large animal model that provides a framework for ocular surface studies in 
clinically relevant subjects, investigating the impact on conjunctivitis on tear film dynamics, 
pharmacokinetics, metabolomics, and other relevant fields. Dogs are an ideal large animal 
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species for such translational model: not only does the canine ocular anatomy better resemble 
humans than small laboratory animals do,14 but dogs also share similar environmental stressors 
to humans and conjunctivitis is a common and naturally occurring disease in this species.2 As a 
proof of concept, our study examined 13 dogs with naturally acquired conjunctivitis and 
confirmed the presence of elevated albumin levels in tears of affected eyes. Similar to histamine-
induced conjunctivitis, eyes with naturally occurring disease exhibited a breakdown of the 
blood–tear barrier regardless of the underlying etiology (e.g., corneal ulceration, uveitis, 
glaucoma, and orbital cellulitis). Of note, the “blood–tear barrier” is not as well defined as other 
ocular barriers (e.g., blood–aqueous and blood–retinal barriers) and would benefit from future 
anatomical and physiological studies to confirm the terminology used in the present study and in 
previous work.4-7,20 
Histamine-induced conjunctivitis is not novel. The ocular use of histamine has been 
described in humans, guinea pigs, and rabbits as the compound is inexpensive and triggers local 
inflammation in a non-specific manner.12,21,22 In dogs, we showed that histamine-induced 
conjunctivitis is non-invasive, self-resolving, and dose- dependent, allowing investigators to 
modulate the severity and duration of conjunctival inflammation by adjusting the dose of 
histamine solution administered. In fact, both parameters increased with histamine concentration 
until saturation in dose response observed at 375 mg/ml. Thus, we propose doses of 1, 10, and 
375 mg/ml to induce a mild, moderate, or severe conjunctivitis in dogs, respectively (Figure 11). 
Of note, histamine is not only associated with ocular allergies but also implicated in general 
inflammation, autoimmune conditions, and possibly cancer.13 Ocular allergy was not the scope 
of the present study, as many models and detailed descriptions of the condition already exist.11,23  
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The model presented herein provides a unique opportunity for scientists to investigate the 
ocular surface in health and disease. First, since topical histamine had no impact on the 
contralateral eye, the model is applicable for studies that compare efficacy between drug and 
placebo, allowing for precise measurements of a drug action given the rapid (1 min) and 
sustained (120–420 min) development of conjunctivitis. Second, the changes noted in tear fluid 
levels of TPC and albumin strongly suggest a breakdown of the blood–tear barrier. In particular, 
albumin represents a marker of vascular permeability and plasma leakage given it is not 
produced by the lacrimal gland or corneo-conjunctival tissue.20 Our findings are consistent with 
previous reports of conjunctivitis, whether experimentally induced or naturally occurring from 
dry eye,4 corneal ulcers, allergies, or others.20,24 The mechanism of histamine-induced disruption 
of the blood–tear barrier is unknown. Increased vascular permeability likely plays a role,6,12,25 
combined with a disruption of tight junctions between conjunctival epithelial cells due to 
increased contractility of actin linked to these adhesion complexes.26 The breakdown of the 
blood–tear barrier could be exploited for assessing the impact of conjunctivitis on drug 
pharmacokinetics, tear film metabolomics, and other fields. In the field of pharmacology, for 
instance, the vast majority of studies to date are limited to healthy subjects with intact blood–tear 
barriers,27 28,29 in whom the lacrimal drug concentrations likely under-estimate the ones noted in 
actual clinical patients with ocular surface inflammation.30 Such discrepancies likely result in 
inappropriate dosing, thus affecting the drug efficacy and increasing the risk of toxicity or 
antimicrobial resistance.31  
In addition to protein quantification, the present study investigated a panel of 
cytokines/chemokines/growth  factors in tear samples of dogs. Similar to human subjects with 
ocular surface disease such as dry eye or vernal keratoconjunctivitis,32,33 an increase in VEGF A, 
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pro-inflammatory cytokines (IL-8, IL-12), and anti-inflammatory cytokine (IL-10) was detected 
in tears of dogs with experimentally induced conjunctivitis. Analysis of other biomarkers such as 
acidic mammalian chitinase34,35 would be beneficial in future studies, but the paucity of tear fluid 
collected in each dog limited the number of compounds that could be analyzed. 
The relatively low number of dogs enrolled in the histamine experiment is a clear 
limitation of our work, although a post hoc power analysis showed that n = 5 dogs were 
sufficient to detect significant differences between histamine doses for the main study outcome 
(clinical severity of conjunctivitis). Furthermore, although the subjectivity of our clinical scoring 
may be perceived as a drawback, given that photograph-based methods are mainstream in human 
studies,36,37 the method described herein is purposely adapted to working with dogs. Indeed, i) a 
handheld slit-lamp greatly facilitates examination of animals for whom the skull conformation 
and behavior traits are poorly suited for table-mounted devices,18 and ii) the presence of the 
nictitating membrane and the minimal bulbar conjunctival exposure in dogs require a “dynamic” 
examination of the ocular surface that is not conducive to photographic scales. The ocular 
adverse effects noted with high doses of histamine represent another potential limitation of the 
proposed model. There was minimal to absent local irritation from all doses, likely favored by 
adjusting the test solutions to more physiologic pH values, but histamine concentrations ≥375 
mg/ml resulted in meaningful side effects in selected cases. A transient breakdown of the blood–
ocular barrier likely explains the anterior uveitis,25 while ocular hypertension maybe linked to the 
aforementioned acute uveitis and/or episcleral venous compression from the overlying swollen 
conjunctiva, causing an increased resistance to aqueous outflow.38,39 Future studies are required 
to characterize these adverse effects in detail. Lastly, the study does not explain the mechanistic 
reason of breakdown of the blood–tear barrier, as we mainly focused on documenting the safety 
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and clinical features of the model in dogs. Our group is now working on characterizing the 
biochemical and histological changes resulting from histamine-induced conjunctivitis in dogs. 
In summary, histamine-induced conjunctivitis in dogs represents a robust and reliable model for 
translational research on the ocular surface. The model is particularly appealing given the low 
cost, non-invasiveness, self-resolving nature, ability to adjust the duration and severity of the 
disease, and shared features with naturally occurring diseases in human and veterinary medicine. 
The model could be used to assess new therapeutics and to better understand the impact of 
conjunctivitis on drug pharmacokinetics–pharmacodynamics, tear film dynamics, and tear film 
composition, among many other applications. 
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Tables and Figures 
 
Table 1. Patient information and tear albumin concentrations in the affected and unaffected eyes of dogs presented to the 
Ophthalmology service at Iowa State University’s Lloyd Veterinary Medical Center with various ocular diseases. * Cases 12 and 13 
were examined twice: findings at the initial visit are shown in the 1st row while findings following treatment of the ocular disease are 
depicted in the 2nd row. yo = year old; FS = female spayed; MC = male castrated; FI = female intact. 
 
Case # Patient information Ocular disease Conjunctivitis score (affected eye / unaffected eye) 
Tear albumin concentration in 
affected eye (mg/mL) 
Tear albumin concentration in 
unaffected eye (mg/mL) 
Ratio affected vs.  
unaffected eye 
1 9 yo FS Yorkshire terrier Keratoconjunctivitis sicca 4 / 0 3.50 1.22 2.87 
2 9 yo MC French Bulldog Corneal ulcer (superficial), Eyelid mass 6 / 1 2.44 0.80 3.05 
3 4 yo MC Shih Tzu Corneal ulcer (superficial), Distichia 3 / 1 1.10 0.38 2.89 
4 6 yo MC English Bulldog 
Spontaneous chronic 
corneal epithelial defect 8 / 0 9.98 1.67 5.99 
5 12 yo FS Shih Tzu Corneal ulcer (stromal) 5 / 0 3.51 0.84 4.18 
6 12 yo FS English Springer Spaniel 
Cataract,  
Lens-induced uveitis 5 / 1 3.51 0.94 3.72 
7 3 yo MC Border Collie Uveitis (blastomycosis) 7 / 0 13.96 3.06 4.57 
8 12 yo FS mixed breed Uveitis,  Glaucoma (secondary) 5/ 0 1.80 0.24 7.52 
9 4 yo MC Japanese Chin Glaucoma (primary) 6 / 1 1.82 0.68 2.67 
10 8 yo FS Beagle Orbital cellulitis 5 / 0 1.93 0.13 14.86 
11 7 yo FI Coonhound Glaucoma (primary),  end-stage 6 / 0 17.95 1.72 10.42 
12 * 5 yo MC Pitbull Spontaneous chronic corneal epithelial defect 
7 / 1  
1 / 1  
6.30  
1.74 
1.77 
1.74 
3.55 
1.0 
13 * 4 yo FS Beagle Uveitis (blastomycosis) 6 / 0  2 / 0  
1.52 
0.37 
0.42 
0.34 
3.60 
1.09 
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Figure 1. A comprehensive evaluation of the canine conjunctiva is facilitated by examination of 
the ocular surface at different angles, including afront view (A), side view (B), top view (C), and 
globe retropulsion with lower lid retraction (D). The latter permits visualization of the palpebral 
conjunctiva and nictitating membrane. 
 
 
Figure 2. Photographs of the left eye in a dog, 30 min following topical administration of 10 
mg/ml histamine solution. The overall conjunctivitis score was 6, based on the absence/presence 
and degree of follicles, hyperemia, and chemosis of both palpebral and bulbar conjunctiva, 
conjunctival discharge, and ocular pruritus.
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Figure 3. Development and progression of conjunctivitis in a representative canine eye receiving topical 375 mg/ml histamine 
solution. Conjunctivitis developed rapidly (< 1 min), with progression of conjunctival hyperemia and chemosis for 20–30 min, and 
subsequent slow improvement and self-resolution by 420 min. 
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Figure 4. (A) Graphs depicting the mean + SD of conjunctivitis score over time in dogs receiving H1 (0.005 mg/ml; white circles), H2 
(0.1 mg/ml; black circles), H3 (1.0 mg/ml; white triangles), H4 (10 mg/ml; black triangles), H5 (375 mg/ml; white squares), and H6 
(500 mg/ml; black squares). Within the same dose, a blue asterisk (*) depicts statistical significance of conjunctivitis scoring 
compared to baseline (for readability, only the first and last significant time points are depicted). (B) Box-and-whiskers plots depicting 
the area under the curve of conjunctivitis score from 0 to 180 min in dogs receiving topical histamine of various concentrations. Mean 
and median values are shown by horizontal dotted and solid lines, respectively. First and third quartiles (25th and 75th percentiles) are 
represented by the lower and upper limits of the box, respectively, while the 2.5th and the 97.5th percentiles are shown as the lower and 
upper whiskers, respectively. The conjunctivitis severity of histamine doses with different letters differ significantly (P < 0.05). 
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Figure 5. Blepharitis (A) and miosis (B) in a dog that received high dose of histamine 
ophthalmic solution (500 mg/ml). 
 
 
Figure 6. Bar charts depicting the total protein content (A, B) and serum albumin levels (C, D) 
in tears of six beagle dogs receiving vehicle or histamine eyedrops. An asterisk (*) indicates 
statistical significance (P < 0.05) between vehicle and histamine (A, C) or among histamine 
doses (B, D).
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Figure 7. Bar charts depicting mean + SD of various chemokines, cytokines and growth factors 
quantified in tears of six beagle dogs receiving vehicle (vehicle) or histamine solutions: 
interleukin-6 (IL-6; A), interleukin-8 (IL-8; B), interleukin-10 (IL-10; C), interleukin-12 (IL-12; 
D), vascular endothelial growth factor A (VEGF A; E), tumor necrosis factor alpha (TNFα; F), 
stem cell factor (SCF; 1.3 ± 4.3 pg/ml; G), and chemokine monocyte chemoattractant protein-1 
(MCP-1; H). Differences among groups are depicted by an asterisk (*) if statistically significant 
(P < 0.05). 
71 
 
 
Figure 8. Clinical photographs of canine eyes from patients presented to the Ophthalmology 
Service at Iowa State University’s Lloyd Veterinary Medical Center. Conjunctivitis is present in 
all eyes, a condition noted concurrently to various ocular diseases. Patient case numbers are 
listed in the top left corner of each photograph (see Table 1 for additional patient information). 
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Figure 9. Clinical photographs of a 7-year-old female intact Coonhound dog (A) diagnosed with 
end-stage glaucoma in the right eye (case #11). Tear concentrations of albumin were much 
higher in the affected right eye (B) compared to the contralateral healthy left eye (C). 
 
 
Figure 10. Clinical photographs of a 5-year-old male castrated Pitbull (A, B) diagnosed with a 
spontaneous chronic corneal epithelial defect (case #12) and a 4-year-old female spayed Beagle 
(C, D) diagnosed with uveitis secondary to blastomycosis (case #13). Following treatment of 
each ocular disease (B, D), the severity of conjunctivitis was reduced and the concentration of 
albumin in tears was lower compared to the initial visit (A, C). 
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Figure 11. Representative clinical pictures of mild conjunctivitis (A; score = 3), moderate 
conjunctivitis (B; score = 6), and severe conjunctivitis (C; score = 9) following topical 
administration of histamine in dogs. 
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Abstract 
Objective:  To investigate the effects of acute conjunctivitis on tear film characteristics 
and corneal sensitivity in dogs.  Animals studied: Eight female spayed Beagle dogs (1.5-2 years 
old, 7.5-10 kg). Procedures: On two consecutive days, one randomly selected eye in each dog 
received 1 or 375 mg/mL histamine solution to induce mild or severe conjunctivitis, while the 
contralateral eye served as control. Diagnostic tests were performed in the following order: 
fluorescein instillation and repeated tear collection over 20 minutes (to determine tear volume 
[TV] and turnover rate [TTR] by fluorophotometry), Schirmer tear test-1 (STT-1), tear ferning, 
corneal esthesiometry and tear film breakup time (TFBUT). Results:  Results are presented as 
median values for severe conjunctivitis, mild conjunctivitis, and control eyes. Eyes with severe 
conjunctivitis had significantly higher STT-1 (24, 19.5, 17.5 mm/min) and significantly lower 
TFBUT (10.5, 13.5, 15.5 sec), but no changes were noted in corneal tactile sensation (2, 2.5, 2.5 
cm) or tear ferning (grades 2, 2, 2.5). Severe conjunctivitis significantly increased TV by nearly 
10-fold (631, 97, 65 µL) initially (reflex tearing), although basal TV returned rapidly (<5 
minutes) in all eyes (46, 58, 48 µL). Finally, there was a non-significant trend for higher reflex 
TTR in the conjunctivitis vs. control eyes (68, 58, 43 %/min). Conclusions:  Acute conjunctivitis 
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increases tear quantity and decreases tear quality in dogs, but has no impact on corneal 
sensitivity. Changes in tear film dynamics could affect ocular pharmacology (e.g. precorneal 
retention time), although homeostasis of lacrimal volume and drainage is rapidly restored. 
 
Introduction 
A thin layer of tears covers the ocular surface and serves vital functions such as 
lubrication, nutrition, removal of debris, and defense against microbes. Thus, ocular surface 
health is compromised when tear film homeostasis is disturbed, as noted with changes in tear 
quantity, tear quality, and tear film dynamic.1,2 Quantitative and qualitative tear film deficiencies 
are well recognized in humans and veterinary species,3,4 but changes in tear film dynamics (i.e. 
production/distribution/drainage) could also play an important role in the pathophysiology of 
ocular surface diseases. For instance, excess lacrimal production dilutes the levels of endogenous 
(e.g. IgA) and exogenous (e.g. medication) compounds in tears,5 while faster drainage reduces 
their contact time with the ocular surface.6 Equally important, diseases of the ocular surface such 
as blepharitis and conjunctivitis often result in, or exacerbate tear film instability.3,7,8  
Conjunctivitis is a common ocular surface disease and is known to lower tear film 
stability in many species, including humans,9 dogs10,11 and cats.12,13 Primarily, the loss of tear 
film homeostasis results from altered mucin secretion onto the ocular surface by the conjunctival 
goblet cells.14 However, the relationship between conjunctivitis and the tear film is more 
complex and also involves neurosensory stimulation from ocular irritation,15,16 changes in tear 
volume, and variations in tear clearance.9,17,18  
In the present study, conjunctivitis was experimentally induced in dogs and a series of 
diagnostic tests were conducted to assess tear quantity, tear quality, tear dynamics, and corneal 
sensitivity. A deeper understanding of the interaction between conjunctivitis and tear film will 
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help clinicians break the vicious cycle whereby ocular surface disease leads to tear film 
instability, which subsequently exacerbates inflammation, and so forth.3 
 
Materials and Methods 
Animals 
Eight Beagle dogs were enrolled in the study. All dogs were female spayed, aged 1.5-2.0 
years, weighed 7.5-10 kg, and confirmed to be healthy based on a complete physical and 
ophthalmic examination, including Schirmer tear test-1 (STT-1; Eye Care Product 
Manufacturing LLC, Tucson, AZ, USA), tonometry (TonoVet, Icare Finland Oy, Espoo, 
Finland), slit-lamp biomicroscopy (SL-17; Kowa Company, Ltd., Tokyo, Japan) and indirect 
ophthalmoscopy (Keeler Vantage; Keeler Instruments, Inc., Broomall, PA, USA). The study was 
approved by the Institutional Animal Care and Use Committee of Iowa State University. 
 
Procedures  
A series of procedures were conducted in both eyes of each dog in a specific order, as 
described in Figure 1. All measurements were completed in the morning (to reduce diurnal 
variability), in the same examination room under controlled temperature (70-72°F) and ambient 
humidity (25-30%). 
• Induction of conjunctivitis: Histamine powder (Histamine dihydrochloride, FCC grade, 
Arcos® organics, Geel, Belgium) was sterily mixed with 1.4% polyvinyl alcohol lubricating 
eye drops (Artificial tears solution, Rugby, Rockville Center, NY, USA) to compound 1 
mg/mL and 375 mg/mL ophthalmic solutions.19 A single drop (35 µL)20 of histamine 
solution was applied onto one randomly selected eye of each dog (Excel software, Microsoft 
Corp., Redmond, WA), while the other eye received artifical tears and served as control. 
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Both mild (1 mg/mL) and severe (375 mg/mL) conjunctivitis were induced in the selected 
eye, one day apart, the order of which was randomized for each dog (Excel software).  
• Fluorophotometry: Tear film fluorophotometry was performed in each eye as previously 
described.21 Briefly, 2 µL of 10% fluorescein (Akorn Inc., Buffalo Grove, IL, USA) was 
instilled onto the dorsal bulbar conjunctiva using a pipette, followed by 3 manual blinks (0 
minutes) and tear collection with 2-µL capillary tubes (Drummond Scientific Co., 
Broomhall, PA) at times 0, 2, 4, 6, 10, 15 and 20 minutes. Fluorescein concentrations were 
measured in each sample with a computerized scanning ocular fluorophotometer (Fluorotron 
MasterTM, Coherent Radiation, Palo Alto, CA), and tear fluorescence was recorded in ng/mL. 
• Schirmer tear test-1 (STT-1): A Schirmer strip (Eye Care Product Manufacturing LLC, 
Tucson, AZ, USA) was placed in the ventrolateral conjunctival fornix of each eye, and tear 
quantity was recorded at 1 minute (mm/min) using a stopwatch. Strips were left until the ≥ 
20-mm mark was reached, followed by centrifugation for 2 minutes at 3,884 g in a punctured 
0.2-mL tube (secured to 2-mL tube) to extract tear fluid for the ferning test.22  
• Tear ferning test:  For each sample, 2 µL of tear fluid was deposited on a glass slide inside 
a 2-mm circular area delineated with a marking pen. Following air drying at room 
temperature for 10 minutes,23 each sample was examined with light microscopy (10 X 
magnification) and classified as grade 1, grade 2, grade 3, or grade 4 according to specific 
criteria described by Oria and colleagues.24 
• Corneal sensitivity: A nylon filament (0.12 mm, Cochet-Bonnet esthesiometer, Luneau 
Ophtalmologie, Chartres, France) was extended to 6 cm and advanced until it contacted the 
central cornea, creating a slight deflection in the filament. The filament length was shortened 
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by 0.5-cm increments until a blink response was consistently noted in at least 3 out of 5 
attempts, recorded in cm as the corneal tactile sensation (CTS).25  
• Tear film breakup time (TFBUT): Fluorescein 10% solution was diluted 1:5 with eyewash 
(OCuSOFT® eye wash, OCuSOFT Inc., Richmond, TX), and 5-µL of the resulting 2% 
fluorescein solution was instilled onto the dorsal bulbar conjunctiva of each eye.26 After 3 
manual blinks, the eyelids were kept open and the dorsotemporal corneal surface was 
observed at 16X magnification with a cobalt blue filter (SL-17). The TFBUT was recorded 
with a stopwatch (to the nearest tenth of a second) as the time from eyelid opening to the 
appearance of ≥ 1 dark spot(s) within the fluorescent green tear film. The average of 2 
measurements per eye was used for data analysis. 
 
 Data analysis 
Tear volume (TV) and tear turnover rate (TTR) were estimated based upon nonlinear 
mixed-effect analysis of fluorescein decay curves in tear samples (Monolix® version 2018R2; 
Lixoft, Orsay, France).21,27,28 The biphasic decay of fluorescein allowed for calculation of reflex 
(first phase) and basal (second phase) values for both tear parameters. Normality of data was 
assessed with the Shapiro-Wilk test. For all parameters, differences among control vs. mild 
conjunctivitis vs. severe conjunctivitis eyes were assessed with the Kruskal-Wallis test and post 
hoc Dunn’s. Statistical analysis was performed using SigmaPlot 14.0 (Systat Software Inc., San 
Jose, CA, USA), and P values < 0.05 were considered statistically significant. 
 
Results 
Results are presented below as median (interquartile range) as the data from tear film 
diagnostic tests and fluorophotometry were not normally distributed. 
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No statistical differences (P = 0.582) were noted in baseline values of STT-1 between 
eyes selected for control [19 (4.8) mm/min], mild conjunctivitis [20 (8.8) mm/min] and severe 
conjunctivitis [20 (2) mm/min]. However, when STT-1 was repeated 20 min after eyedrop 
administration (Fig. 1), tear values were higher in eyes with conjunctivitis [mild = 19.5 (5.5) 
mm/min; severe = 24 (3.3) mm/min] compared to control eyes [15.5 (9.8) mm/min], with 
statistical differences noted between control and severe conjunctivitis groups (P = 0.002) (Fig. 
2A). 
Differences in tear production were also noted with fluorophotometry data (Table 1). 
Compared to control, median reflex TV was 1.5-fold and 9.7-fold higher in eyes with mild and 
moderate conjunctivitis, respectively, a difference that was statistically significant for the severe 
conjunctivitis group (P = 0.015). However, no statistical differences were noted among groups 
for basal TV (P = 0.965), basal TTR (P = 0.402) or reflex TTR (P = 0.201). 
While tear quantity increased with conjunctivitis, the tear quality was reduced (Fig. 2B). 
Median (interquartile range) TFBUT was lower in eyes with conjunctivitis [mild = 13.5 (2.6) 
seconds; severe = 10.5 (2.3) seconds] compared to control eyes [15.5 (5.1) seconds], with 
statistical differences noted between control and severe conjunctivitis groups (P = 0.002). Lastly, 
tear ferning (Fig. 2C) and corneal sensitivity (Fig. 2D) were not affected by conjunctivitis (P ≥ 
0.322). 
 
Discussion 
The present study demonstrates that acute conjunctivitis increases tear quantity and 
decreases tear quality in dogs, but has no significant impact on corneal sensitivity or tear ferning. 
These results provide useful information for clinicians who manage canine patients with an acute 
injury to the ocular surface (e.g. corneal ulcer, foreign body or chemical burn with secondary 
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conjunctivitis), and for basic scientists who utilize histamine-induced conjunctivitis as a model to 
investigate ocular pharmacology and therapeutics.19  
It is well established that corneal irritation causes reflex tearing across species,29-32 with 
greater corneal nociceptive stimulation leading to greater tear production.32 In contrast, little is 
known about the impact of conjunctival irritation on lacrimal secretion. Here, we showed that 
tear production was increased in the presence of conjunctivitis in dogs – irrespective of corneal 
stimulation (no changes noted in corneal tactile sensation) – as demonstrated by STT-1 values 
and TV calculation (fluorophotometry). In fact, the quantity of tears increased with the severity 
of conjunctivitis, a finding likely explained by increasing noxious stimulation to the conjunctival 
nerves that contribute to the afferent pathway of lacrimation, activating the efferent 
parasympathetic and sympathetic nerves to the lacrimal gland.33 Similar findings were noted in 
humans with acute catarrhal conjunctivitis9 and in cats with experimentally induced herpetic 
conjunctivitis, in whom STT-1 doubled (from 8 to 16 mm/min) concurrently with conjunctival 
disease scoring.29 Further, the amplitude of STT-1 increase with conjunctivitis (15.5 to 19.5-24 
mm/min) is similar to changes noted in the presence of corneal ulceration; Williams and Burg 
showed that dogs with a unilateral corneal ulcer had significantly greater STT-1 values in the 
affected eye compared to the non-ulcerated fellow eye (20.2 vs. 16.7 mm/min, respectively).30  
Importantly, the present study demonstrates the tremendous capacity of the canine ocular 
surface to restore tear homeostasis in a rapid manner. Indeed, the volume of tears quickly 
stabilized (<5 min) after induction of conjunctivitis, despite ongoing conjunctival inflammation 
(lasting ≥ 1h with topical histamine),19 and no significant differences were noted in basal TV 
among control, mild conjunctivitis or severe conjunctivitis eyes.  
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This finding could be explained by rapid increase in the drainage of tears through the 
nasolacrimal duct, as shown in rabbit eyes that were instilled various volumes of eyedrops.6 
However, tear drainage (assessed with TTR) did not differ significantly in dogs with or without 
conjunctivitis (present study), nor did it change in a recent report of dogs receiving artificial tears 
at a volume of 10 to 100 µL.27 Discrepancies between rabbits and dogs are likely due to notable 
differences in blinking rates (3-6 blinks/h vs. 14.2 blinks/min, respectively),34,35 an important 
physiologic response that promotes spillage of excessive tearing onto the periocular skin.27 
The quality of tears, or tear film stability, was reduced in canine eyes with acute 
conjunctivitis. Shortened TFBUT is an established feature of dogs,11 cats29 and humans9 with 
chronic conjunctivitis, as chronicity of inflammation reduces the density of goblet cells that 
secrete pre-ocular mucins, although this finding is not well documented in eyes with acute 
conjunctivitis. The authors hypothesize that excessive aqueous secretion onto the ocular surface 
(reflex tearing) changes the relative abundance of lipids and mucins in the tear film, resulting in 
faster tear evaporation and shorter TFBUT, although rapid loss of conjunctival goblet cells could 
also be an explanation; future studies assessing tear composition and conjunctival impression 
cytology are therefore needed to support that hypothesis. Regardless of the underlying cause, a 
short TFBUT is important to recognize in practice as it can participate to ocular discomfort 
experienced by the patient, necessitating mucinomimetic supplementation to relieve irritation 
and prevent exacerbation of conjunctival inflammation;3,29 in fact, rapid TFBUT results in the 
same degree of ocular discomfort than patients with aqueous tear deficiency, likely due to 
development of neuropathic pain.16,36  
Evaluation of tear ferning can provide valuable information in patients with ocular 
surface disease.37 In fact, a recent study showed that all dogs with keratoconjunctivitis sicca had 
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abnormal ferning patterns (grades 3-4) while the majority of healthy canine eyes had a normal 
ferning pattern.38 In contrast, our study did not find significant differences in tear ferning 
between control eyes and eyes with acute conjunctivitis. This finding may be physiologically 
true, although it could also be skewed by the low sample size, possible technical issues (e.g. 
inconsistent drying times among samples), relative inexperience of the investigators with tear 
ferning, or lack of standardization of grading. The latter was addressed in a recent equine study 
by using a computerized stereology tool to characterize the tear crystallization in an objective 
manner.23  
The present study is limited to the short-term effects of conjunctivitis on ocular surface 
homeostasis, in a relatively small population of dogs of a single breed. Topical histamine 
provides a robust method to induce conjunctivitis in a rapid and non-invasive manner in dogs,19 
however the duration of conjunctivitis is limited in time as the disease is self-resolving (average 
duration of 115 and 390 min with 1 mg/mL and 375 mg/mL solutions, respectively).19 One could 
consider repeating administration of topical histamine to prolong the duration of conjunctivitis, 
as recently performed in a pharmacokinetic study of prednisone in dogs,39 although the safety 
profile of consistent extended dosing with histamine is currently unknown. Nevertheless, the 
present study shows that conjunctivitis alone is enough to activate the lacrimal functional unit 
and cause reflex tearing, irrespective of noxious stimulation to the cornea, and that the 
homeostasis of the ocular surface is rapidly restored. This is important because tear film 
disturbances noted with acute conjunctivitis likely affect the comfort level of canine patients, and 
might justify the use of hyaluronic acid-based lacrimomimetics to improve tear stability and 
reduce discomfort; further, the kinetics of solutions delivered to the ocular surface might be 
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affected in the short-term (e.g. dilution factor, precorneal retention time), influencing the 
bioavailability of topical drugs. 
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Tables and Figures 
 
Table 1. Median (interquartile range) of basal and reflex tear film dynamics in healthy eyes 
(control) and eyes with acute conjunctivitis. TV = Tear volume; TTR = Tear turnover rate. † 
Kruskal-Wallis test. * Significant difference between control and severe conjunctivitis eyes (post 
hoc Dunn’s test). 
 Control Mild conjunctivitis 
Severe 
conjunctivitis P value † 
Basal TV (µL) 48.5 (121.2) 53.7 (73.1) 46.1 (3.8) 0.965 
Reflex TV (µL) 65.1 (314.5) 97.2 (257.3) 630.8 (891.3)* 0.015 
Basal TTR 
(%/min) 5.8 (10.2) 7.0 (4.9) 3.9 (6.1) 0.402 
Reflex TTR 
(%/min) 43.2 (46.4) 57.7 (32.9) 65.7 (30.8) 0.201 
 
 
 
Figure 1. Flow chart of the ophthalmic procedures performed in 8 healthy Beagle dogs, before 
and after experimental induction of conjunctivitis with topical histamine. STT-1 = Schirmer tear 
test-1; TFBUT = Tear film breakup time. 
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Figure 2. Box-and-whiskers plots depicting test results of Schirmer tear test-1 (A), tear film 
breakup time (B), tear ferning (C) and corneal tactile sensation (D) in 8 healthy Beagle dogs 
receiving artificial tears (control, white), 1 mg/mL ophthalmic histamine (mild conjunctivitis, 
light gray) or 375 mg/mL ophthalmic histamine (severe conjunctivitis, dark gray). Each plot 
represents the mean (dashed line), median (solid line), 2.5th percentile (lower whisker), 25th 
percentile (lower limit of box), 75th percentile (upper limit of box), and 97.5th percentile (upper 
whisker). 
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Abstract 
Purpose: To describe the pharmacokinetics of prednisone and prednisolone in tear fluid 
of dogs receiving oral prednisone at anti-inflammatory to immunosuppressive doses, and to 
assess the impact of induced conjunctivitis on lacrimal drug levels. Methods:  Six healthy Beagle 
dogs were administered 4 courses of prednisone at 0.5, 1.0, 2.0 and 4.0 mg/kg given orally once 
a day for 5 days. At steady state, topical histamine was applied to induce mild (1 mg/mL) or 
severe (375 mg/mL) conjunctivitis in one eye of each dog and tear samples were collected from 
both eyes at selected times. Prednisone and prednisolone were quantified in tears by liquid 
chromatography-mass spectrometry. Results: Lacrimal prednisone and prednisolone 
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concentrations ranged from 2-523 ng/mL and 5-191 ng/mL, respectively. Drug concentrations 
were overall greater in dogs receiving higher doses of prednisone, but were not correlated with 
tear flow rate. Eyes with conjunctivitis often had larger amounts of prednisone and prednisolone 
in tear fluid compared to control eyes (up to +64%), but differences were not statistically 
significant. Significantly greater, but clinically insignificant, levels of prednisolone were found 
in eyes with severe vs. mild conjunctivitis for oral prednisone doses ≥ 1.0 mg/kg. Conclusions: 
Disruption of the blood-tear barrier with conjunctivitis did not significantly affect drug levels in 
tears. Based on drug pharmacokinetics in tears, oral prednisone is likely safe for the management 
of reflex uveitis and ocular surface diseases. However, further prospective trials using systemic 
corticotherapy in diseased animals are warranted to confirm findings from this preclinical study.  
 
Introduction 
Prednisone is a corticosteroid with a wide range of pharmacological indications that is 
commonly used for the treatment of inflammatory and immune-mediated diseases in human and 
veterinary medicine. In ophthalmology, corticosteroids can alleviate ocular inflammation and 
help prevent devastating sequelae that could be painful or vision threatening.1 Of the various 
routes of administration, systemic therapy is generally recommended when the target tissue 
cannot be reached with topical ophthalmic corticosteroids (e.g. eyelids, posterior segment, orbit), 
or as a complement to topical medications in cases of anterior uveitis.2  
Systemically administered medications readily distribute to the vascular tissues of the 
eye, but can also affect the ocular surface if the drug reaches the tear compartment. For instance, 
oral doxycycline can be used as adjunctive therapy for keratomalacia in dogs and horses,3,4 while 
oral famciclovir is highly effective in managing herpetic keratoconjunctivitis in cats.5,6 For oral 
prednisone, detection of steroid levels in the tear film could support the use of systemic 
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corticotherapy for adjunctive treatment of inflammatory diseases such as chronic superficial 
keratitis, immune-mediated keratitis, and keratoconjunctivitis sicca. Conversely, lacrimal levels 
of corticosteroids could inhibit corneal wound healing and potentiate infection.7,8 This 
therapeutic dilemma is exemplified in patients with ulcerative keratitis and concurrent reflex 
uveitis: systemic steroids are superior to nonsteroidal anti-inflammatory medications for 
controlling severe uveitis and preventing devastating sequelae,9 yet ulceration could worsen and 
result in corneal perforation if wound healing is compromised and infection is potentiated. 
The main goal of the study was to describe the PK of prednisone and its active metabolite 
prednisolone in tear fluid of dogs following oral administration at doses ranging from anti-
inflammatory to immunosuppressive use (0.5 to 4 mg/kg/d). We hypothesized that prednisone 
and prednisolone would be quantifiable in canine tear fluid and concentrations would be greater 
with increasing oral dosing. In an effort to make the findings of this study more clinically 
relevant, a secondary objective was to determine the impact of conjunctivitis on drug 
concentrations in tears. Indeed, conjunctivitis, a common bystander of most ocular diseases, 
increases conjunctival vascular permeability and therefore enhances vascular leakage of plasma 
compounds onto the ocular surface.10,11 We hypothesized that tear concentrations would be 
greater in eyes with conjunctivitis (i.e. compromised blood-tear barrier) compared to healthy 
eyes. 
 
Materials and Methods 
Animals 
Six Beagle dogs were included in the study. All were spayed females of 1.5-2 years old 
and weighing 7.5-10 kg. Prior to study inclusion, dogs were confirmed to be healthy based on 
physical and ophthalmic examination, complete blood count, serum chemistry and urinalysis. 
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The study was approved by the Institutional Animal Care and Use Committee of Iowa State 
University, and adhered to the Association for Research in Vision and Ophthalmology (ARVO) 
statement for the Use of Animals in Ophthalmic and Vision Research. 
 
Procedures 
Over a period of 2 months, all dogs received 4 successive dosing regimens of oral 
prednisone (CadistaTM predniSONE tablets, Jubilant Cadista Pharmaceuticals Inc., Salisbury, 
MD, USA), characterized by 5 days of drug administration interrupted by 9 days washout period, 
which included: (i) 0.5 mg/kg once daily for 5 days; (ii) 1.0 mg/kg once daily for 5 days; (iii) 2.0 
mg/kg once daily for 5 days; and (iv) 4.0 mg/kg once daily for 5 days. The following procedures 
were performed on Day 4 of each dosing regimen, a time chosen to ensure steady state drug 
levels were reached:12 
• Induction of conjunctivitis in one eye: Histamine ophthalmic solutions were formulated by 
mixing histamine powder (Histamine dihydrochloride, FCC grade, Arcos® organics, Geel, 
Belgium) with 1.4% polyvinyl alcohol lubricating eye drops (Artificial tears solution, Rugby, 
Rockville Center, NY, USA) in a sterile manner under a laminar flow hood. Twenty minutes 
prior to prednisone administration, a single drop of histamine solution was applied to one 
randomly selected eye in each dog, while the other eye received artificial tears (Control). 
This ocular selection was kept constant throughout the study. Histamine rapidly induced 
conjunctivitis (<1 min) that was either mild (n = 3 dogs, 1.0 mg/mL histamine solution; 
Figure 1A) or severe (n = 3 dogs, 375 mg/mL histamine solution; Figure 1B), as previously 
described.11 Conjunctivitis was maintained throughout the 12 h collection period by repeating 
topical histamine administration every 1-4 h as needed to maintain effect. Topical 0.035% 
ketotifen fumarate (Zaditor®, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
92 
 
USA) was instilled onto each eye at the end of the day to control any residual conjunctival 
swelling. 
• Tear collection: Tear fluid was sampled simultaneously in both eyes before prednisone 
administration (t = 0 min) and at 15, 30, 60, 90, 120, 240, 480, and 720 min following drug 
administration. The bent tip of a Schirmer tear strip (Eye Care Product Manufacturing, LLC, 
Tucson, AZ, USA) was placed in the ventrolateral conjunctival fornix of each eye. While 
recording test duration with a stopwatch, each Schirmer strip was removed and transferred 
into a 2-mL Eppendorf tube when the 20-mm mark of wetness was reached, as to standardize 
the volume of tears collected in each sample. The distal portion of each strip (25-35 mm 
marks, not wetted with tears) was spiked with 5 μL internal standard (prednisone-d7, Toronto 
Research Chemicals, North York, Canada) prepared as 10 ng/µL solution in 1:1 
acetonitrile:water, and samples were stored at -80°C until analysis.  
 
Preparation of tear samples for analysis 
The details of tear fluid extraction are described in Appendix E. Briefly, both 
centrifugation and elution in solvent were used as complementary methods to extract the drug 
from Schirmer strips.13 Wetted strips containing tear fluid and internal standard were first 
centrifuged to retrieve the majority of absorbed tear fluid, followed by cutting and shredding the 
strips into small pieces and eluting them in methyl tert-butyl ether (MTBE). Of note, this 
particular solvent was chosen based on its superior ability to extract prednisone from Schirmer 
strips as compared to methanol, acetonitrile and water (small pilot study, data not shown). 
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Liquid chromatography – mass spectrometry 
Prior to study initiation, blank tears were collected from the same Beagle dogs using 
polyvinyl ophthalmic sponges as previously described.14 Eight standard curve solutions were 
prepared by spiking blank canine tears with stock solutions of prednisone/prednisolone 
(Cerriliant, Round Rock, Texas, USA) to obtain the following concentrations: 1, 2, 5, 10, 20, 50, 
100 and 200 ng/mL. Calibration curve samples were processed in a similar fashion to biological 
tear samples, which involved wetting Schirmer strips with standard solutions until the 20-mm 
mark was reached, spiking prednisone-d7 internal standard onto the distal (dry) portion of the 
strips, centrifugation and elution in MTBE, etc. (see Appendix D for details). Concentrations of 
prednisolone and prednisone in canine tears were determined using high-pressure liquid 
chromatography (Agilent 1100 Pump, Column Compartment, and  Autosampler, Santa Clara, 
CA, USA) with ion trap mass spectrometry detection (LTQ, Thermo Scientific, San Jose, CA, 
USA). The injection volume was set to 20 μL. The mobile phases consisted of A: 0.1% formic 
acid in water and B: 0.1% formic acid in acetonitrile at a flow rate of 0.25 mL/min. The mobile 
phase began at 20% B with a linear gradient to 95% B in 5.0 minutes, which was maintained for 
2 minutes at 0.325 mL/min, followed by re-equilibration to 20% B at 0.325 mL/min for 3.5 min. 
Separation was achieved with an ACE Ultracore C18 column, 100 mm x 2.1 mm , 2.5 µm 
particles (Mac-Mod Analytical, Chadds Cord, PA, USA) maintained at 40°C. The 
chromatographic peaks for the internal standard, prednisone and prednisolone (each eluted at 
4.69± 0.05 min) were integrated using Xcalibur software (Thermo Scientific, San Jose, CA, 
USA). Drug quantitation was based on linear regression analysis of calibration curves (weighted 
1/X) using the analyte to internal standard area ratio. Calibration curves exhibited a correlation 
coefficient (r2) exceeding 0.995 across the concentration range. The limits of quantitation for 
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prednisone and prednisolone were 2 ng/mL and 5 ng/mL, respectively, while the limits of 
detection for prednisolone and prednisolone were 0.5 ng/mL and 1 ng/mL, respectively.   
 
Data analysis 
Noncompartmental analysis of prednisone and prednisolone pharmacokinetics was 
conducted with Phoenix software (WinNonlin, version 8.0, Pharsight Corporation, CA, USA) to 
determine the maximum concentration (Cmax), time to maximum concentration (Tmax), and area 
under the curve from time zero to time of last measurable concentration (AUClast). 
The Shapiro-Wilk test was used to assess data for normality. Non-normally distributed 
data were expressed as median and 95% central range (2.5-97.5th percentiles) and were analyzed 
with nonparametric statistics. Normally distributed data were expressed as mean ± standard 
deviation (95% central range), and were analyzed with parametric statistics. Associations 
between tear flow rate and lacrimal concentrations of prednisone or prednisolone were assessed 
with the Spearman’s correlation test. The Student t-test was used to assess differences in AUClast 
between eyes with mild or severe conjunctivitis. For each oral dose and for each PK parameter 
(AUClast, Cmax, Tmax), differences between control and conjunctivitis eyes (mild + severe) were 
assessed with the Student t test or Mann-Whitney test. For each PK parameter, differences 
among oral doses (0.5, 1.0, 2.0 and 4.0 mg/kg) were assessed with the one-way ANOVA or 
Kruskal Wallis test. Statistical analysis was performed using SigmaPlot 14.0 (Systat Software 
Inc., San Jose, CA, USA), and values P < 0.05 were considered statistically significant. 
 
Results 
Following oral administration of prednisone, both prednisone and prednisolone were 
quantifiable in tear fluid, with concentrations ranging from 2-523 ng/mL and 5-191 ng/mL, 
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respectively. Lacrimal concentrations were not correlated with tear flow rate for either 
prednisone (P ≥ 0.412) or prednisolone (P ≥ 0.388). However, higher doses of oral prednisone 
resulted in higher tear concentrations of both steroids, as depicted by the individual 
concentration-time curves in Figure 2. In fact, the overall drug exposure in tears (depicted by 
AUClast) was statistically different among the 4 doses for both prednisone (P ≤ 0.002; Figure 
3A) and prednisolone (P ≤ 0.001; Figure 3B). Similarly, statistical differences were detected 
among oral doses for prednisone Cmax (P = 0.008) and for prednisolone Cmax (P = 0.003) and 
Tmax (P = 0.039; Table 1). In general, eyes with conjunctivitis showed a trend for larger 
concentrations of prednisone and prednisolone in tear fluid compared to control eyes (Figures 2 
and 3), with differences in average concentrations ranging from +5% to +64%. However, 
differences in AUClast between control and conjunctivitis eyes were not statistically significant 
for either prednisone (P ≥ 0.095; Figure 3A) or prednisolone (P ≥ 0.485; Figure 3B). The 
severity of conjunctivitis did have an impact on lacrimal concentrations, as significantly greater 
levels of prednisolone were found in eyes with severe vs. mild conjunctivitis for oral doses 2-4 
mg/kg/d (P ≤ 0.042; Figure 4), although these changes were not considered to be large enough 
to be clinically relevant.  
 
Discussion 
The present study describes, for the first time, the tear film pharmacokinetics of 
prednisone and prednisolone in veterinary medicine. Tear film concentrations of prednisone and 
prednisolone varied from 2-523 ng/mL and 5-191 ng/mL respectively, with higher doses of oral 
prednisone leading to higher lacrimal levels of both steroids. The question remains whether 
concentrations of the active metabolite (prednisolone) are relevant in clinical patients, that is 
potentially beneficial or detrimental to managing ocular surface diseases. Overall, tear film 
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prednisolone levels were ≥ 10-9 M (i.e. 0.4 ng/mL) in all dogs throughout the 12-hour sampling 
time, a concentration shown to decrease the expression of deleterious cytokines (TNF-α, IL-6) 
and matrix metalloproteinases in a rat model of keratitis.15 Therefore, oral prednisone might have 
therapeutic benefits in managing corneal inflammation, assuming similar exposure-response 
between species. In fact, although the use of corticosteroid in infectious keratitis remains 
controversial,16 some authors believe that a judicious use of corticosteroids (combined with the 
appropriate antimicrobial) could improve the outcome of keratitis as it reduces damage caused 
by the host’s inflammatory response, decreases corneal scarring, and inhibits 
neovascularization.17,18 From a safety viewpoint, the use of corticosteroids is known to 
potentially delay corneal wound healing and exacerbate signs of ocular infection. In vitro, 
inhibition of corneal wound healing in dogs is only reported for prednisolone concentrations that 
are much higher (≥ 620 µg/mL)19 than the ones reported herein. In vivo, topical corticosteroid 
use can be detrimental in patients with ulcerative keratitis2 although tear film concentrations 
following topical 1% prednisolone acetate are unknown to date in any species. Data 
extrapolation from pharmacokinetics of 0.3% ciprofloxacin in dogs20 shows that (i) topical 1% 
prednisolone acetate could reach concentrations as high as 909 µg/mL, which is 1,000 to 10,000-
fold greater than drug levels noted in the present study; and (ii) topical 1% prednisolone acetate 
(applied every 6h) could result in drug exposure over 12h that is 14,000-27,000 fold and 3,300-
5,300 fold greater than oral prednisone given at anti-inflammatory dose (0.5-1 mg/kg/d) or 
immuno-suppressive dose (2-4 mg/kg/d), respectively. Of note, drug exposure over time is more 
relevant than single lacrimal concentrations (e.g. Cmax) given differences in pharmacological 
disposition between topical and oral routes. While the ocular bioavailability of topical 
administration is <10-20% given efficient washout by tears,21 oral administration could be 
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considered as a form of sustained-release at the ocular surface through lacrimal gland diffusion 
and conjunctival leakage. As for the negative impact on the immune system, there is no 
consensus on what concentration is considered harmful. In one study, prednisolone levels as low 
as 0.005 µg/mL were shown to reduce the phagocytosis function of human leucocytes,22 while 
prednisolone concentrations as high as 4.32 µg/mL did not impact leucocyte phagocytosis or 
bactericidal activity in another study.23  
Conjunctivitis is a common disorder in dogs that develops concurrently to most ocular 
diseases, whether affecting the adnexa (e.g. blepharitis), ocular surface (e.g. corneal ulcer) or 
intraocular tissues (e.g. uveitis). With conjunctivitis, plasma constituents tend to ‘leak’ into the 
tear compartment as the permeability of conjunctival vessels is typically increased.10,11 This 
breakdown of the blood-tear barrier explains the large quantities of albumin in tears of diseased 
eyes, regardless of the underlying etiology of conjunctivitis (e.g. dry eye, corneal ulcer, 
allergies).24,25 Thus, to make the present PK findings more clinically relevant, conjunctivitis was 
experimentally induced in selected canine eyes using a recently described model.11 Lacrimal 
levels of prednisone and prednisolone were overall higher in conjunctivitis vs. control eyes, with 
greater disease severity leading to generally greater drug levels in tears, especially for 
prednisolone. However, differences between control vs. conjunctivitis eyes were not statistically 
significant, and were fairly minimal (up to 64% increase) when compared to plasma albumin (up 
to 12,000%).11 Unlike albumin, a very large molecule (66,500 Da) that does not permeate 
through intact conjunctival tissue,24 we suspect that smaller molecules like prednisone (358 Da) 
and prednisolone (360 Da) readily cross the blood-tear barrier under normal conditions, and are 
therefore not significantly impacted by conjunctival inflammation. However, we cannot exclude 
that larger amounts of corticosteroids actually reach the lacrimal fluid in eyes with conjunctivitis; 
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although the concurrent leakage of albumin binding to free prednisolone would probably reduce 
its bioavailability at the ocular surface.26 Further, physicochemical properties other than 
molecular weight may explain differences in lacrimal distribution between prednisone, 
prednisolone, and other drugs reported in the veterinary literature3, 5, 13 – namely protein binding, 
lipophilicity and degree of ionization.27 Here, the competitive nature of plasma protein binding 
between prednisone and prednisolone could justify the slightly higher lacrimal concentrations of 
prednisone in canine tears.28  
The present study has a few limitations. First, the sample size of our experiment was 
relatively small, and only females from a single dog breed were evaluated. Tear film PK could 
theoretically differ in male vs. female dogs,29 or breeds other than Beagle, especially in 
brachycephalic dogs in whom the lacrimal lipid layer is thin and corneal exposure is large.30 Yet, 
previous studies did not find significant differences between mesocephalic and brachycephalic 
dogs in regards to tear film dynamics (tear volume, tear turnover rate)31 or tear film drug 
concentrations.20 Second, it is possible that we did not find statistical differences in tear film 
concentrations between healthy vs. conjunctivitis eyes because of the conjunctivitis model itself. 
Experimental induction of conjunctivitis, although rapid and non-invasive,11 could have falsely 
lowered lacrimal concentrations by causing reflex tearing and accelerated tear turnover. We 
minimized this risk by inducing conjunctivitis ≥ 20 min before drug administration and sample 
collection, but a small degree of ocular irritation could have lingered. Regardless, increased 
tearing should not have affected drug levels in a notable manner, as we did not find a significant 
correlation between tear flow rate and prednisone/prednisolone levels in tears. Last, the present 
study used Schirmer strips to collect tears in dogs, and although this method yielded sufficient 
tear fluid for analysis, the method has several disadvantages that could partly explain the large 
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variability in tear concentrations noted among subjects. Not only do Schirmer strips absorb tear 
fluid but they also retain a certain amount of tear components (adsorption), the degree of which 
can vary depending on the concentration.13 Here, we minimized the impact of adsorption by 
incorporating two important steps in our sample preparation: (i) the internal standard was spiked 
onto the distal end of Schirmer strips before tear extraction, and (ii) standard curves were 
processed in a similar fashion to biological samples. We also maximized the amount of drug 
extracted from Schirmer strips by combining centrifugation with solvent elution.13 Such 
combination may improve the assay sensitivity (i.e. able to detect lower concentrations), but the 
process is very labor intensive and may not be necessary for all drugs. Future studies should 
consider a pilot experiment to assess the extraction efficacy of the combination method vs. 
centrifugation or solvent elution alone.  
In conclusion, our data indicate that oral prednisone might be safe and beneficial as 
adjunctive therapy for reflex uveitis, ulcerative keratitis or other ocular surface disease in dogs. 
However, these preliminary pharmacokinetic findings need to be complemented with prospective 
controlled studies using systemic corticotherapy in diseased animals. Similarly, future 
anatomical and physiological studies are needed to better understand the role of conjunctivitis in 
diffusion of systemically administered drugs into the tear film. 
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Tables and Figures 
 
Table 1. Mean ± standard deviation of the maximal concentration (Cmax) and time to reach Cmax (Tmax) for prednisone and 
prednisolone in control and conjunctivitis eyes. Within the same dose, comparisons between control and conjunctivitis eyes are 
described with P values above the plots and an asterisk (*) if statistically significant (P < 0.05). Within the same group (control or 
conjunctivitis), differences among doses are depicted with symbols to demonstrate statistically greater values compared to dose 1 (#), 
dose 2 (†) and dose 3 (‡). 
  Prednisone Prednisolone 
  Cmax (ng/mL) Tmax (min) Cmax (ng/mL) Tmax (min) 
Dose 1  
(0.5 mg/kg) 
Control 23.2 ± 13.4 77.5 ± 89.7 19.2 ± 19.5 115.0 ± 99.3 
Conjunctivitis 55.1 ± 68.1 87.5 ± 85.1 22.4 ± 26.7 130.0 ± 86.3 
Dose 2  
(1.0 mg/kg) 
Control 47.7 ± 26.4 140.0 ± 187.3 29.2 ± 24.9 215.0 ± 257.0 
Conjunctivitis 48.1 ± 25.5 87.5 ± 85.1 37.1 ± 32.1 145.0 ± 166.9 
Dose 3  
(2.0 mg/kg) 
Control 91.7 ± 74.7 127.5 ± 97.6 75.3 ± 64.3  420.0 ± 211.3 # 
Conjunctivitis 137.2 ± 115.5 65.0 ± 22.6 62.7 ± 31.3 320.0 ± 196.0 
Dose 4  
(4.0 mg/kg) 
Control 116 ± 67.2 # 127.5 ± 93.8 123.6 ± 47.8 # † 160.0 ± 92.3 
Conjunctivitis 204.3 ± 173.5 120.0 ± 180.7 120.0 ± 38.1# † ‡ 160.0  ± 92.3 
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Figure 1. Topical histamine rapidly induced conjunctivitis (<1 min) that was either mild [(A); 
1.0 mg/mL solution] or severe [(B); 375 mg/mL solution]. Color images are available online. 
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Figure 2. Tear film concentrations (mean + standard deviation) of prednisone (A, B) and prednisolone (C, D) in dogs receiving oral 
prednisone at 0.5 mg/kg once daily (black line, circles), 1.0 mg/kg once daily (red lines, down triangles), 2.0 mg/kg once daily (green 
lines, squares), and 4.0 mg/kg once daily (blue lines, up triangles). The concentrations are depicted for control eyes (A, C) and eyes 
with experimentally induced conjunctivitis (B, D). Of note, the conjunctivitis group includes eyes with mild and severe conjunctivitis.  
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Figure 3. Box-and-whiskers plots depicting the area under the tear concentration–time curve 
from time zero to time of last measurable concentration (AUClast). Each plot depicts the mean 
(dotted line), median (solid line), 2.5th percentile (lower whisker), 25th percentile (lower limit of 
box), 75th percentile (upper limit of box), and 97.5th percentile (upper whisker). Data for 
prednisone (A) and prednisolone (B) are shown for all 4 oral doses of prednisone (0.5–4.0 
mg/kg) in both control eyes (white boxes) and eyes with experimentally induced conjunctivitis 
(dark gray). Of note, the conjunctivitis group includes eyes with mild and severe conjunctivitis. 
Within the same drug dose, comparisons between control and conjunctivitis eyes (t test) are 
described with P values above the plots. Within the same ocular group (control or conjunctivitis), 
differences among doses (one-way analysis of variance) are depicted with symbols to 
demonstrate statistically greater AUClast compared to dose 1 (#), dose 2 (†) and dose 3 (‡). 
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Figure 4. Bar charts depicting mean + standard deviation of area under the tear concentration-
time curve from time zero to time of last measurable concentration (AUClast). Data for tear 
concentrations of prednisone (A) and prednisolone (B) are shown for all 4 oral doses of 
prednisone (0.5–4.0 mg/kg) in eyes with experimentally induced mild conjunctivitis (light gray) 
or severe conjunctivitis (dark gray). Within the same dose, statistical comparisons between mild 
and severe conjunctivitis (t test) are described with P values above the plots, and statistical 
significance (P < 0.05) is depicted with an asterisk (*). 
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Abstract 
The breakdown of blood-tear barrier that occurs with ocular pathology allows for large 
amounts of albumin to leak into the tear fluid. This process likely represents an important 
restriction to drug absorption in ophthalmology, as only the unbound drug is transported across 
the ocular tissue barriers to exert its pharmacologic effect. We aimed to investigate the effects of 
albumin levels in tears on the bioavailability of two commonly used ophthalmic drugs: 
tropicamide, an antimuscarinic that produces mydriasis and cycloplegia, and latanoprost, a 
PGF2α analog used for the treatment of glaucoma. Eight female beagle dogs underwent a 
randomized, vehicle-controlled crossover trial. For each dog, one eye received 30 µL of artificial 
tears (control) or canine albumin (0.4 or 1.5%) at random, immediately followed by 30 µL of 1% 
tropicamide (2 days, 24h washout) or 0.005% latanoprost (2 days, 72h washout) in both eyes. 
Pupil diameter (digital caliper) and intraocular pressure (IOP; rebound tonometry) were recorded 
at various times following drug administration (0 to 480 min) and compared between both 
groups with a mixed model for repeated measures. Albumin in tears had a significant impact on 
pupillary diameter for both tropicamide (P≤0.001) and latanoprost (P≤0.047), with no 
differences noted between 0.4% and 1.5% concentrations. Reduction in the maximal effect (pupil 
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size) and overall drug exposure (area under the effect time-curve of pupil size over time) were 
significant for tropicamide (6.2-8.5% on average, P≤0.006) but not for latanoprost (P≥0.663). 
The IOP, only measured in eyes receiving latanoprost, was not significantly impacted by the 
addition of either 0.4% (P = 0.242) or 1.5% albumin (P = 0.879). Albumin in tear film, 
previously shown to leak from the conjunctival vasculature in diseased eyes, may bind to 
topically administered drugs and reduces their intraocular penetration and bioavailability. Further 
investigations in clinical patients and other commonly used ophthalmic medications are 
warranted.  
 
Introduction 
Topical instillation is the most common route of drug administration in ophthalmology, 
especially for the treatment of anterior segment diseases.1 This mode of administration is 
convenient and non-invasive, although drug bioavailability is generally poor (typically < 10%) 
due to physiological, structural, and biochemical barriers to drug penetration into the eye.1-3 
Upon instillation, an eyedrop is immediately diluted in the tear film and a large portion of the 
drug is lost through reflex tearing, nasolacrimal drainage, and systemic absorption. Residual drug 
has to cross ocular tissue barriers (i.e. cornea, sclera and conjunctiva) to reach targets within the 
globe.1,3,4 In general, small lipophilic drugs permeate through the cornea while larger or 
hydrophilic compounds permeate through the conjunctiva and sclera.4 Protein binding in tear 
film represents another important restriction to drug absorption, as only the unbound drug is 
transported across the tissue barriers.5 In fact, the presence of albumin in tears can dramatically 
reduce the bioavailability of topical drugs via protein-drug interactions, as previously shown for 
pilocarpine in rabbit eyes.5  
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Albumin is a relatively large (66 kDa) and negatively charged protein that is widely 
distributed in the body. Given the protein’s remarkable capacity for binding ligands,6 albumin 
serves as a reservoir and transporter for drugs and other molecules such as hormones, 
metabolites, and nutrients. At the level of the eye, plasma-derived albumin leaks onto the ocular 
surface from conjunctival vessels and mixes with the tear film.7 Albumin concentration in tears 
is generally low in healthy state but increases substantially in diseased eyes.7 In fact, albumin is 
often considered a biomarker of ocular insult or inflammation as the breakdown of blood-tear 
barrier noted with ocular pathology allows for large amounts of albumin to leak into the lacrimal 
fluid.7-9 A recent study by Sebbag et al. showed that canine eyes with diverse ocular diseases 
(e.g. corneal ulcer, uveitis, glaucoma) had lacrimal albumin levels that were up to 14.9-fold 
greater than contralateral healthy eyes.10  
The impact of albumin binding on the drug’s pharmacological activity is extensively 
studied in blood,11 yet little is known about the physiology and function of albumin in tears or 
other biological fluids. In the present study, we examined the bioavailability of topically 
delivered drugs in the presence of clinically relevant levels of albumin in tears.10 We 
hypothesized that the drugs’ intraocular effect will be reduced by lacrimal albumin given the 
inability of protein-bound drugs to permeate through ocular tissue barriers. Two ophthalmic 
medications were investigated as a proof-of-concept experiment: 0.005% latanoprost and 1% 
tropicamide. These drugs are commonly used in human and veterinary practice, and possess 
different physicochemical properties (e.g. solution pH, drug concentration) that could influence 
protein-drug interactions. Latanoprost, a PGF2α analog, is used for the treatment of glaucoma 
and ocular hypertension in human and veterinary patients.12,13 Tropicamide, an antimuscarinic 
drug, is used to achieve short-acting mydriasis for enhanced visualization of the lens, vitreous 
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body and fundus, as well as cycloplegia to control accommodation during the assessment of 
refractive error.14 Pupil response to tropicamide was also suggested as a noninvasive 
neurobiological test for Alzheimer’s disease and other neurodegenerative disorders,15,16 although 
this diagnostic test fell out of favor given large inter- and intra-individual variations and 
subsequent poor test specificity.17 Drug binding to proteins in tear fluid could partly explain the 
aforementioned variability in pupil size, a phenomenon our group investigated in the present 
study to help guide future diagnostic and therapeutic applications in ophthalmology. The present 
work was conducted in dogs, a species that represents an excellent large animal model for 
translational research in humans given similarities in ocular anatomy18 and physiologic 
parameters pertinent to topical route of drug administration,19 as well as spontaneous disease 
development such as glaucoma,20 dry eye21 and conjunctivitis.10  
 
Materials and Methods 
Animals 
Eight female spayed Beagle dogs (1.5-2.0 years, 7.5-10 kg) were recruited. Prior to study 
enrollment, dogs were part of a teaching colony and underwent weekly physical and ophthalmic 
examinations, including tonometry (TonoVet, Icare Finland Oy, Espoo, Finland). At study 
inclusion, dogs were confirmed to be healthy based on a complete physical and ophthalmic 
examination, including tonometry (TonoVet), Schirmer tear test-1 (STT-1; Eye Care Product 
Manufacturing LLC, Tucson, AZ, USA), slit-lamp biomicroscopy (SL-17; Kowa Company, Ltd., 
Tokyo, Japan) and indirect ophthalmoscopy (Keeler Vantage; Keeler Instruments, Inc., 
Broomall, PA, USA). The study was approved by the Institutional Animal Care and Use 
Committee of Iowa State University (protocol # 19-049), and conducted in accordance with the 
Association for Research in Vision and Ophthalmology guidelines for animal use. 
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Experiment 
Two canine albumin ophthalmic solutions (0.4% and 1.5%) were formulated by mixing 
canine albumin lyophilized powder (Animal Blood Resource International, Stockbridge, MI) 
with lubricating eye drops (Artificial tears solution, Rugby, Rockville Center, NY, USA) in a 
sterile manner under a laminar flow hood. Of note, albumin concentrations selected herein (0.4% 
and 1.5%) aimed to achieve tear film albumin levels of ~ 1 to 5 mg/mL (i.e., after dilution of the 
instilled drop with the canine tear film, accounting for ~ 3-fold dilution)19 thus representing a 
spectrum of albumin levels in tears of dogs with spontaneous or experimentally-induced 
conjunctivitis.10 Artificial tears solution without albumin (vehicle only) was used as control for 
the experiment. Albumin and vehicle solutions were kept in the refrigerator (4 °C) and used 
within 7 days of preparation.  
For each dog, one eye was randomly selected to receive albumin solutions while the 
contralateral eye served as control (vehicle solution); this choice was kept constant throughout 
the study. Tropicamide 1% (Sandoz Inc., Princeton, New Jersey, USA) and latanoprost 0.005% 
(Sandoz Inc., Princeton, New Jersey, USA) were each investigated over two separate days. To 
allow pupil size to return to baseline and avoid a carry-over effect, the washout between 
experimental days was 24h for tropicamide22 and 72h for latanoprost.23 For each drug, the eye 
allocated to albumin was randomly assigned to receive either 4 mg/mL or 15 mg/mL albumin 
solution on the first experimental day, and vice versa on the second day.  
The experiments took place in a quiet and uniformly illuminated room (500 lux) under 
controlled temperature (70-72°F) and ambient humidity (25-30%). Measurements of pupil 
diameter (PD) were obtained with a digital Vernier caliper (± 0.01 mm, Ultratech No. 1433, 
General Tools & Instruments, Secaucus, NJ) held adjacent to the cornea, while measurements of 
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intraocular pressure (IOP) were obtained with rebound tonometry (TonoVet, Icare Finland Oy, 
Espoo, Finland). Baseline PD and IOP were recorded in both eyes of each dog at the beginning 
of each study day.  
Using a pipette, 30 µL of experimental solution were delivered topically: albumin in one 
eye, vehicle in the other. This was immediately followed (<10 sec) by topical instillation of 30 
µL of the drug (tropicamide or latanoprost) in both eyes. Then, PD (tropicamide and latanoprost) 
and IOP (latanoprost only) were recorded in both eyes at the following time points: 2, 4, 6, 8, 10, 
15, 20, 30, 45, 60, 90, 120, 180, 240, and 480 min. 
 
Data analysis 
Normality of data was assessed with the Shapiro-Wilk test. Differences in pupil diameter 
(tropicamide, latanoprost) and IOP (latanoprost) between eyes receiving saline (control) or 
albumin (0.4% or 1.5%) were assessed with a mixed model for repeated measures (MMRM)24 
using the R software version 3.6.0. In the model, PD or IOP were the response variable, the 
group (control or albumin), time (0 to 480 min) and group-by-time interaction were treated as 
fixed effects, and the animal and animal-by-group interaction were treated as random effects, 
using animal as block. After the model was fit, the fixed effects were tested, and comparisons 
between control and albumin eyes at baseline and each time point were made. The R software 
was also used to calculate the area under the effect-time curve (AUETC) and the maximal effect 
on pupil diameter (maximal dilation for tropicamide, maximal constriction for latanoprost). 
Paired t-tests were conducted with SigmaPlot 14.0 (Systat Software Inc., San Jose, CA, USA) to 
assess the following parameters: (i) AUETC for tropicamide and latanoprost, (ii) PDmax for 
tropicamide, and (iii) PDmin for latanoprost. P values < 0.05 were considered statistically 
significant. 
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Results 
Results from the Shapiro-Wilk test confirmed that the experimental data were normally 
distributed. Results are therefore presented as mean ± standard deviation (SD). 
 
Pupil dilation from tropicamide  
 Taking the variable ‘time’ into account, albumin had a significant effect on pupil 
diameter post- tropicamide administration for both 0.4% (P = 0.001) and 1.5% concentrations (P 
= 0.001). Compared to the contralateral eye (control), pupillary dilation was significantly 
reduced in eyes receiving 0.4% albumin as early as 8 min (P = 0.043) and as late as 240 min (P = 
0.009)(Figure 1A), and in eyes receiving 1.5% albumin as early as 8 min (P = 0.027) and as late 
as 240 min (P = 0.021)(Figure 1B) following instillation of 1% tropicamide. A representative 
clinical image is depicted in Figure 2, showing a lower degree of mydriasis in the dog’s left eye 
(0.4% albumin and 1% tropicamide) compared to the right eye (artificial tears and 1% 
tropicamide) at 45 min following eyedrop administration. Further, the cumulative effect of 
tropicamide on pupillary dilation (from 0 to 480 min) was significantly reduced with the addition 
of 0.4% or 1.5% albumin (P < 0.001), representing an average reduction in biological response 
of 7.1% and 7.2% compared to controls, respectively (Figure 3); however, no differences were 
noted in AUETC (pupil size over time) between both albumin concentrations (P ≥ 0.625). Last, 
mean ± SD maximal pupillary dilation in eyes receiving tropicamide and 0.4% albumin (11.9 ± 
0.7 mm) or 1.5% albumin (11.7 ± 1.3 mm) was significantly lower (P ≤ 0.006) compared to 
contralateral controls (12.7 ± 0.8 mm, and 12.8 ± 1.1 mm, respectively), representing a reduction 
in biological response of 6.2% and 8.5%, respectively (Figure 4).  
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Pupil constriction from latanoprost 
Taking the variable ‘time’ into account, albumin had a significant effect on pupil 
diameter post- latanoprost administration for both 0.4% (P = 0.016) and 1.5% concentrations (P 
= 0.047). Compared to the contralateral eye (control), pupillary constriction was overall reduced 
in eyes receiving 0.4% albumin (Figure 5A) or 1.5% albumin (Figure 5B), although differences 
in pupil diameter were not statistically significant at any time point following instillation of 
0.005% latanoprost (P ≥ 0.158 and P ≥ 0.416, respectively). No differences were noted in 
AUETC (pupil size over time) between groups (P ≥ 0.663), nor in maximal pupillary constriction 
(P = 1.000) obtained with 0.4% albumin (1.5 ± 0.1 mm), 1.5% albumin (1.5 ± 0.2 mm) and their 
respective contralateral controls (1.5 ± 0.1 mm and 1.5 ± 0.2 mm).  
 
IOP changes from latanoprost 
Compared to the contralateral eye (control), IOP was significantly lower in eyes 
receiving 0.4% albumin at 10 min (P = 0.010), 20 min (P = 0.010), 45 min (P = 0.010) and 240 
min (P = 0.010) following instillation of 0.005% latanoprost (Figure 6A), while no significant 
changes were noted at any time point (P ≥ 0.262) for the 1.5% albumin group (Figure 6B). 
However, after taking ‘time’ into account in the mixed effects model, it is important to note that 
the impact of albumin on IOP was not statistically significant for either 0.4% (P = 0.242) or 
1.5% concentration (P = 0.879). Further, no differences were noted in AUETC (IOP over time) 
between control and albumin groups (P ≥ 0.351) or between both albumin groups (P = 0.979). 
 
Discussion 
The bioavailability of ophthalmic drugs can be reduced by the presence of albumin in 
tears, a protein that leaks onto the ocular surface in large amounts in the diseased eye. A deeper 
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understanding of albumin-drug interactions in tears is critical to basic researchers in 
pharmacology and vision science, but also physicians and veterinarians. Indeed, drug binding to 
albumin may partly explain the challenge of treating certain diseases in ophthalmology. For 
instance, a poor response of uveitis to topical corticosteroid may be due to high affinity of the 
drug to albumin in tears, while a poor response of infectious keratitis to topical antibiotics may 
be explained by the fact that only the unbound portion of an antimicrobial is microbiologically 
active.25 Here, we showed a differential impact of albumin in tears on the ocular response of 
tropicamide and latanoprost, two common ophthalmic drugs in human and veterinary patients, 
and the same could be investigated in the canine model for other relevant drug classes. Dogs are 
particularly suited for translational research in ocular pharmacology as – unlike small laboratory 
animals – dogs share similar anatomical and physiological features to humans, similar 
environmental stressors and genetic variation, and a range of naturally occurring ophthalmic 
diseases that resemble the ones diagnosed in human patients.  
 
Ocular response of tropicamide and latanoprost in the presence of albumin 
The biological effect of tropicamide (i.e. mydriasis) was significantly reduced in canine 
eyes that received concurrent topical administration of serum albumin, regardless of the protein’s 
concentration. Albeit minimal (6.2-8.5 %), the impact of albumin on tropicamide-induced 
pupillary dilation is likely underestimated compared to clinical patients given limitations 
inherent to the study design (described below). Interestingly, this lower degree of tropicamide-
induced mydriasis was also noted in canine eyes covered with a soft contact lens, a physical 
barrier to drug penetration.26 Similar findings were noted by Mikkelson et al. in rabbit eyes 
receiving pilocarpine,5 although the magnitude of drug-response reduction was much greater in 
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rabbits (75-100 fold) compared to the present study in dogs (6-8%). Such discrepancy is likely 
explained by two important differences in study designs. In the present experiment, the 
concentrations of albumin (0.4% and 1.5%) were specifically chosen based on clinically-relevant 
albumin levels detected in canine patients with diverse ocular diseases,10 taking into account the 
3-fold dilution effect from resident tears.19 to better account for the true binding constant seen in 
dialysis experiments.27 In contrast, the concentrations of albumin used in rabbits were higher 
(1% and 3%) and may not reflect the range of biological concentrations of albumin at the ocular 
surface. Another key difference is the way albumin was delivered to the ocular surface. While 
albumin was pre-mixed with pilocarpine solution in the rabbit study, allowing for protein-drug 
binding to occur ex situ (i.e. away from the ocular surface) over an extended duration, albumin 
and tropicamide were delivered separately in the present study (albumin first, tropicamide within 
<10 seconds) so that protein-drug interactions would occur in-situ (i.e. in the tear film) over a 
short duration. From a physiological standpoint, the latter method is more appropriate as the 
interaction time of a topical drug to albumin in tears is generally short, limited by the rapid tear 
turnover rate that occurs following eyedrop administration in dogs19 or other species.28,29 Of 
note, tonometry was not performed in dogs receiving tropicamide (with or without albumin) in 
the present study given the lack of effect of tropicamide on IOP in healthy canine eyes,30 but this 
parameter could be considered in future studies as IOP can vary from tropicamide in dogs 
receiving sedation30 or dogs with glaucomatous eyes. 
The pharmacological activity of latanoprost (i.e. miosis) was also reduced in the presence 
of albumin in tears, although not to the same extent as for tropicamide. Indeed, differences in 
pupil size between albumin and control eyes were limited in duration (up to 30 min, compared to 
240 min for tropicamide) and somewhat limited in magnitude (1% non-significant change in 
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AUETC). These findings are likely explained by the high sensitivity of the iris sphincter muscle 
to the drug.31 The minimum amount of PGF2α required to generate contraction of the iris 
sphincter in dogs is 10-10 M,31 while the concentration of latanoprost applied topically is 
approximately 106 higher (0.005% ~ 10-4 M). The amount of drug lost to albumin in tears is 
therefore insignificant, as only a small fraction of intraocular drug penetration is sufficient to 
cause miosis. Furthermore, once latanoprost reaches the anterior chamber, the drug acts directly 
on the iris sphincter muscle but also indirectly through the release of endogenous 
prostaglandins.32,33 Endogenous PGF2α, which further acts on the prostanoid FP receptors and 
contributes to the sphincter muscle’s tone in dogs,31 is released inside the anterior chamber and is 
thereby not affected by albumin levels in the tear film.  
Following latanoprost administration, the overall effect of lacrimal albumin on IOP 
values was non-significant for either albumin concentration. Compared to control eyes, a 
significantly lower IOP was noted at selected times (10, 20, 45 and 240 min) in eyes receiving 
0.4% albumin concurrently to latanoprost, although it is important to note that IOP readings 
displayed a large variability within -and between-subjects in all groups. To reduce IOP 
variability, a recent study in healthy Beagle dogs34 recommended a minimum of 5 training days 
immediately prior to the start of the study, and collecting IOP readings in triplicate at each time. 
In absence of such precautions, the IOP results of the present study are likely confounded by a 
large measurement noise.  
 
Factors affecting the impact of albumin on drug bioavailability  
The present findings provide evidence that albumin levels in tears does not affect all 
drugs in a uniform manner. Rather, the mechanism of action of a drug and/or potency for its 
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biological target can modulate the impact of lacrimal albumin on the drug’s pharmacological 
activity. The dose-response relationship, a cornerstone of pharmacology/toxicology, defines the 
role of a dose for a chemical (e.g. drug, toxic agent) in evoking biological response.35 Figure 7A 
depicts two drugs (A & B) with different dose-response profiles. In this scenario, if lacrimal 
albumin reduces the amount of free drug available inside the eye by 50%, the response observed 
(e.g. pupillary dilation) will be greatly reduced for drug B but minimally affected for drug A. 
Along the same line, the amount of drug applied topically is an important factor to take into 
consideration. For a given drug, if the dose administered topically falls in the ‘far right’ of the 
drug’s dose-response curve, a reduction in drug available after albumin binding would only 
minimally affect the observed response (dose X, Figure 7B); in contrast, if the dose delivered 
produces an effect that falls within the steep portion of the dose-response curve, the impact of 
dose reduction from albumin would be more pronounced (dose Y, Figure 7B). Mikkelson and 
colleagues showed that the entire biological response (pilocarpine-induced miosis) could be 
suppressed when low drug concentrations were used in the presence of serum albumin.5 Future 
studies leveraging this work should assess the ocular response obtained from different 
concentrations of the same drug (e.g. tropicamide 0.05%, 0.5%, 1%, 2%) in the presence of 
albumin in tears.  
A number of other factors can influence the drug-protein interactions on the ocular 
surface, including albumin concentrations in tears and physicochemical properties of the 
individual drug. In plasma, higher levels of albumin can further reduce the biological response of 
a drug, as exemplified by lower antimicrobial activity of fluoroquinolones with increasing levels 
of serum albumin.36 In tears, however, the present study did not find statistical differences 
between 0.4% and 1.5% albumin for either tropicamide or latanoprost. It is possible that the 
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magnitude of albumin levels is not as critical in tears as it is in plasma, as lacrimal concentrations 
of albumin are relatively small (< 2%)10 in comparison to blood (≥ 4%).36 Similarly, the 
influence of molecular weight on drug-albumin affinity may be minimal in tears, as most 
ophthalmic drugs have a relatively small and narrow range of molecular weights (e.g. 284 Da for 
tropicamide, 432 Da for latanoprost). In contrast, the pH of ophthalmic drugs is likely more 
impactful: pH varies from one ophthalmic solution to another, and albumin is known to change 
its binding affinity and conformation when exposed to changes in solution pH.37 Here, 
tropicamide solution is slightly more acidic (pH 5.8) than latanoprost solution (pH 6.7), although 
both solutions are near physiologic pH for the ocular surface and may have minimal impact on 
albumin affinity compared to other ophthalmic drugs such as dorzolamide (pH 4.5). Future 
studies should investigate the importance (or lack thereof) of other relevant biological factors on 
albumin-drug interactions in tear fluid, such as drug lipophilicity, viscosity, temperature at the 
ocular surface, fatty acids levels in tears, and drug-drug interactions.38 
 
The study may underestimate drug-proteins interactions and their impact on bioavailability   
The present work likely underestimates the true impact of proteins on ocular 
bioavailability of drugs, as the study design has two noteworthy limitations. First, although the 
lag time between albumin and drug instillation was short (<10 s), it may be sufficient for a 
portion of the administered albumin to be washed out of the ocular surface by the time the drug 
mixes with the tear film, as most of an administered eyedrop is lost to drainage in the first 15 to 
30 seconds.28,29 Second, although albumin is a major actor of drug-protein binding on the ocular 
surface, other proteins play a critical role too. Using equilibrium dialysis, Chrai and Robinson 
showed that sulfisoxazole primarily binds to albumin in tears, but also α-globulin and (to a lesser 
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extent) γ-globulin and lysozyme,27 all of which are normal components of tears in dogs and other 
species. Ultimately, the authors recommend that future investigations be conducted with 
experimental models of blood-tear barrier breakdown, such as histamine-induced conjunctivitis 
in dogs.10 With such models, albumin and other key proteins are already present on the ocular 
surface when the drug is administered topically, although individual protein concentrations may 
vary from one eye to another, and this variability should be accounted for in the interpretation of 
study results. Furthermore, such models would account for other important changes that occur 
with ocular surface inflammation and that could affect drug-protein interactions, such as altered 
tear volume and turnover rate, tear film instability, and variations in mucin composition.39 
 
Strategies to minimize drug-proteins interactions and enhance ocular bioavailability    
A few strategies can be used to minimize the effects of drug-protein interactions on the 
ocular surface, and thereby maximize the drug pharmacological action by enhancing intraocular 
bioavailability. First, a higher drug concentration should be considered, especially if available 
commercially (e.g. tropicamide 1% instead of 0.5%), as the resulting concentration gradient of 
unbound drug will be higher (Fick’s first law of diffusion). Second, the amount of protein 
leakage into the tear film can be reduced by stabilizing the blood-tear barrier in the diseased eye, 
a process achieved by treating the underlying ocular disease10 and/or using vasoprotective drugs 
such as calcium dobesilate.40 Last, drug-protein interactions can be reduced by using competitive 
inhibitors of protein binding; for instance, Mikkelson and colleagues showed that the biological 
activity of pilocarpine (a miotic agent) increased 10-fold in the presence of the competitive 
inhibitor cetylpyridinium chloride.41 However, the use of competitive inhibition of albumin 
binding is discouraged until the importance of albumin on the ocular surface is fully elucidated. 
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In fact, albumin in tear film may serve as a double-edged sword, being detrimental to the ocular 
bioavailability of topically administered medications, but also beneficial for symptomatic relief 
of dry eye,42,43 corneal wound healing,42 and anti-oxidative and anti-inflammatory activities.44 
 
Conclusion 
Albumin in tears modulate the ocular bioavailability of topically administered drugs, as 
observed in a ‘large animal’ model that shares similar anatomical and physiological features with 
humans. The effect of albumin depends on the medication (e.g. drug concentration and inherent 
physicochemical properties) and was overall mild (<10%) in the present work on healthy canine 
eyes, albeit likely underestimated given the rapid tear turnover rate following eyedrop 
administration. Models of ocular surface inflammation could enable future pharmacological 
studies to gain a deeper understanding of protein-drug interactions, accounting for albumin 
leakage in tears as well as other relevant factors that affect ocular surface homeostasis. 
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Tables and Figures 
 
 
 
Figure 1. Mean + SD pupil diameter from 0 to 480 min in dogs receiving 1% tropicamide in 
both eyes, immediately preceded by topical instillation of artificial tears (control, white circles) 
in one randomly selected eye, and either 0.4% albumin (A, black triangles) or 1.5% albumin (B, 
black triangles). Statistical differences (P < 0.05) obtained with mixed model for repeated 
measures are depicted by gray asterisks (*). 
 
 
 
Figure 2. Clinical image of a Beagle dog at 45 min following topical instillation of 1% 
tropicamide in both eyes, immediately preceded by topical artificial tears (right eye, control) and 
0.4% albumin (left eye). Note the lower degree of mydriasis in the left eye. 
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Figure 3. Box-and-whisker plots depicting the area under the effect-time curve (AUETC) of 
pupil diameter over time (0 to 480 min) in dogs receiving 1% tropicamide in both eyes, 
immediately preceded by topical instillation of artificial tears (control, white boxes) in one 
randomly selected eye, and either 0.4% albumin (light gray box) or 1.5% albumin (dark gray 
box) in the other eye. Mean and median values are shown by horizontal dotted and solid lines, 
respectively. First and third quartiles (25th and 75th percentiles) are represented by the lower and 
upper limits of the box, respectively, while the 2.5th and the 97.5th percentiles are shown as the 
lower and upper whiskers, respectively. 
 
 
Figure 4. Box-and-whisker plots depicting the maximal pupillary diameter in dogs receiving 1% 
tropicamide in both eyes, immediately preceded by topical instillation of artificial tears (control, 
white boxes) in one randomly selected eye, and either 0.4% albumin (light gray box) or 1.5% 
albumin (dark gray box) in the other eye. Mean and median values are shown by horizontal 
dotted and solid lines, respectively. First and third quartiles (25th and 75th percentiles) are 
represented by the lower and upper limits of the box, respectively, while the 2.5th and the 97.5th 
percentiles are shown as the lower and upper whiskers, respectively. 
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Figure 5. Mean + SD pupil diameter from 0 to 480 min in dogs receiving 0.005% latanoprost in 
both eyes, immediately preceded by topical instillation of artificial tears (control, white circles) 
in one randomly selected eye, and either 0.4% albumin (A, black triangles) or 1.5% albumin (B, 
black triangles). No statistical differences were noted between groups at any time point (mixed 
model for repeated measures, P ≥ 0.05). 
 
 
 
Figure 6. Mean + SD intraocular pressure from 0 to 480 min in dogs receiving 0.005% 
latanoprost in both eyes, immediately preceded by topical instillation of artificial tears (control, 
white circles) in one randomly selected eye, and either 0.4% albumin (A, black triangles) or 
1.5% albumin (B, black triangles). Statistical differences (P < 0.05) obtained with mixed model 
for repeated measures are depicted by gray asterisks (*). 
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Figure 7. Hypothetical scenarios highlighting the importance of dose-response relationship in 
understanding the impact of albumin in tears on the biological activity of an ophthalmic drug. 
(A) A 50% reduction in the amount of drug that can penetrate inside the eye will have a minimal 
effect on the biological effect of drug A (dotted line), but a profound effect on drug B (solid 
line). (B) For the same drug, a 50% reduction in the amount of drug that can penetrate inside the 
eye will have a minimal effect on the biological response if the initial drug concentration was 
high (X), but a profound effect if the initial drug concentration was relatively low (Y).  
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Abstract 
Preclinical animal studies provide valuable opportunities to better understand human 
diseases and contribute to major advances in medicine. This review provides a comprehensive 
overview of ocular parameters in humans and selected animals, with a focus on the ocular 
surface, detailing species differences in ocular surface anatomy, physiology, tear film dynamics 
and tear film composition. We describe major pitfalls that tremendously limit the translational 
potential of traditional laboratory animals (ie., rabbits, mice and rats) in ophthalmic research, and 
highlight the benefits of integrating companion dogs with clinical analogues to human diseases 
into preclinical pharmacology studies.  
This One Health approach can help accelerate and improve the framework in which 
ophthalmic research is translated to the human clinic. Studies can be conducted in canine 
subjects with naturally occurring or non-invasively induced ocular surface disorders (eg., dry eye 
disease, conjunctivitis), reviewed herein, and tear fluid can be easily retrieved from canine eyes 
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for various bioanalytical purposes. In this review, we discuss common tear collection methods, 
including capillary tubes and Schirmer tear strips, and provide guidelines for tear sampling and 
extraction to improve the reliability of analyte quantification (drugs, proteins, others). 
 
Introduction 
Preclinical animal models provide critical information to better understand human 
diseases’ characteristics, identify biomarkers, develop diagnostic tools and novel therapeutics. 
Rabbits and laboratory rodents (mice, rats) are widely used for ophthalmic research as they are 
economical and easy to handle;1 however, serious drawbacks limit the translational usefulness of 
data obtained in these species, notably due to the need to artificially induce pathology in these 
animals (eg., through genetic manipulation or experimental surgery), as well as apparent 
differences in ocular anatomy and physiology compared to humans. For instance, precorneal 
residence time of topically applied solutions is much prolonged in rabbits owing to their low 
blink rate, resulting in 3-fold overestimation of ocular drug exposure if findings were directly 
extrapolated from rabbits to humans.2 Another example is topical nepafenac, a potent 
nonsteroidal anti-inflammatory drug (NSAID) that reaches therapeutic levels in the posterior 
segment of mice (owing to their thin cornea and small globe size), inhibiting choroidal 
neovascularization by decreasing production of VEGF3 – in contrast, humans require intravitreal 
injections of anti-VEGF compounds to achieve the same outcome. Multiple other examples exist 
in the scientific literature, together participating to the unacceptably low success rate of 
ophthalmic clinical trials to date, and resulting in substantial economic loss and burden for 
scientists, consumers, and society overall.4 In fact, the main cause for clinical trial failure is 
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either lack of safety or efficacy,5 two components that are supposedly ‘validated’ in initial 
preclinical animal studies. 
Under the umbrella of the One Health Initiative, a growing number of investigations have 
integrated companion animals into preclinical studies to complement and expand the knowledge 
gained from studies in other animal models, accelerate and improve the framework in which 
research is translated to the human clinic, and ultimately generate discoveries that will benefit 
the health of humans and animals.6 Over the last few years, several review articles have 
highlighted the benefits of using dogs for translational research in oncology,7 neurology8 and 
other biomedical fields,6 yet such information is not available in ophthalmology. 
The present review provides a comprehensive comparison of key ocular parameters in 
humans, dogs and traditional laboratory animals (ie., rabbits, mice, rats), highlighting selected 
strengths and important pitfalls that must be addressed when ocular research is conducted in 
animal models. This review is focusing on the ocular surface, a critical element of vision that 
includes the secreted tear film, lacrimal gland(s), eyelids, meibomian glands, cornea, 
conjunctiva, sclera, and nasolacrimal drainage apparatus. The ocular surface dictates the 
bioavailability of medications administered topically to the eye,9 and is a common site of 
pathology in both human and veterinary medicine. Methods of tear fluid collection for 
bioanalytical purposes are also being discussed, with special consideration on the safety and 
efficiency of the collection technique at hand. Lastly, this review highlights on spontaneous and 
experimental ocular surface disorders in dogs, providing a tool for researchers to better model 
disease pathophysiology in clinical patients suffering from ocular surface disorders. 
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Comparative anatomy and physiology of the ocular surface 
Anatomy 
The anatomy of the ocular surface is depicted in Figure 1 for dogs, and its parameters are 
being summarized in Table 1 for all species discussed in this review (ie., humans, dogs, rabbits, 
mice, rats).  
Lacrimal glands - Four types of lacrimal glands can be distinguished in mammals: (i) the 
orbital lacrimal gland (glandulae lacrimales superior), located in the dorsolateral orbit just 
caudal to the orbital rim, with secretory ducts that open into the upper conjunctival fornix 
(humans, dogs, rabbits); (ii) the gland of the third eyelid, located in the ventromedial orbit at the 
base of the nictitating membrane with secretory ducts than open into the nictitans’ bulbar 
conjunctiva (dogs); (iii) the infraorbital gland (glandulae lacrimales inferior), located either 
intraorbital and ventromedial to the globe (rabbits) or extraorbital and caudal to the globe 
(rodents), with a single secretory duct that opens into the lower conjunctival fornix; and (iv) the 
Harderian gland, or Harder’s gland, extending from the base of the third eyelid into the caudal 
orbit, with secretory ducts opening at the nictitating membrane (rabbits, rodents).10,11 The 
histomorphology of lacrimal glands varies with age and sex of the individual.12 In dogs, an 
orbital lacrimal gland and gland of the third eyelid contribute to 60-70% and 30-40% of the 
overall tear secretion, respectively.13 The morphological and histological features of the canine 
glands resemble the human lacrimal gland including distinct lobules and acini that provide 
serous and mucous secretions, as well as intralobular ducts that drain into small excretory 
tubules.14,15 Likewise, an Harderian gland is not present in the canine or human orbit.14-16 
However, two notable differences exist between species: (i) the combined volume of the two 
canine glands is smaller than the main lacrimal gland in humans (0.24 vs. 0.60 cm2)17,18; and (ii) 
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the accessory lacrimal glands of Krause and Wolfring are absent in dogs (or not yet reported), 
presumably being consolidated through evolution into the single gland of the third eyelid.19 
These accessory glands account for 10% of the total lacrimal secretory mass in humans but their 
contribution to the overall tear secretion is negligible (1-2%).20,21 In rabbits, the histoarchitecture 
of the main lacrimal gland is comparable to humans with loosely packed acini and round/oval 
lumen; in contrast, mice and rats have densely packed acini with small pleiomorphic lumen and 
numerous intercellular tight junctions.22 Like humans, rabbits also possess accessory lacrimal 
glands of Wolfring in the tarsal portion of the palpebral conjunctiva.23 However, the Harderian 
gland present in rabbits and rodents is a unique anatomical feature that has important 
repercussions for comparative studies; in fact, the gland’s lipid secretions in the tear film have 
profound effects on the ocular surface physiology (eg., tear composition, tear film dynamics, 
blink rate) and pharmacology of topically applied medications (see sections 2.2 and 2.3). 
Nasolacrimal apparatus - The morphology of the canine lacrimal drainage system is 
remarkably similar to that of humans, except for a longer nasolacrimal duct (notably in long-
nosed dogs), and the presence of accessory duct openings into the nasal cavity.24 In both species, 
tear drainage begins with the lower and upper nasolacrimal puncta and canaliculi in the medial 
canthus, joining into a lacrimal sac in the bony lacrimal fossa, and extending into the 
nasolacrimal duct that runs through an osseous channel towards the nasal cavity.25 Species 
similarities are also evident on a microscopic level, including an epithelial lining with microvilli 
and mucin-secreting goblet cells, sub-epithelial seromucous glands, and mucosal-associated 
lymphoid tissue.24 In contrast, the nasolacrimal apparatus of rabbits has distinct differences 
compared to humans. Rabbits only have a single nasolacrimal punctum/canaliculus (medial 
lower eyelid) and the nasolacrimal duct has two very distinct flexures due to the ventral 
134 
 
 
 
deflection of the snout, a unique feature that results in a convoluted path for tear drainage.25,26 
The fetal development of the rabbit’s nasolacrimal apparatus is also unique in mammals, more 
closely resembling reptiles vs. humans.27 At an ultrastructural level, the epithelium lining the 
duct is double-layered (similar to humans) but there are no goblet cells or subepithelial 
seromucous glands.28 Nonetheless, the use of the rabbit is still recommended as a practical model 
to characterize the nasolacrimal apparatus,29 albeit this choice is described as ‘less than ideal’ by 
the authors. Mice and rats have a well-developed nasolacrimal apparatus that shares similar 
ontogenetic origin to humans,27 although the histological features are different. The duct lining is 
covered by a multi-layered stratified squamous epithelium with goblet cells but without sub-
epithelial seromucous glands.25 
Third eyelid - The nictitating membrane (third eyelid) is a large fold of the conjunctiva 
that protrudes from the medial canthus over the anterior surface of the globe in many animals, 
including dogs, rabbits and rodents. The counterpart in humans is the plica semilunaris, a 
vestigial remnant in the form of a crescent-like conjunctival fold in the medial canthus.11,30 
Despite gross differences, both structures have important physio-morphological similarities such 
as the presence of goblet cells and lymphoid follicles, contributing to the lubrication and immune 
protection of the ocular surface.30 Nonetheless, the presence of a third eyelid should be 
considered in comparative studies as it could impact ocular examinations (eg., third eyelid 
protrusion from ocular irritation) or ocular drug delivery (eg., altered retention time of a contact 
lens),31 among others. If required for ease of experimentation, a simple fixation of the nictitating 
membrane can be performed31 as an alternative to complete surgical removal,13,32,33 as the latter 
negatively impacts ocular surface homeostasis.13,34 
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Eyelids - Similar to humans, the canine upper and lower eyelids are comprised of an 
outer dermis, tarsus, orbicularis oculi muscle, palpebral conjunctiva and secretory tissues 
including meibomian glands (20-40 per eyelid), glands of Zeis and Moll.35,36 The main 
anatomical difference is the tarsal plate, which is comprised of dense fibrous tissue and cartilage-
specific components in humans37 – providing a rigid internal support to the eyelids – compared 
to a much thinner and poorly-developed fibrous tissue in dogs.38 Also, the interpalpebral fissure 
area is approximately 20% larger in dogs (2.2 vs. 1.8 cm2)39,40, although the measurements of the 
palpebral fissure width depend on the dog’s size and body weight.40 
The palpebral opening in the rabbit is relatively small (10-16 mm),38,41,42 albeit much 
larger than mice (3.7-5 mm)43 and rats (6-9 mm)44,45, with a shorter and thicker upper eyelid 
compared to the inferior palpebrae; consequently, the interpalpebral fissure area is 20% smaller 
in rabbits than in man (1.44 vs. 1.8 cm2).39 The meibomian gland ducts and acini are also larger 
in rabbits than mice and rats,46 but the overall volume and distribution of meibomian glands is 
different than in humans: the total meibomian gland volume in the human (39.5 mm3) is twice 
that of the rabbit (18.8 mm3), with a larger volume in the upper eyelid (man) compared to similar 
volumes in the upper and lower eyelids (rabbit).39  
Conjunctiva - The conjunctiva is a thin mucous membrane that serves important roles on 
the ocular surface including mucin secretion and immune surveillance. The anatomical 
subdivision of the conjunctiva is the same in humans, dogs, and common laboratory species 
(rabbits, rodents): the palpebral conjunctiva – lining the inside of the eyelids – reflects back at 
the level of the conjunctival fornix to form the bulbar conjunctiva, a region that covers the 
anterior portion of the sclera and attaches to the corneoscleral limbus.16 However, the amount of 
bulbar conjunctiva exposed (‘scleral show’) is notably larger in humans compared to animals 
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given differences in eyelid opening and/or corneal diameter. Another important species 
difference is the presence of a nictitating membrane in animals (but not man), as the third eyelid 
is covered by conjunctiva on its anterior and posterior surfaces. As such, animals have two 
conjunctival fornices in the inferonasal region – one on each side of the third eyelid – and the 
overall conjunctival surface is generally larger in animals compared to humans. In dogs, the 
conjunctival area is supposedly larger than in humans given the depth of the canine conjunctival 
fornices and the amount of conjunctiva covering the canine nictitating membrane,47 although no 
objective data exist to date. In rabbits, the upper conjunctival fornix depth (20.36 mm)48 is larger 
than in humans (15 mm),49 while the conjunctival area is reportedly comparable (13.34-18.48 vs. 
17.65 cm2, respectively), although the measurements did not include the rabbit’s third eyelid 
(surgically removed by investigators).50  
Conjunctival goblet cells are distributed individually in humans, dogs and rabbits, in 
contrast to clustered organization in mice and rats.51,52 The distribution of goblet cells is overall 
similar in dogs and humans, with high density in the canine third eyelid and human plica 
semilunaris, relatively high density in the conjunctival fornices and palpebral conjunctiva, and 
lower density in the bulbar conjunctiva.30,52-56 In rabbits, the highest density is noted at the lid 
margin of both upper and lower palpebral conjunctivae,57,58 while the density in the bulbar 
conjunctiva is generally higher than in humans (399-1576 cells/mm2 vs. 7-979 cells/mm2).56,59 In 
addition to mucin-secreting goblet cells, the conjunctiva also contains an organized immune 
network termed conjunctiva-associated lymphoid tissue (CALT), a structure that plays a key role 
in protecting the ocular surface by initiating and regulating immune responses.60 The presence of 
lymphoid follicles was confirmed in the conjunctiva of most mammals studied by Chodosh and 
colleagues – including humans, dogs, rabbits – with the exception of mice and rats,61 although a 
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later report detected lymphoid tissue in the nictitating membrane of BALB/c mice.62 At an 
ultrastructural level, specialized M cells are present in the epithelium overlying the conjunctival 
follicles in dogs63 and rabbits,64 similar to humans.65  
Cornea - The anatomy of the cornea is unique to each species with important differences 
in corneal dimensions and ultrastructural features (eg., thickness, collagen arrangement, nerve 
supply).11,38,50,66-70 First, the cornea is generally larger in dogs and rabbits compared to humans, 
while the dimensions are much smaller in mice and rats.41,44,71-77 As such, the relative amount of 
cornea and conjunctiva exposed on the ocular surface varies among species, an anatomical fact 
that has important implications in ocular pharmacology and other research fields; for instance, 
the surface area ratio of conjunctiva to cornea is two times smaller in rabbits (8.6-8.9) than 
humans (17.1), a finding that could largely explain species differences in drug penetration into 
the anterior chamber.50 Second, the corneal thickness varies among mammals and is generally 
correlated to the size of the animal.68 From highest to lowest, the mean central corneal thickness 
is 497-594 µm in dogs,68,78 505-563 µm in humans,79 354-407 µm in rabbits,41,79,80 159-170 µm 
in rats68,80 and 90-137 µm in mice.68,74,80 The average canine cornea is only slightly thicker than 
in humans. In contrast, the thinner cornea in rabbits and rodents can limit the use of these 
laboratory species for selected experiments; for instance, cross-linking is discouraged in corneas 
thinner than 400 µm due to potential damage to the corneal endothelium or intraocular tissues.81  
On a structural level, the main layers of the cornea are the same in humans and animals 
(epithelium, stroma, Descemet membrane, endothelium) with the notable exception of the 
Bowman’s membrane.11,70 Bowman’s membrane is present in nearly all primates (including 
humans) and selected animals (eg., sheep, deer, giraffe),82 but is absent in dogs and common 
laboratory species.68,70,82 The number of layers and overall thickness of the corneal epithelium 
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vary among species: humans (5-7 layers, 44-55 µm),79,83 dogs (6-9 layers, 52-64 µm),70,71,78 
rabbits (5-7 layers, 45-49 µm),38,79,83 rats (10-14 layers, 26-33 µm),84,85 and mice (13 layers, 37-
46 µm).74 The corneal stroma, comprising nearly 90% of the total corneal thickness in most 
mammals, is primarily composed of collagen fibrils arranged in lamellae. While extensive 
collagen intertwining is noted in the majority of the corneal stroma in humans, it is only present 
in the anterior most-aspect of the cornea in dogs and rabbits.86,87 Differences in collagen 
intertwining, along with the absence of Bowman’s membrane in laboratory species, explain the 
vast disparity in stiffness of the anterior stroma (16.2, 1.3 and 1.1 kPa) and posterior stroma (2.5, 
0.5 and 0.4 kPa) in humans, dogs and rabbits, respectively.86,87 The elastic modulus of the cornea 
is reportedly higher in rodents, although the methodology used was different.88,89 Corneal rigidity 
should be considered in comparative studies in which the biophysical attributes of the cornea are 
important (eg., wound healing, keratoprosthesis). The corneal endothelium shares a similar 
morphological blueprint among species (single cell layer, honey-comb pattern), while the 
cellular density varies from 3233 cells/mm2 in rabbits, 2875 cells/mm2 in mice, 2818 cells/mm2 
in dogs, 2732 cells/mm2 in humans, and 2242 cells/mm2 in rats.68,90  
The mammal cornea is the most densely innervated tissue in the body. Corneal nerves 
play important roles to maintain ocular surface health and homeostasis, including sensory 
functions (touch, pain, temperature), release of trophic neuropeptides, maintenance of the limbal 
stem cell niche, and activation of brainstem circuits to promote reflex blinking and lacrimation. 
From highest to lowest, the sensitivity of the cornea to mechanical stimulus is as follows: 
humans (0.2-1.0 g/mm2), rats (0.42-0.47 g/mm2), mice (0.59 g/mm2), dogs (2.16-2.9 g/mm2), and 
rabbits (6.21-10 g/mm2).2,91-95 The murine model is the most extensively studied of all laboratory 
species given gross similarities between mice and humans in corneal sensitivity and nerve 
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architecture.67,96 The canine model is also studied in detail given shared features with humans in 
several spontaneous diseases such as diabetes mellitus, herpetic keratitis, and non-healing 
corneal ulcers;97-100 importantly, investigators should account for the canine breed selected for 
the experiment as corneal sensitivity depends on the dog’s cephalic conformation.95 In regard to 
rabbits, two striking species differences exist: (i) Corneal sensitivity in rabbits is much lower 
than in humans, dogs and rodents;2,92 and (ii) Morphology of the rabbit subbasal plexus is 
unique, with nerve fibers sweeping horizontally across the corneal surface in a temporal-to-nasal 
direction compared to a typical whorl-like or spiraling pattern in other species.67  
 Sclera - Humans have a widely exposed white sclera, a feature that is unique when 
compared to other primate species (Kobayashi, 1997). In contrast, the scleral exposure is 
minimal in dogs and routine laboratory species. The thickness of the sclera also differ among 
species: at the ocular surface (limbal sclera), recorded measurements vary from 0.8 mm in 
dogs,101 0.5 mm in humans,102 0.29 mm in rabbits,103 0.1 mm or less in rats,104 and 0.05-0.06 mm 
in mice.105 
 
Tear film dynamics 
Effective tear dynamics, combined with well-balanced composition of the tear film 
(discussed in the next section), are critical for the maintenance of ocular surface homesostasis 
and physiology. Tear fluid dynamics – or the balance between tear secretion, distribution, 
absorption, evaporation, and drainage – are closely regulated by the lacrimal functional unit. The 
lacrimal functional unit is unique to each species (see aforementioned anatomical differences), 
comprised of secreting glands (orbital, accessory, third eyelid, Harder’s, meibomian), eyelids, 
conjunctival goblet cells, corneo-conjunctival surface, and their interconnecting innervation.106 
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Key physiological parameters provide insight into the complex tear dynamics – highlighted in 
Figure 2 and Table 2 – and are therefore important to account for in translational studies that 
involve the ocular surface: 
• Basal tear turnover rate: Tear turnover rate is considered a global measure of the tear 
dynamics and integrity of the lacrimal functional unit.107,108 The basal tear turnover rate is 
reportedly 13.1-17.5 %/min in humans,109,110 12.1 %/min in dogs,111 6.2-7.1 %/min in 
rabbits112 and 5.2 %/min in mice;113 no information was available in rats. In other words, it 
takes approximately the same time for the tear film to replenish in dogs and humans (~6-8 
min) but the duration is longer in rabbits (~14-16 min) and mice (~20 min). The slow tear 
turnover of rabbits and rodents has important repercussions in translational research, 
including a longer precorneal retention time of instilled eyedrops (see next subsection), or 
exaggeration of ocular surface disease due to delayed clearance of inflammatory mediators 
from the tear film.114  
• Tear volume: The volume of tears on the ocular surface is highest in dogs (65.3 µL),111 
followed by humans (7-12.4 µL),109,115 rabbits (1.9-7.5 µL)112,116 rats (4.6 µL)117 and mice 
(0.06-0.2 µL).113,118 Canine tear volume depends on the subject’s body weight but not the 
dog’s cephalic conformation.111 Differences in study methodology notwithstanding, the 
canine tear volume is approximately 5 to 9-fold larger than in humans. This discrepancy can 
be partly explained by the additional secretory tissue in dogs (third eyelid gland) and the 
larger corneal surface to lubricate in dogs (1.2-2.1 cm2 vs. 1.04-1.3 cm2).50,71,77 The canine 
tear film may also be thicker than in humans (15.1 µm vs. 2.3-11.5 µm), although 
measurements of tear thickness were only obtained in 6 dogs111 and the calculation of tear 
thickness is reportedly highly variable within and between species.119  
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• Spontaneous blink rate: The blink action distributes fresh tears on the ocular surface in a 
uniform layer, promotes secretion of tears from the accessory tear glands, and pumps excess 
tears (or instilled drop) into the nasolacrimal drainage system. Spontaneous blinking is 
triggered by higher centers in response to corneo-conjunctival nerve stimulation, presumably 
due to changes in ocular surface temperature that result from thinning and evaporation of 
unstable tear film.120 The spontaneous blink rate is very similar between dogs (14.2 
blinks/min)121 and humans (8.5-17.6 blinks/min),122-124 although it is lower in rodents (< 5.3 
blinks/min)91,124-126 and much lower in rabbits (0.05-0.19 blinks/min).2,123,127 In other words, 
humans and dogs blink approximately every 4-7 seconds, while mice/rats blink every 11 
seconds (or more) and rabbits only blink every 313-1200 seconds. This large disparity in 
mammals’ blink rate can be explained by species differences in (i) ocular surface sensitivity, 
(ii) tear composition, and (iii) the inherent stability of the animal’s tear fluid. In fact, (i) the 
corneo-conjunctival sensitivity is higher in humans > rodents > dogs >> rabbits, a key 
parameter that is linked to spontaneous blinking as well as reflex secretion of tear 
components from the lacrimal glands, conjunctival goblet cells and meibomian glands;128 (ii) 
tear composition is unique to each species (see next section), for instance large discrepancies 
exist in the tear lipidomic profile of rabbits vs. man;129 and (iii) tear film stability is strongly 
associated with the maximum blink interval, as recently shown in humans.130 Tear stability is 
often measured with the tear film breakup time (TFBUT), defined as the interval between the 
last complete blink and the first appearance of a dry spot in the tear film. Results of TFBUT 
and other tear film diagnostics are summarized in Table 2, with care given to discard or 
highlight values obtained in anesthetized or sedated animals (eg., TFBUT of 29.8 min in 
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sedated rabbits)131 as chemical intervention negatively impacts ocular surface homeostasis 
(ie., abolished blinking, reduced tear secretion). 
 
Importantly, investigators should account for additional parameters (and their species 
differences) in any study that involves topical drug administration. In fact, an eyedrop can be 
considered as a transient ocular irritant – especially if the solution’s pH or osmolarity is different 
than the tear film – thereby stimulating reflex blinking and lacrimation upon contact with the 
ocular surface.132 
• Reflex blinking (or lack thereof): In dogs, a blink occurs immediately after eyedrop 
administration and is responsible for removal of any excess solution onto the periocular skin 
and nasolacrimal drainage system.40 The same is true in humans, in whom an instilled 
eyedrop is partially lost (20-30%) due to reflex blinking and spillage onto the eyelids and 
eyelashes.133 Blinking in response to eyedrop instillation is also reported in mice134 and 
rats.135 In contrast, rabbits rarely blink following eyedrop administration, or do so 
infrequently. In one study, rabbits did not blink for 20-30 minutes after instillation of an 
eyedrop, and this alone could result in overestimating ocular drug exposure by 3-fold if 
findings were to be extrapolated to humans.2  
• Reflex tear turnover rate: Eyedrop administration abruptly increases the volume of fluid in 
the conjunctival sac and ocular surface. The sudden disruption in homeostasis promotes a 
faster nasolacrimal drainage until baseline conditions return. This physiologic response is 
prominent in dogs (50 %/min)111 and humans,109,115 but is minimal in rabbits (6.1-6.9 
%/min).112 In fact, the tear turnover rate in rabbits is mostly unchanged whether a small (1-5 
µL) or large volume (25-50 µL) of eyedrop is instilled on the ocular surface,112 a finding 
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likely related to the poor corneal sensitivity and inexistent/minimal reflex blinking in this 
species.2,92 No available report in mice or rats can be found in the literature. 
• Volumetric capacity of the palpebral fissure: The surface of the canine eye can ‘hold’ on 
average 31.3 µL of fluid,40 nearly identical to the volumetric capacity of the human eye (25-
30 µL)109,136 and the volume of a single ophthalmic drop (35 µL).137 Of note, the volumetric 
capacity of the canine eye is positively correlated with the length of the palpebral fissure,40 
and may be larger in breeds larger than Beagles (eg., German Shepherd dogs).137 The exact 
volumetric capacity of the eye is not reported in laboratory species, but is presumably around 
10-25 µL in rabbits (based on drug quantification in tears at various instilled volumes),112,138 
≤ 5 µL in mice139,140 and ≤ 20 µL in rats.141 
 
Tear film composition 
The tear film is a complex biological fluid containing thousands of compounds of diverse 
structures and functions, including proteins, lipids and mucins, as well as minor constituents such 
as electrolytes, vitamins, and growth factors.36,142 The integrated interactions of these 
constituents are responsible for the promotion of a stable tear film and, ultimately, the 
homeostasis of the ocular surface. Species differences in tear film components are summarized in 
Table 3.  
Proteins – The total protein content is generally similar in dogs (5.2-14.6 mg/mL)143 and 
humans (6.0-11.0 mg/mL),144 although qualitative and quantitative differences exist. 
Specifically, the three major constituents of the human tear proteome (lactoferrin, lysozyme, 
lipocalin)144 are only detected at low levels in dogs,145-150 although the relative abundance of 
other common proteins (eg., lacritin, secretory IgA, serum albumin) is generally similar between 
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the two species. Importantly, homologous proteins have been described in canine tears and may 
play similar functions to their human counterparts – for instance, transferrin is an iron-binding 
protein with similarities to lactoferrin, while major canine allergen is an abundant protein in 
canine tears with similarities to lipocalin.148-150 From a qualitative aspect, a recent in-depth 
proteomic study showed that 25 out of 125 proteins detected in canine tears were common to 
humans.149 In rabbits, Wei et al. found that the total protein content was two-fold higher in 
rabbits compared with humans (20.6 mg/mL vs. 9.4 mg/mL), although the number of different 
proteins detected in tear samples was lower in rabbits.151 Other differences in tear proteins 
among species are summarized in Table 3.  
Mucins – Ocular mucins are large glycoproteins expressed by conjunctival goblet cells, 
the corneal epithelium and the lacrimal gland(s), playing important roles on the ocular surface in 
lubrication, wettability and barrier function.152 The main secretory mucin, MUC5AC, is 
described at large levels on the ocular surface of humans and animals.11,55,152 The expression of 
membrane-associated mucins, however, differs among species. In a recent study by Leonard et 
al., dogs were found to have a very similar pattern of mucin expression to that of humans and 
rhesus macaques, with MUC16 being the most abundant mucin transcript.153 In contrast, the 
rabbit had a unique mucin expression pattern with all mucin transcripts expressed at relatively 
similar levels; as such, the authors concluded that the predictive value of the rabbit as a model in 
ocular surface studies should be called into question.153 In another study, the majority of ocular 
mucins detected in dogs and rabbits were neutral fucosylated glycans, while the ones in humans 
were mainly negatively charged sialylated glycans;154 however, the experiment lysed the ocular 
surface epithelium and could not discriminate between mucins of differing origin.  
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Lipids – In a comprehensive lipidomic study comparing the meibum collected in several 
species, Butovich et al. found that the highest degree of biochemical similarity with humans was 
observed in mice, closely followed by the dog.129 An earlier study by Butovich et al. also 
reported the close resemblance of the tear lipid composition between dogs and humans.155 In 
these 3 species (humans, dogs, mice), the major lipid classes included wax esters, cholesterol 
esters, and o-acyl-ω-hydroxy fatty acids (OAHFA). In contrast, the major lipid classes in rabbit 
tears were DiHL esters (24,25-dihydro--lanosterol esters), diacylated diols, and OAHFA, with 
low to trace amounts of wax and cholesterol esters.129 Such discrepancy between rabbits and 
humans was confirmed in a separate study by Wei et al, who noted significant differences in the 
tear film concentrations of triglycerides (higher in rabbits), free cholesterol (lower in rabbits), 
phosphatidylcholine (higher in rabbits) and phosphatidylethanolamine (higher in rabbits).151 
Taken together, the authors of these two studies argued that the rabbit is too different to serve as 
a valid animal model for humans, at least from a biochemical standpoint. 
 
Tear collection for bioanalytical purposes 
The tear film, a complex body fluid uniquely exposed to both internal and external 
environments, contains numerous endogenous and exogenous molecules (eg., proteins, lipids, 
mucins, xenobiotic) that can be assayed for clinical or research purposes. Topically and 
systemically administered drugs can be quantified in tear fluid to determine the clinical efficacy 
and dosing frequency from fitting of kinetic data.156-160 Multiple ‘omics’ approaches can also be 
utilized for analysis of the tear fluid including proteomics,149,150,161-166 lipidomics129,155,167,168 and 
metabolomics,168 providing valuable information for the development of novel diagnostics and 
therapeutics in ophthalmology, as well as biomarkers identification for various ocular and 
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systemic diseases.169-171 However, collecting tears and obtaining reproducible analytical results 
in ophthalmology is challenging; in particular, the volume of tear fluid is limited (unlike other 
biological fluids, such as blood or urine), and the biochemical profile of a tear sample is 
intimately affected by the collection, storage, extraction, handling, and analytical methods used 
by the investigator. 
In this section, we review the main sampling methods reported in the scientific literature 
and discuss their respective advantages and limitations. Further, based on the authors’ experience 
with dogs in clinical and research settings (board-certified veterinary ophthalmologist [LS] and 
pharmacologist [JPM]), the section provides recommendations specific to canine subjects and 
their use in translational research (Figure 3). 
 
Direct tear sampling  
A microcapillary glass tube (1-10 µL) placed in contact with the inferior lacrimal lake is 
the most commonly reported technique to collect tear fluid. This method directly samples tear 
fluid by capillary action and is extensively described in humans,144,161,166,172-185, dogs,147,150,186-189 
rabbits,183,184,187,190,191 mice,192,193 and rats.147,183,194,195 Other direct techniques (seldom reported) 
involve micropipettes,196 polypropylene tubing147 or polytetrafluoroethylene tubing.172 With 
capillary glass tubes, it is possible to obtain unaltered tear samples by avoiding reflex tearing 
from ocular irritation, especially if the collection is performed by an experienced operator on a 
cooperative patient. The minimal binding of tear compounds to glass is another reported 
advantage of capillary tubes. However, the main limitation of microcapillary collection is the 
long collection time, generally ≥ 5 min174,180,184,185,190,193 – this is particularly true in small 
laboratory animals, with up to 15-30 minutes and 15-60 min required to collect sufficient tear 
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fluid in rabbits184,190 and rodents (mice and rats),193,194 respectively. Another critical limitation of 
direct sampling is the low volume of tear fluid retrieved, generally ≤ 5 µL144,147,166,172,175,177-
179,182,183,185,191-193 – as such, the small sample collected may be grossly insufficient in some 
individuals,144,188 may require excessive dilution that renders the target analyte undetectable,189 
and does not take into account possible losses (eg., transfer, storage) or the need to repeat certain 
assays in duplicates.  
Several strategies can be used to overcome current obstacles with the volume of the tear 
volume; however, each come with its own set of drawbacks (listed in parentheses): (i) Sedate or 
anesthetize the animal to extend collection duration and obtain a larger volume (altered lacrimal 
functional unit and ocular surface homeostasis);147,184,190,192-195 (ii) Pool tear samples from several 
subjects (reduced statistical power and loss of information regarding inter-individual 
variability);161,187,192 (iii) Induce reflex tearing with a stimulant – either physical (eg.. irritation to 
nasal mucosa or cornea), chemical (eg., parenteral pilocarpine or ammonium fumes) or 
physiological (eg., yawn or sneeze reflex) – thereby accelerating tear flow and shortening 
collection time (diluted tear sample, unable to control flow rates);180,193,194,197 (iv) Instill fluid 
(eg., saline) on the ocular surface immediately prior to tear collection, a process called ‘flush’ or 
‘washout’ that yields a larger tear sample in a shorter amount of time (diluted tear sample, non-
standardized instilled volume, non-homogenous mixing of fluid with tears).174,180,192,193,195,197,198 
In particular, the diluting effect of reflex tearing or flush methods may drop the concentration of 
low-abundant compounds below the analytical limit of quantification, and potentially mask 
differences between groups due to reduced variance in tear composition.174,199 A third limitation 
of microcapillary tubes is the technical difficulty associated with the collection method. In fact, 
it is nearly impossible (or very challenging) to avoid reflex lacrimation in a consistent manner, 
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even with cooperative patients and experienced personnel;175,176,180,197,200 for instance, capillary 
tear collection by Markoulli et al. resulted in tear secretion that was approximately 4-fold faster 
than basal tear flow in humans (4.6 vs. 1.2 µL/min, respectively).109,180 Of note, sampling itself 
may act as a stimulant due to environmental factors (air movement, light)200 and the 
stress/anxiety experienced by patients when capillary tubes are used.173,176,179,197 Importantly, the 
technical challenge of capillary tubes is amplified in animals given their uncooperative nature, 
and in any patient with aqueous tear deficiency given the low tear volume; tear sampling can be 
extra slow in these cases, possibly impeded/interrupted if an air bubble or mucinous material 
enters the capillary lumen.185  
Taken together, although direct tear collection remains the preferred method of some 
investigators given the ‘undisturbed’ tear sample retrieved,199 the serious drawbacks listed above 
have prompted a growing number of clinicians and researchers to consider indirect tear sampling 
in humans as suitable alternatives.149,176 It is the authors’ opinion that indirect tear sampling is 
also preferred in dogs, cats and laboratory animals. Ultimately, the patient’s safety and comfort 
during tear collection is paramount and, as suggested by Berta, ‘it is better to use well-controlled 
methods than to try to cause as little irritation as possible’.200  
 
Indirect tear sampling 
Indirect techniques involve tear fluid absorption with either Schirmer tear strips or 
absorbent sponges, followed by extraction of tear compounds by centrifugation and/or solvent 
elution. 
Schirmer tear strips are routinely used to measure tear volume for clinical assessment of 
dry eye disease in humans and veterinary species.165,201-206 The strips are made of Whatman no. 
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41 cellulose filter paper and possess specific characteristics to promote tolerance (5mm width x 
35mm length, 0.22 mm thick, 20-25 µm porosity, foldable extremity for ease of insertion).197,207 
In addition to their conventional use for aqueous tear assessment, Schirmer strips can retrieve 
tear fluid for bioanalytical purposes in humans,144,161,165,166,173,176,208 dogs,143,149,156,159,160,186,209 and 
small laboratory species.191,210,211 For instance, Schirmer strips were used for in-depth 
characterization of proteomics in human162 and canine tears,149 and can also successfully recover 
specific analytes such as cytokines,208,212 clusterin,144 and xenobiotics.156,158-160,191,213  
Absorbent sponges exist in different material types such as cellulose,179,181,214,215 
polyvinyl acetal,143,159,173,181,191,214,216,217 polyester,185,188,217 and polyrurethane.181 A material with 
hydrophilic and hydrophobic properties (eg., polyvinyl acetal, polyurethane)181,214 is generally 
preferred in order to optimize the amount of fluid absorbed and the amount of fluid retrieved 
from the sponge. For tear fluid collection, the sponge is held against the lacrimal lake by the 
operator (to minimize reflex tearing),179,185,188,191,217 or placed beneath the lower eyelid for a 
given period of time.159,181,214 Tear fluid recovered from absorbent sponges can be assayed for 
selected tear compounds, similar to Schirmer strips. 
Indirect tear collection is superior to direct capillary sampling in many aspects, namely: 
(i) Improved tolerance and acceptability by patients;144,176,217,218 (ii) Ease of use and operator 
safety, especially for Schirmer strips, allowing non-specialists to perform the procedure with 
minimal training;176,181,217 and (iii) Larger volume of tears collected in a shorter 
duration.179,181,185,191 Absorbent materials collect tears but can also pick up cellular and 
extracellular ‘debris’, an attribute considered beneficial by some as the sample obtained is more 
representative of the dynamic microenvironment at the ocular surface,219 but also perceived as a 
limitation by others as the fluid retrieved is not ‘pure’ tears.199 On this note, the main limitation 
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of indirect sampling is the ‘invasiveness’ of the technique, at risk of promoting reflex tearing and 
altering the composition of the tear fluid; indeed, several studies showed variable tear 
composition between directly- and indirectly- collected samples, with notable differences in the 
qualitative and quantitative profiles obtained for tear lipids167 and tear proteins.161,166,182,220 
Another important drawback is related to the adsorptive properties of Schirmer strips or 
absorbent sponges, ie. incomplete release of tear compounds following extraction;143,159,207,208,216 
however, the authors believe this limitation can be minimized/controlled with adequate 
precautions (see section 3.3). 
 
Proposed strategy for lachrymal determinations in dogs 
Schirmer strips vs. absorbent sponges – Sponges can rapidly absorb up to 106 µL of tear 
fluid in dogs,214 while the maximum absorptive capacity of Schirmer strips is ~ 31 µL (ie., 35 
mm wetness).221 With sponges, however, the operator can only control the duration of tear 
collection and not the volume of tears soaked up in each individual. The resulting variability in 
tear volume absorbed often translates into large intra- and inter-subject variability in the 
concentration of the compound(s) of interest, as shown for protein content143 and various drugs 
such as doxycycline,159 minocycline,222 voriconazole,223 and ofloxacin.191 On the other hand, the 
ability to control the volume of tears absorbed with Schirmer strips (ie., same mm mark) 
generally improves the reproducibility of the results.143,159,160,224  
As such, the authors prefer (i) absorbent sponges for collecting large volumes of tears in 
canine subjects – ie., for further use as blank tears in bioanalytical assays for example – and (ii) 
Schirmer strips for collecting known amounts of tears in any scenario where reproducibility of 
the data is important (ie., for group comparisons, or follow-up of the same individual over time). 
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Schirmer strips for protein quantification – For consistency purposes, the authors 
recommend the use of dye-free Schirmer tear strips, being consistent with the manufacturer and 
lot number (given the reported variability in absorptive and adsorptive properties among 
Schirmer strips),225,226 as well as the time of collection (eg., morning)176, because of known 
diurnal variability in lacrimal protein composition in humans182,197 and dogs.224 The distal end of 
the Schirmer strips should remain in position (ventrolateral conjunctival fornix) until 20 mm, 25 
mm or 30 mm wetness is reached.160,186,209,221,224 Strip wetness < 20 mm is discouraged given the 
potential ‘concentrating effect’ of the absorbent filter with low tear volumes,143 while complete 
wetness of the strip (35 mm) should be avoided as the total protein content is significantly 
greater with 35 mm compared to 20-30 mm mark,221 likely due to vascular fragility and 
excessive irritation ensued by the prolonged test duration. Importantly, investigators should be 
consistent with the selected mm- mark (strip wetness) within and between patients in order to 
standardize the volume of tears collected among subjects. This strategy provides a lower 
coefficient of variability in tear protein content compared to ophthalmic sponges143 and capillary 
glass tubes224 in dogs, thereby improving the reliability and reproducibility of the data. Tear 
extraction and protein analysis can be done directly after tear collection, or can be postponed to a 
future date as long as Schirmer strips are stored immediately at -80°C and the stability of the 
compound(s) of interest is verified.197 Following tear extraction with centrifugation,143,176,221,224 
elution in solvent,144,149,161,162,186 or a combination of both,208,227 total protein content (TPC) 
should be quantified in order to standardize the amount of sample used for subsequent 
analyses.149,162 The authors’ preferred method is infrared spectroscopy with Direct DetectTM 
(EMD Millipore, Danvers, MA) as the technique utilizes merely 2 µL of tear sample, without 
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any of the drawbacks of colorimetric protein assays (eg., Bradford, Lowry), including variability 
with specific protein composition and potential contamination from the absorbent material.179,228  
Schirmer strips for drug quantification – The following steps should be considered to 
optimize drug quantification in pharmacological studies: 
• Study design: In studies that assess tear film pharmacokinetics following topical drug 
administration, one must consider a potential limitation associated with Schirmer strips 
which remove most of the tear fluid in early collection times, thereby negatively impacting 
the ‘true’ tear concentration at later time points.197 For this reason, the authors recommend to 
conduct pharmacokinetic studies in tears over several days (eg., 10 days for 10 collection 
time points), repeating topical administration each day with a standardized volume and 
limiting the collection to a single time point per day. An alternative is to use a larger sample 
size and randomly allocate each time point to a subset of individuals or eyes (eg., 40 eyes 
with n = 5 eyes for 8 separate time points),156 although this method should account for 
differences between subjects such as greater tear volumes in dogs of larger body weight.111 
Another aspect to consider in the study design is the assessment of drug kinetics in diseased 
eyes, rendering the study results more clinically applicable (see section 4.2); in fact, tear film 
concentrations and ocular bioavailability are likely to differ in healthy vs. diseased eyes (eg., 
excessive lacrimation, increased absorption into congested conjunctival vessels, albumin 
binding),160,229 yet the majority of ocular studies to date are conducted in healthy individuals 
which is a clear limitation for translation of research findings from bench to bedside. 
• Tear collection with Schirmer strips: It is important to homogenize the volume collected 
within and between subjects by standardizing the extent of strip wetness (≥ 20 mm mark) – 
this approach limits the variability in tear concentrations related to the collection method 
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itself.159,160 The amount of wetness is then converted to a volume (µL) in order to calculate 
actual tear film concentrations;221 data reporting is otherwise limited to µg/g of strip.156,191 In 
dogs, the median volume absorbed by Schirmer strips is 18 µL (20 mm), 22 µL (25 mm), 26 
µL (30 mm) and 31 µL (35 mm), information obtained from hundreds of in vivo collections 
with pre- and post- weighing of Schirmer strips).221 This method is preferred over in vitro use 
of phosphate buffered saline208 given differences in fluid viscosities and the inability of an in 
vitro experiment to mimic the complex dynamics of tear absorption noted in vivo (eg., rapid 
initial uptake,204 tear evaporation). In parallel, investigators should record the duration of tear 
collection (eg., 50 seconds to reach 20 mm) in order to calculate a flow rate (µL/min) for 
each sample obtained.159,180 In one of our experiments with doxycycline in dogs, flow rate 
did not influence tear concentrations,159 but this finding might not be generalizable to other 
drugs and/or other species of interest. 
• Extraction protocol optimization: A drug can be extracted from Schirmer strips via 
centrifugation, solvent elution, or a combination of both methods. However, a single 
extraction protocol cannot be generalized to all pharmacological studies as the specific 
physicochemical properties of each drug (eg., molecular weight, lipophilicity) can affect the 
extraction efficiency from the filter papers.207 As such, investigators should consider 
conducting a preliminary experiment to determine the optimal extraction protocol for the 
drug studied, and report specific recovery rates (mean ± standard, range). For instance, the 
recovery of prednisone and prednisolone was maximized with a combination of 
centrifugation and elution in methyl tert-butyl ether, a solvent chosen over methanol and 
acetonitrile based on superior drug extraction from Schirmer strips (Figure 4).160 Of note, a 
comprehensive review of all reported protocols is beyond the scope of the present work, and 
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further research is warranted to assess the potential benefits (or lack thereof) of extraction 
steps reported in the literature, such as cutting Schirmer strips into small pieces162,165,213 or 
using ultrasonic agitation.160,165,197 Ultimately, an optimized extraction protocol is important 
as it enhances the reliability of the data at hand, improving the sensitivity of the bioassay, and 
providing drug concentrations closer to ‘true’ biological levels in the tear film.  
• Bioanalytical method optimization: First, internal standard should be applied directly onto 
the dry portion of the Schirmer strip (Figure 4),160 ie. before tear extraction instead of post-
elution with solvent as routinely described;156,213 this step allows for drug quantification to 
account for potential variability in extraction efficiency between samples. Second, the 
standard calibration curve solutions should be constructed by spiking known drug 
concentrations and internal standard onto Schirmer strips, followed by the same extraction 
protocol as for biological samples; this step is equivalent to ‘spike and recover’ experiments 
recommended for other analytes such as cytokines216 and proteins.207 Third, actual tear fluid 
should be used whenever possible as the selected matrix for standard calibration curve and 
quality control solutions,159,160,223 as the reported surrogates (eg., artificial tear solution)230 do 
not account for chemical interferences and matrix effects that typically occur with a complex 
biological fluid (eg., ionization suppression).223 Blank tears can be collected with absorbent 
materials prior to study initiation, retrieving up to 84 µL in 1 min with ophthalmic sponges in 
dogs214 and 132 µL in 12 min with successive substitutions of polyurethane mini-sponges in 
humans.181 
 
Spontaneous and experimental models of ocular surface disorders in dogs 
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Spontaneous ocular surface diseases in dogs with translational applications to humans 
Spontaneous ocular surface disorders are common in dogs and represent one of the major 
causes for referral visits to veterinary practitionners.231 In contrast, naturally-acquired ocular 
surface pathology is much less common in rabbits232,233 and is rare in mice and rats.234-23 
 
Keratoconjunctivitis sicca 
Keratoconjunctivitis sicca (KCS), or ‘dry eye’, represents one of the most common ocular 
diseases in humans with an estimated prevalence ranging from 5 to 50% in different regions 
worldwide.237 The disease is also very common in dogs (prevalence 1.5 to 35%),231 although not 
a single report of spontaneous KCS case exists in laboratory animals such as rabbits, mice and 
rats.  
The pathogenesis of KCS is very complex, involving diverse physio-anatomical factors 
such as lacrimal gland integrity, meibomian glands function, hormonal balance and neuronal 
input.237 Numerous models of dry eye have been established in animals over the years,238-240 
helping to elucidate complex pathological mechanisms involved in KCS and develop novel 
therapeutics for humans. However, the major drawbacks of most animal models are the acute 
nature of the induced pathology (vs. chronic disease in humans) and the focus on a single 
component of the lacrimal functional unit, such as surgically removing the lacrimal gland in 
mice to reduce tear secretion,32 cauterizing the lid margin in rats to induce meibomian gland 
dysfunction,241 or instilling topical 1% atropine in rabbits to disrupt the efferent neural input.242 
These experimental models can be generally improved by increasing the number of interventions 
in the study animals, for instance combining lacrimal glands removal with chemical destruction 
of the conjunctiva in rabbits,243 or combining scopolamine administration with desiccating 
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environmental stress in mice; yet, these complex models remain suboptimal at best given the 
acute nature and the inability to fully encompass the complexity of KCS pathophysiology.244 
Dogs, on the other hand, develop KCS in a spontaneous manner and do not require invasive 
procedures to disrupt the lacrimal functional unit.201,205 Most importantly, the disease is clinically 
and immunopathologically similar to dry eye in humans, and possesses several attributes that are 
beneficial for translational research: 
• Canine KCS is typically bilateral, develops in middle-aged animals, is more common in 
female dogs and in certain breeds (eg., American Cocker spaniel, English Bulldog), 
mimicking the diversity of dry eye in humans related to sex and race.201,237 
• Immune-mediated dacryoadenitis is the most common etiology of KCS in dogs – similar to 
human patients with Sjögren’s syndrome – in which progressive lymphocytic infiltration of 
the lacrimal gland(s) damages the secretory tissues and reduces aqueous tear production.201 
• Meibomian gland dysfunction is recognized in many canine patients with ocular surface 
disorders, affecting tear film stability in a similar manner than evaporative dry eye in human 
patients.245  
• Spontaneous symptoms of ocular irritation, conjunctival hyperemia and corneal scarring 
correlate directly with aqueous tear production, a parameter that is easily 
measured/quantified using a standard Schirmer tear test strip. 
• Multiple diagnostic tools used in humans can easily be applied in dogs (but not rodents) 
given the large size of the canine globe,205,239 including tear osmometry, vital staining, strip 
meniscometry test, infrared meibography and corneo-conjunctival impression cytology. 
• Dogs and humans display a similar responses to common therapeutics for dry eye disease; in 
fact, the two FDA approved anti-inflammatory drugs for dry eye disease in humans 
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(cyclosporine, lifitegrast) were first developed in canine patients with spontaneous 
KCS.201,246 
The main limitation to consider in dogs is the tendency for clinical signs to be more 
pronounced in that species vs. humans (eg., tenacious mucoid discharge, corneal melanosis, 
neovascularization), in part because canine KCS is often diagnosed at a later stage when owners 
fail to recognize more subtle clinical signs early on. 
 
Allergic conjunctivitis  
Allergic conjunctivitis is a common disorder in humans with an approximate prevalence 
of 40% in the North American population.247 The disease is characterized by an 
immunopathological reaction of the ocular surface to the external environment, resulting in 
clinical symptoms that range from mild conjunctivitis (seasonal or perennial) to the more severe, 
vision-threatening vernal keratoconjunctivitis and atopic keratoconjunctivitis.247 Over the past 
few decades, extensive research on small laboratory species (mice, rats, guinea pigs) has helped 
elucidate some of the complex molecular and cellular processes involved in the pathogenesis of 
ocular allergies.248,249 However, these experiments primarily relied on a relatively small selection 
of allergens (eg., ovalbumin, compound 48/80, ragweed pollen), using an experimental design 
that merely mimics acute forms of the disease – not chronic allergen exposure over months to 
years – therefore limiting the long-term clinical significance of these findings. On the other hand, 
dogs possess notable benefits for the comparative study of allergic conjunctivitis, especially 
when considering companion animals rather than laboratory Beagles: (i) these animals share the 
same environment (and related allergens) as their human owners, unlike commonly used species 
who are housed in a laboratory setting; (ii) companion dogs are outbred, providing a genetic 
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diversity background that better reflects the human population than inbred laboratory species; 
and (iii) dogs develop a spontaneous form of allergic conjunctivitis. Spontaneous allergic 
conjunctivitis is relatively common in dogs, often associated with other allergic disorders such as 
canine atopic dermatitis.250 Similar to humans, the clinical signs of allergic conjunctivitis involve 
conjunctival hyperemia, chemosis, pruritus and ocular discharge, the disease can be diagnosed 
with high sensitivity and specificity using the conjunctival provocation test,250 and similar 
therapeutics are used in both species including topical antihistamines, mast-cell stabilizers, 
NSAIDs and immunomodulators.247 
 
Microbial keratitis 
It is well recognized that a natural host is best suited for studying infection, as several 
species-specific factors (eg., anatomical, physiological, genetic, immune) closely influence the 
host-pathogen interactions and subsequent clinical response.251 These factors likely explain why 
rabbits and rodents – traditionally used to model ocular surface infections in humans – cannot 
fully recapitulate the disease presentation and progression that occur in human patients.252,253 As 
such, there is an emerging appreciation for the translational advantage of studying spontaneous 
(and not experimental) ocular infections in dogs:  
• Herpetic keratitis: Recent work has highlighted the robustness and reproducibility of the 
canine model to study ocular herpesvirus infections and disease,253,254 showing striking 
similarities in the pathogenesis of canine herpesvirus-1 and herpes simplex virus-1, both 
members of the alphaherpesvirinae subfamily with a seroprevalence of 21-98% in dogs 
(CHV-1) and 67-90% in humans (HSV-1).253 
159 
 
 
 
• Bacterial keratitis: The most common bacterial genera isolated from canine patients overlap 
with the ones recognized in human patients (Staphylococcus, Streptococcus, 
Pseudomonoas).255,256 In fact, the major culprit in canine bacterial keratitis (Staphylococcus 
pseudintermedius) is now considered an emerging zoonosis in humans.257 
 
Others 
Dogs can serve as models for other ocular surface diseases such as corneal endothelial 
dystrophy (analogous to Fuch’s dystrophy in humans),258 limbal stem cell deficiency,259 ocular 
surface squamous neoplasia260 and neurotrophic keratopathy,261 among others. 
 
Breakdown of the blood-tear barrier in dogs: A model for ocular pharmacology and 
therapeutics 
 
Histamine-induced conjunctivitis  
To date, the vast majority of preclinical ocular studies for evaluation of candidate drug 
efficacy and safety are conducted in healthy eyes – in part for simplicity, but at a higher risk of 
treatment failure rate when translating these findings to clinical studies. Indeed, healthy eyes do 
not account for the disruption of ocular homeostasis that occurs with inflammatory diseases, 
including (but not limited to) changes in tear film dynamics, tear composition and permeability 
of ocular tissues. To address this shortcoming, the authors have recently established a robust in 
vivo model of conjunctivitis in dogs, a translational large animal model that provides a unique 
opportunity for scientists to investigate the ocular surface in health and disease states.212 The 
model specifically focused on conjunctivitis as this condition is frequently encountered in 
humans and dogs,262,263 developing either as a primary condition (eg., bacterial, viral), or as a 
bystander to common ophthalmic diseases such as blepharitis, keratitis, uveitis and glaucoma. 
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This model is particularly appealing given the low cost, non-invasiveness, self-resolving nature, 
ability to adjust the duration and severity of the disease, and shared features with naturally 
occurring diseases in human and veterinary medicine. The main highlights of the translational 
‘large animal’ model are as follows: 
• The selected compound (histamine) is inexpensive and triggers local inflammation in a non-
specific manner. 
• Disease severity is dose-dependent, allowing investigators to induce mild (1 mg/ml), 
moderate (10 mg/ml) or severe (375 mg/ml) conjunctivitis (Figure 5). 
• Disease duration is dose-dependent, self-resolving within an average of 115 min (1 mg/ml), 
190 min (10 mg/ml) or 390 min (375 mg/ml). The duration of conjunctivitis can be 
lengthened by repeating topical histamine administration at set intervals.160  
• Topical histamine is safe and generally well-tolerated, although selected eyes receiving the 
highest dose of histamine (375 mg/ml) can develop mild ocular irritation (lasting < 1 min), 
blepharitis or miosis. 
• Tear film composition changes in eyes with experimentally-induced conjunctivitis (eg., 
higher levels of serum albumin and inflammatory cytokines), mimicking clinical patients 
with ocular surface inflammation. 
• A transient increase in tear quantity and decrease in tear quality occur, although tear film 
homeostasis is rapidly restored in ≤ 5 min.264  
Levels of serum albumin are increased in tear film of canine eyes with experimentally-
induced or naturally-acquired conjunctivitis,212,224 a physiological variation caused by the 
breakdown of the blood-tear barrier (Figure 6). Disruption of the blood-tear barrier is also 
described in human patients with spontaneous ocular surface disorders (eg., dry eye, allergic 
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conjunctivitis)182,265-267 and other animal species (rabbits, horses, guinea pigs).268-270 Increased 
vascular permeability and disruption of tight junctions between conjunctival epithelial cells 
likely play a role (Figure 6),271,272 although the exact etiopathogenesis is unknown and require 
further investigation. A few noteworthy limitations are listed here: (i) the model is not adequate 
to study ocular allergy given the lack of characteristic features noted in canine patients with 
allergies (eg., follicular conjunctivitis); (ii) pro-inflammatory mediators other than histamine are 
also responsible for triggering conjunctival inflammation in clinical patients (eg., leukotrienes, 
cytokines); (iii) conjunctival inflammation is relatively short-lived (115-390 min) and cannot 
mimic the physiological changes noted in patients with chronic conjunctivitis (eg., reduced 
goblet cell density).  
 
Clinical relevance of serum albumin leakage in tear film 
Elevated serum albumin levels in the tear film represents a biomarker for ocular insult or 
inflammation in humans, dogs and other species.182,212,265,270 In brief, plasma-derived albumin 
leaks onto the ocular surface from congested conjunctival vessels and mixes with the tear film; 
as such, albumin concentration in tears is generally low in healthy state but increases 
substantially in diseased eyes.182 For instance, a recent study showed that canine eyes with 
diverse ocular diseases (eg., corneal ulcer, uveitis, glaucoma) had lacrimal albumin levels that 
were up to 14.9-fold greater than contralateral healthy eyes.212 Albumin is a relatively large 
protein that has a remarkable capacity for binding ligands.273 At the level of the eye, protein 
binding represents an important restriction to drug absorption as only the unbound fraction of the 
drug diffuses across the ocular tissue barriers.268 Combined with the rapid drainage of tears 
following eyedrop administration (in humans/dogs, not true in rabbits), any portion of drug that 
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binds to albumin in tear film can be considered as ‘lost’ from a pharmacological standpoint. 
Broader implications of the blood-tear barrier breakdown on ocular drug pharmacokinetics are 
listed below: 
• Reduced bioavailability for intraocular targets: The inability of bound therapeutic drugs 
to penetrate the cornea lowers the amount of drug available inside the eye to exert its 
pharmacological action. The physiological effects of increased albumin levels in tears was 
recently demonstrated with tropicamide (and to a lesser extent latanoprost) in dogs,229 as well 
as pilocarpine in rabbits.268 Of note, the impact of lacrimal albumin on the pharmacological 
activity of a given drug is likely modulated by various factors, the concentration of the 
formulation, the mechanism of action and the potency of the drug for its biological target.229  
• Reduced bioavailability for ocular surface targets: Drug-albumin interactions in the tear 
film could also be detrimental for management of ocular surface disorders, for instance 
reducing the efficacy of therapeutics for bacterial keratitis as only the unbound portion of an 
antibiotic is microbiologically active.274 Preliminary experiments conducted by the authors 
showed that the presence of albumin results in higher minimal inhibitory concentrations (ie., 
reduced susceptibility) for various antibiotics against common bacterial isolates in dogs (in-
house unpublished data).  
• Tear film concentrations of systemically administered drugs: Drug in the plasma 
compartment can access the tear film by active secretion from the lacrimal gland, or passive 
diffusion through the conjunctival vessels. The latter is theoretically enhanced when the 
blood-tear barrier is disrupted. In humans, this physiological feature could explain why the 
concentration-time profiles of cetirizine were similar in serum and tears in patients with 
allergic conjunctivitis.157 In dogs, tear film corticosteroid levels were generally higher in 
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conjunctivitis vs. control eyes following oral prednisone administration (up to +64%), 
although differences were not statistically significant.160 The degree of conjunctival 
permeation is likely to vary among therapeutic drugs given differences in their physico-
chemical properties.275,276 
These findings highlight the importance of conducting pharmacological studies in 
clinically relevant preclinical species that are able to recapitulate leaky conjunctival vessels and 
elevated albumin levels in the tear film of clinical patients with ocular diseases. For topical drug 
administration, the authors recommend using an experimental model of blood-tear barrier 
breakdown (eg., histamine-induced conjunctivitis or alkali burn models)212,277 so that albumin 
and other relevant proteins are already present on the ocular surface at the time the drug mixes 
with the tear film.229 For systemic drug administration, the authors suggest conducting a 
preliminary experiment to assess whether conjunctival inflammation affects tear film 
concentrations to a significant extent. If not, pharmacological assessment in healthy eyes should 
be sufficient. Incidentally, the physico-chemical properties of some drugs (eg., size, lipophilicity, 
polar surface area)275,276 may allow for high conjunctival permeation under normal conditions, 
thereby rendering differences between healthy vs. diseased eyes insignificant. 
 
Corneal injury in dogs: in vivo and ex vivo models 
Corneal injury is common in human and veterinary patients – whether due to trauma, 
surgery, or other causes – and the resulting corneal scar remains one of the leading causes of 
blindness in animals and people worldwide.278 Although small laboratory animal species are 
commonly used in corneal scarring research,279 results derived from these models have several 
limitations. The corneal thickness is much smaller in rabbits and rodents compared to humans 
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(Table 1). In addition to thin corneas, mice and rats have corneas that are much smaller in 
diameter compared to people; consequently, it is often difficult to isolate the central cornea when 
performing the experimental procedure (eg., chemical burn) and the damage caused to 
surrounding limbal stem cells negatively impacts the wound healing process. Using the dog as an 
animal model is therefore more appropriate, not only due to closer resemblances in ocular 
surface anatomy and physiology with humans, but also the relatively high prevalence of 
naturally-acquired corneal pathology in the canine species. In that regard, Gronkiewicz et al. 
recently developed a novel in vivo corneal fibrosis model in canines;277 the authors induced 
corneal scarring with an alkali burn and investigated the ability of suberanilohydroxamic acid 
(SAHA) to inhibit fibrosis using this large animal model. The availability of such a model 
presents a clear opportunity for translational research (ie., intact innervation, tear film, blood supply), 
although experimentally-induced corneal wounding (at risk of secondary infection) and subsequent 
corneal scar in dogs represent potential ethical challenges. As an alternative, other authors have 
established ex vivo canine corneal cultures that can be used to model wound healing and assess anti-
fibrotic compounds,280-282 or better understand the pathophysiology of herpesvirus in a virus-natural-host 
environment;283 in that study, the authors established an air-liquid canine corneal organ culture model to 
study acute herpetic keratitis, showing important similarities in the response to CHV-1 to what has been 
described for HSV-1.283 
 
Conclusions 
“Considerable reservations may be felt about comparing results from rabbits with those 
from humans because of the differences between the physiology of tear flow and mixing and 
general anatomy. Nevertheless, the rabbit is the principal experimental animal in ophthalmology, 
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so comparisons are needed”.284 Sadly, this quote published over 45 years ago is still 
representative of today’s state of ophthalmic research. Rabbits and small laboratory rodents 
continue to be used primarily (if not exclusively) in most areas of ophthalmic research,1 a 
concerning fact given the vast anatomical and physiological differences that exist with humans. 
Of note, such differences should not be regarded as merely ‘weaknesses’ for translational 
research, but rather evolutionary adaptations optimally suited to the environment and behavior of 
each species; for instance, rabbits likely developed a very stable tear film to limit intermittent 
blindness that occurs with each blink,285 thereby reducing the risk of predation. Noteworthily, 
recent innovations have helped mitigate some of the drawbacks of traditional laboratory species 
– for instance providing manual blinking and supplementary tear flow in anesthetized rabbits,286 
or reverse engineering the ocular surface using human cells in vitro287 – however the authors 
believe the complexity of the ocular surface and integrated lacrimal functional unit cannot be 
fully recreated without in vivo conditions in awake subjects. 
The comparative work presented throughout this review provides evidence that dogs are 
best suited for translational research in ophthalmology. Unlike small laboratory animals, dogs 
share similar anatomical and physiological features to humans, similar environmental stressors 
and genetic variation, and a range of naturally occurring ophthalmic diseases that closely 
resemble clinical phenotypes in human patients. The resemblance between dogs and humans is 
particularly relevant in the field of ocular pharmacology, with notable similarities in blink rate, 
tear turnover rate (basal, reflex), volumetric capacity of the palpebral fissure, and other factors 
pertinent to drug diffusion (eg., globe volume, corneal thickness); nonetheless, a few differences 
should be accounted for in comparative studies, such as the presence of a nictitating membrane, 
greater tear volume, larger corneal size and lower corneal elastic modulus in dogs. Similar to 
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other fields of medicine, preclinical studies in ophthalmology could involve canine patients with 
spontaneous ocular diseases – many of which share striking resemblances with their human 
counterparts – integrating the expertise of veterinarians, physicians and basic science researchers 
under the umbrella of the One Health Initiative.6,288 Alternatively, or complementarily, 
preclinical animal work could be performed in laboratory dogs in whom ocular disease is 
experimentally-induced, making sure to account for the blood-tear barrier breakdown (noted in 
clinical patients with ‘red eyes’). In all cases, tear fluid can be easily collected from canine eyes 
for various bioanalytical purposes, favoring Schirmer tear strips over other collection methods 
given the excellent safety profile and enhanced reliability in analyte quantification (eg., proteins, 
drugs) provided by this method. 
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Tables and Figures 
 
Table 1. Comparative anatomy of the ocular surface and globe between humans, dogs and common laboratory species used in 
preclinical ophthalmic research. 
  Human Dog Rabbit Mouse Rat 
Lacrimal 
glands and 
nasolacrimal 
apparatus 
Lacrimal glands 
 
Lacrimal gland 
Accessory glands 
of Wolfring and 
Krause  
20 
Lacrimal gland, 
Third eyelid gland  
11,14 
Lacrimal gland, 
Third eyelid gland, 
Infraorbital 
(intraorbital), 
Accessory glands of 
Wolfring  
10,11,22,23 
Infraorbital 
(extraorbital) 10,11,22 
Infraorbital 
(extraorbital) 10,11,22 
Lacrimal glands 
volume (cm3) † 
0.59-0.61  
18 
0.14 / 0.1  
17 
– / 1.5  
289 
– – 
Harderian gland 
Absent  
22 
Absent  
11,16 
Present  
11,22 
Present  
11,22 
Present  
11,22 
Nasolacrimal drainage 
apparatus 
Two 
puncta/canaliculi, 
no flexure  
25,27 
Two 
puncta/canaliculi, 1 
dorsal flexure  
16,25,27  
Single 
punctum/canaliculus, 
two pronounced 
flexures  
27,38,41 
Two 
puncta/canaliculi  
25 
Two 
puncta/canaliculi  
25 
Eyelids 
Third eyelid 
Absent  
66 
Present  
16,66 
Present  
66 
Present  
66 
Present  
66 
Palpebral fissure 
width (mm) 
21.3-34.5  
290 
18.9-34.1  
40,291 
10-16  
38,41,42 
3.7-5 ‡ 
43 
6-9  
45 
Interpalpebral fissure 
area (cm2) 
1.8 39 
2.2 § 
290 
1.4  
39 
0.13 ‡ 
43 
0.5 ¶ 
45 
Meibomian glands 
(/eyelid) 
20-40  
39,292 
20-40  
16 
30-50  
38,39,41 
20  
293 
20-30 # 
241 
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Table 1 Continued 
  Human Dog Rabbit Mouse Rat 
Conjunctiva 
Conjunctival fornix 
depth (mm) †† 
15  
49 
– 
20.36  
48 
– – 
Conjunctival surface 
(cm2) 
17.65  
50 
– 
13.3-18.48 ‡‡ 
50 
– – 
Conjunctiva/Cornea 
surface ratio 
17.17  
50 
– 
8.62-8.94  
50 
– – 
Goblet cell spatial 
configuration 
Individual  
51 
Individual  
52 
Individual  
51 
Clusters  
51 
Clusters  
51 
Goblet cell 
distribution 
Highest in plica 
semilunaris and 
lower nasal fornix 
Low in bulbar 
conjunctiva 
30,53,54,56 
Highest in third 
eyelid and lower 
nasal fornix 
Low in bulbar 
conjunctiva 
52,55 
Highest in palpebral 
conjunctiva 
Relatively dense in 
bulbar conjunctiva 
57-59 
– 
Highest in fornix 
Low in bulbar 
conjunctiva 
Kim 2019 
Conjunctiva-
associated lymphoid 
tissue 
Present  
61 
Present  
16,61 
Present  
61 
Only present in 
nictitating 
membrane  
61,62 
Absent  
61 
Cornea 
and 
Sclera 
Corneal diameter, 
horizontal/vertical 
(mm) 
11.8 / 11.2 
75,77 
13-17 / 12-16 
71,77 
13.4-15 / 13-14 
41,76,77 
2.3-2.6 / – 
74 
2.0-6.8 / 2.0-6.7 
44,72,73 
Corneal surface (cm2) 
1.04-1.3 
50 
1.2-2.1 
71,77 
1.55-2.03 
50 
0.04-0.05 h 
74 
0.27-0.36 §§ 
72,73 
Corneal thickness 
(µm) 
505-563 
79 
497-594 
68,78 
354-407 
41,76,79,80 
90-137 
11,74,80 
159-170 
68,80 
Corneal epithelial 
thickness (µm) 
44-55 
79 
52-64 
71,78 
45-49 
79 
37-46 
74 
26-33 
85 
Endothelial cell 
density (cells/mm2) 
2732 
90 
2818 
68 
3233 
68 
2875 
68 
2242 
68 
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Table 1 Continued 
 
  Human Dog Rabbit Mouse Rat 
 
Subbasal nerve plexus 
pattern 
Whorl-like 
67 
Whorl-like 
67 
Horizontal 
67 
Whorl-like 
67 
Whorl-like 
67 
Corneal sensitivity 
(g/mm2) 
0.2-1.0 
2 
2.16-2.9 
92,95  
6.21-10 
2,92 
0.59 
93 
0.42-0.47 
91,94 
Stiffness/elastic 
modulus (kPa) ¶¶ 
16.2-33.1 
87,294 
1.3 
87 
1.1 
86 
25-40 
89 
6.2 
88 
Scleral thickness at 
the limbus (mm) 
0.50 
102 
0.80 
101 
0.29 
103 
0.05-0.06 
105 
< 0.1 
104 
Globe 
Globe volume (mL) 
5.7-6.0 
295 
5.0-5.8 
296 
2.3-2.9 
296 
0.014 j 
297 
  0.13 ## 
72 
Anterior chamber 
(mL) 
0.17-0.31 
66,77 
0.77 
101 
0.28-0.30 
41,66,77 
0.0044-0.007 
11,66,77 
0.0136-0.015 
11,66,77 
Vitreous chamber 
(mL) 
3.5-5.4 
65 
1.7-3.0 
101,296 
1.1-1.8 
66,296 
0.0053 
11,65 
0.013-0.054 
11 ,65 
 
– Information not available or not found  
† Lacrimal gland (human), Lacrimal gland / TEL gland (dog), Lacrimal gland / Harderian gland (rabbit) 
‡ Estimated based on clinical images43  
§ Estimated based on clinical images40  
¶ Calculated based on average palpebral fissure length45  
# Estimated based on clinical images241  
†† Central upper conjunctival sac (from fornix to lid margin) 
‡‡ Does not account for the nictitating membrane, surgically removed prior to the experiment 
§§ Estimated from corneal radius, assuming a circular shape for the cornea in rodents72 
¶¶ Whole cornea in rats, epithelium and anterior stroma in other species 
## Estimated from axial length, assuming a spherical shape for the globe 
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Table 2. Comparative physiology and characteristics of the ocular surface and tear film between humans, dogs and common 
laboratory species used in preclinical ophthalmic research. 
 
  Human Dog Rabbit Mouse Rat 
Ocular surface 
physiology 
Blink rate (blinks/min) 
 
8.5-17.6 
122-124 
14.2 
121 
0.05-0.19 
2,123,127 
0-4 
125,126 
2-5.3 
91,124 
Volumetric capacity of 
the palpebral fissure 
(µL) 
25-30 
109,136 
31.3 
40 
10-25 † 
112,138 
≤ 5 
139,140 
≤ 20 
141 
Ocular surface 
temperature (°C) 
32.8-37.1 
298,299 
35.2 
300 
39.1 
298 
37.2 
298 
36.5 
298 
Tear film 
characteristics 
Tear film thickness 
(µm) 
2.3-11.5 ‡ 
119 
15.1 
111 
6.5-18.4 
119 
7.4-21.1 
119,301 
2-12.6 
119,302 
Lipid layer thickness 
(nm) 
62-78 
123,303 
13-581 
121 
> 180 
123 – 
12 
301 
Tear volume 
(µL) 
7-12.4 
109,115 
65.3 
111 
1.9-7.5 
112,116 
 
0.06-0.2 
113,118 
4.6 
117 
Basal tear turnover rate 
(%/min) 
13.1-17.5 
109,110 
12.1 
111 
6.2-7.1 
112 
5.2 
113 – 
Reflex tear turnover rate 
(%/min) 
31.5-100 
109,115 
50 
111 
6.1-6.9 § 
112 
– 
 
– 
 
Evaporative rate 
(µm/min) 
3.22 
304 
– 
0.47 
127 – – 
Tear film 
diagnostics ¶ 
Schirmer tear test-1 
(mm) # 
10.0-18.6 
305,306 
18.1-24.3 
13,52,95,205,307,308 
4.6-7.6 
42,116,309 – 
5.6-9.4 
91,241 
Phenol red thread test 
(mm/15s) 
9-20 
310 
17.5-39.2 
95,205,307,308 
20.9-25.0 
42,309 
2.8-11.2 
125,244,311 
7.6 
312 
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Table 2 Continued 
  Human Dog Rabbit Mouse Rat 
 
Tear film breakup time 
(sec) 
7.4-13.0 
305,306 
13.9-24.0 
13,52,205,307 
2-1788 †† 
313 
5-25 
125,129 
5.2-6.0 
241 
Tear osmolarity ‡‡ 
(mOsm/L) 
300.8 
202 
337.4-339.0 
205,314 
291.3 
315 
346.3-366.8 
310 
284.8 
312 
Tear pH 
7.83 
316 
8.05 
215 
8.2 
316 
7.59 
317 
– 
 
– Information not available or not found  
† Based on greater percent of drug lost at 1 min in rabbit eyes receiving 25 or 50 µL eyedrop vs. 5 or 10 µL eyedrop,138 despite no 
changes in tear turnover rate for instilled volumes up to 50 µL112  
‡ Excludes an outlier measurement of 41-46 µm318  
§ Estimated from rabbit eyes receiving a large volume instilled eyedrop (25-50 µL) 
¶ Reported values prioritized studies that did not use sedation or general anesthesia 
# Values reported in mm/5min (humans) or mm/min (all other species) 
†† Large variability in studies’ methodology, most using topical and/or general anesthesia prior to testing, resulting in non-physiologic 
and highly variable measurements for tear film break up time 
‡‡ Measurements obtained with the same device (TearLabTM, OcuSense Inc., San Diego, CA) 
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Table 3. Comparative composition of the major components in tear film between humans, dogs and common laboratory species used 
in preclinical ophthalmic research. 
 
  Human Dog Rabbit Mouse Rat 
Proteins 
 
Lactoferrin † 
Abundant 
144,147 
Low 
146,147 
Low 
319,320 
Low 
147 
Low 
147 
Lysozyme 
Abundant 
144,147 
Low 
145,146 
Low 
190,319 
Low 
147 
Low 
147 
Lipocalin ‡ 
Abundant 
144,147,148 
Low 
to moderate 
146,147,149,150 
Low 
147,148,319,321 
Low 
147,198 
Absent 
147,148 
Lacritin 
Moderate 
144 
Moderate 
322 – 
Absent 
198 
Present 
323 
Secretory IgA 
Moderate 
144 
Moderate 
146,324,325 
Present 
22 
Low 
11 
Moderate 
326 
Serum albumin 
Low 
182 
Low 
146,150,212 
Low 
190,319 
Present 
198 – 
Peroxidase 
Low 
327 
Low 
146,325 
Absent 
190 
– 
Abundant 
194  
Amylase 
Low 
327 – 
Absent 
190 
– 
Low 
194 
Mucins 
 
MUC5AC 
Present 
11 
Present 
11,55 
Present 
11 
Present 
11 
Present 
11 
MUC1, MUC4, 
MUC16 
MUC16 >> MUC1 
> MUC4 
153 
MUC16 >> MUC1 > 
MUC4 
153 
MUC1 ≈ MUC4 ≈ 
MUC16 
153 
Present 
328 
Present 
329 
Major O-glycans 
Sialylated glycans 
154 
Fucosylated glycans 
154 
Fucosylated glycans 
154 – – 
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Table 3 Continued 
 
  Human Dog Rabbit Mouse Rat 
Lipids 
 
Wax esters 
Abundant 
129,155 
Abundant 
129,155 
Low 
129 
Abundant 
129 
Present 
330 
Cholesterol 
Low 
129,155 
Low 
129,155 
Low 
129 
Low 
129 
Abundant 
330 
Cholesteryl esters 
Abundant 
129,155 
Abundant 
129,155 
Low 
129 
Abundant 
129 
– 
DiHL 
Low 
129,155 
Low 
129,155 
Low 
129 
Low 
129 
– 
DiHL esters 
Low 
129,155 
Low 
129,155 
Abundant 
129 
Low 
129 
– 
DiAD 
Low 
129,155 
Low 
129,155 
Abundant 
129 
Low 
129 
– 
OAHFA 
Abundant 
129,155 
Abundant 
129,155 
Abundant 
129 
Abundant 
129 
– 
Chl-OAHFA 
Moderate 
129,155 
Moderate 
129,155 
Low 
129 
Moderate 
129 
– 
Others § 
Low 
129,155 
Low 
129,155 
Low 
129 
Low 
129 
– 
 
– Information not available or not found 
† Homologous iron-binding protein called transferrin is reported in dogs146 and rabbits319  
‡ Homologous proteins are reported in dogs (major canine allergen),148-150 rabbits (lipophilin)151 and rats (VEGr1)148  
§ Triacylglycerol, squalene, ceramides, phospholipids and sphingomyelins 
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Figure 1. Graphical representation of the canine ocular surface and lacrimal functional unit. 
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Figure 2. Diagram depicting the complexity of tear film dynamics and ocular surface physiology. Secretion of tear components, 
distribution of tears through blinking, and elimination through nasolacrimal drainage and evaporation must be precisely regulated to 
maintain homeostasis. Drug kinetics following topical eyedrop administration are impacted by key parameters highlighted in yellow, 
each being unique in different species. Adapted with permission from “Tsubota K, Tseng SCG, Nordlund ML. Anatomy and 
Physiology of the Ocular Surface In: Holland EJ,Mannis MJ, eds. Ocular Surface Disease Medical and Surgical Management. New 
York, NY: Springer New York, 2002;3-15”.
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Figure 3. Tear collection in dogs using microcapillary glass tubes (a), Schirmer tear strips (b) or 
absorbent sponges (c). 
 
 
 
Figure 4. Step-by-step protocol to exact tear fluid from Schirmer strips for analytical purposes, 
using a combination of centrifugation and solvent wash. Centrifugation of wetted Schirmer strip 
(containing tear sample and internal standard) retrieves tear fluid in a large tube, while 
subsequent solvent elution washes residual content from the absorbent filter paper.  
201 
 
 
 
Figure 5. Representative clinical pictures of mild conjunctivitis (a), moderate conjunctivitis (b), 
and severe conjunctivitis (c) in dogs following topical administration of histamine at 
concentrations of 1 mg/mL, 10 mg/mL and 375 mg/mL, respectively. Reprinted from “Sebbag L, 
Allbaugh RA, Weaver A, et al. Histamine-Induced Conjunctivitis and Breakdown of Blood-Tear 
Barrier in Dogs: A Model for Ocular Pharmacology and Therapeutics. Front Pharmacol 
2019;10:752”.
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Figure 6. Graphical representation of the blood-tear barrier in the canine eye. The barrier is intact in healthy eyes (left) but is 
disrupted in diseased eyes (right), enhancing the flow of compounds (eg, albumin, xenobiotics) between the tear film and the blood 
compartments. Breakdown of the blood-tear barrier can have important clinical implications such as enhanced systemic absorption 
from greater conjunctival vascular permeability, or reduction in ocular drug bioavailability due to drug-albumin interactions in the tear 
film. 
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APPENDIX A.    MATHEMATICAL MODELING USING NONLINEAR MIXED-
EFFECTS 
 
Parameters estimation was performed using the stochastic approximation expectation 
maximization (SAEM) algorithm for nonlinear mixed effects-models as implemented in the 
Monolix Suite. Competing models were evaluated numerically using Bayesian information 
criteria (BIC) and precision of parameter estimates – defined as relative standard error of the 
estimate (RSE). Standard goodness-of-fit diagnostics, including observed vs. predicted 
fluorescein concentrations, individual fits and weighted residuals time-course were used to 
graphically assist comparison. SAEM convergence and final model parameterization were 
assessed graphically by inspection of search stability, distribution of the individual parameters, 
distribution of the random effects, individual prediction vs. observation, individual fits, and 
distributions of the weighted residuals. The numerical precision of parameter estimates was 
assessed using RSE. The numerical normality of individual parameters was assessed using a 
Shapiro-Wilk test for normality. The normality of the distribution of residuals was assessed using 
a Shapiro-Wilk test and the centering of the distribution of residuals (i.e. 0) was assessed using a 
Van Der Waerden test. P values < 0.05 were considered as statistically significant. 
 
A suitable mathematical model has the following features (see Figures below): (i) the line of 
identity is aligned with the regression line while (ii) the residues (differences between 
observations and predictions) are centered on a mean value of 0, with (iii) a homogeneous 
dispersion around the mean. 
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Figure A1. Comparison of predicted tear fluorescence over time (purple curve) to observed data 
(blue points) for a random sample of dogs (A) and cats (B). Censored data are shown as vertical 
red bars. The ID of each individual is listed above the individual fit, followed by #1 for the right 
eye, and #2 for the left eye. 
 
 
 
Figure A2. Standard Goodness-Of-Fit diagnostics: Individual predictions vs. Observations 
(log10) for the fluorophotometry data in dogs (A) and cats (B). The solid black line represents 
the identity line; the regression line is portrayed in light green color; censored data points 
(<10%) are represented with red dots. 
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Figure A3. Individual weighted residuals (IWRES) vs. fluorescein concentrations in tears of 
dogs (A) and cats (B). Censored data points (<10%) are represented with red dots. The turquoise 
line represents the spline (loess regression). 
 
 
 
Figure A4. Simulations of fluorescein vs. time disposition from 500 Monte Carlo simulations 
using final parameter estimates from the NLME model. Predictions derived from the 5th to the 
95th percentile of the model simulations were able to reproduce the variability in the observed 
data from the original population of dogs/cats.  
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APPENDIX B.    TEAR FILM THICKNESS AND THEORETICAL TEAR VOLUME 
 
Tear thickness was measured with spectral-domain optical coherence tomography (SD-
OCT, Optovue iVue, Fremont, CA) in six beagle dogs, selected based on their homogenous 
subject characteristics (e.g. similar breed, age, skull type, body weight, etc.). Dogs were 
manually restrained with their eyelids held open by an assistant. Tear thickness was measured 
with ImageJ software (National Institutes of Health,  
Bethesda, MD) from images captured with the SD-OCT. The average tear thickness from all 
eyes (d = 0.01512 mm) was used to calculate the theoretical canine tear volume (TV), assuming 
a radius of the canine globe (r) of 10.45 mm.  
 
TV (µL) =
1
2
�
4
3
𝜋𝜋(𝑟𝑟 + 𝑑𝑑)3� −  
1
2
�
4
3
𝜋𝜋𝑟𝑟3� 
 
The theoretical TV value calculated with this method (10.4 µL) was lower than the one 
calculated with fluorophotometry (59 µL for a median beagle body weight of 9 kg), a finding 
likely explained by the unevenness of tear film thickness on the ocular surface. The 
mathematical equation assumes the tear film thickness to be homogenous when in reality tears 
are pooling in conjunctival fornices and tear film is much thicker at the lower and upper tear 
menisci. However, the tear menisci could not be readily imaged in our dogs as we did not use 
sedation or general anesthesia. 
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APPENDIX C.    MATHEMATICAL MODELING USING NONLINEAR MIXED-
EFFECTS 
 
 
Figure C1. Individual predictions versus observations (log10) for the fluorophotometry data in 8 
dogs (16 eyes) receiving 10-100 µL of 0.1% fluorescein solution. The solid black line represents 
the identity line; the regression line is portrayed in light green color. 
 
 
 
Figure C2. IWRES plotted against the tear fluorescein concentrations in 8 dogs (16 eyes) 
receiving 10-100 µL of 0.1% fluorescein solution. The orange line represents the spline (loess 
regression). IWRES, individual weighted residuals. 
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Figure C3. Simulations of fluorescein vs. time disposition from 500 Monte Carlo simulations 
using final parameter estimates from the NLME model. Predictions derived from the 5th to the 
95th percentile of the model simulations were able to reproduce the variability in the observed 
data from the original population dogs. NLME, nonlinear mixed effects.
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APPENDIX D.    HISTAMINE-INDUCED CONJUNCTIVITIS 
 
Figure D1: Diagram of the study design showing the balanced crossover trial (top) and the timing of the procedures prior to and 
following topical histamine/placebo administration (bottom). BP= Blood pressure; CS = Conjunctivitis scoring; IOP = Intraocular 
pressure. 
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Table D1: A semi-quantitative conjunctivitis scoring system. 
 
 
 Score Description 
Palpebral conjunctiva  
Chemosis 
0 (none) No swelling of the palpebral conjunctival tissue.  
1 (mild) Diffuse thin swelling with no eversion of the eyelid(s) or change in eyelid margin contour. 
2 (moderate) Diffuse definite swelling with misalignment of the normal approximation of the lower and upper eyelids.  
3 (severe) Diffuse marked swelling with partial eversion of the eyelid(s). The eyelid margin(s) may have an irregular, ‘undulating’ contour, but can still be closed completely. 
4 (very 
severe) 
Extremely severe swelling with pronounced eversion of both eyelids. Eyelid closure is incomplete with exposed swollen conjunctiva protruding between the 
eyelid margins and masking the corneal surface. 
Hyperemia 
0 (none) Small individual vessels are noted, blanched to pale pink in color. It is normal to observe a few prominent vessels on the palpebral surface of the third eyelid.  
1 (mild) Dilatation of only a few vessels with minimal branching and/or tortuosity. Pink to light red in color. 
2 (moderate) Dilatation of the majority of vessels with pronounced branching and/or tortuosity. Bright red to crimson red in color. The conjunctiva between large vessels may have a flushed pink-to-red appearance. 
3 (severe) Diffuse beefy red appearance to the conjunctiva, difficult to distinguish individual blood vessels.  
Follicles 
0 (none) No manifestations 
1 (mild) 1-9 follicles 
2 (moderate) 10-19 follicles 
3 (severe) 20 or more follicles 
Bulbar conjunctiva  
Chemosis 
0 (none) No swelling of the bulbar conjunctival tissue. 
1 (mild) Focal perilimbal and/or diffuse thin swelling. Underlying episcleral tissue is easily observed through the conjunctiva. 
2 (moderate) Diffuse definite swelling. Underlying episcleral tissue is difficult to observe. 
3 (severe) Diffuse marked swelling, masking the corneoscleral limbal region. 
Hyperemia 
0 (none) Small individual vessels are noted, blanched to pale pink in color.  
1 (mild) Dilatation of only a few vessels with minimal branching and/or tortuosity. Pink-to-reddish in color. 
2 (moderate) Dilatation of the majority of vessels with pronounced branching and/or tortuosity.  Bright red to crimson red in color. The conjunctiva between large vessels may have a flushed pink-to-red appearance. 
3 (severe) Diffuse beefy red appearance to the conjunctiva, difficult to distinguish individual blood vessels.  
Follicles 
0 (none) No manifestations 
1 (mild) 1-9 follicles 
2 (moderate) 10-19 follicles 
3 (severe) 20 or more follicles 
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Table D1 Continued 
 
 
 
 
  
 Score Description 
Conjunctival discharge  
 
0 (none) No discharge, or small amount of clear/mucoid material found in the medial canthus 
1 (mild) Discharge is above normal and present on the surface of the eye or in the medial canthus, but not on the lids or hairs of the eyelids 
2 (moderate) Discharge is abundant, easily observed, and has collected on the lids and around the hairs of the eyelids. 
3 (severe) Discharge has been flowing over the eyelids so as to wet the hairs substantially on the skin around the eyes, past the orbital rim  
Ocular pruritus  
 
0 (none) No ocular itching 
1 (mild) Subtle, rapidly resolving itch 
2 (moderate) Mild persistent itch, resolving within 30 seconds 
3 (severe) Pronounced itch, not resolving within 30 seconds 
4 (extremely 
severe) Incapacitating itch 
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Table D2: Summary table detailing each subsection of the conjunctivitis score for each histamine dose. The score selected in each 
individual was the maximal score documented between 0 and 420 min following histamine administration. Tmax describes the time (in 
min) to reach this maximal score in each dog. Results are described as mean ± standard deviation. 
 Palpebral 
chemosis 
Palpebral 
hyperemia 
Palpebral 
follicles 
Bulbar 
chemosis 
Bulbar 
hyperemia 
Bulbar 
follicles 
Conjunctival 
discharge 
Ocular 
pruritus 
H1  
(0.005 
mg/mL) 
Dogs 
affected 0/6 6/6 0/6 1/6 3/6 0/6 0/6 0/6 
Score  0 1.2 ± 0.4 0 1 1.0 ± 0 0 0 0 
Tmax (min) 0 4.7 ± 1.5 0 7 15 ± 10 0 0 0 
H2  
(0.1 mg/mL) 
Dogs 
affected 0/6 6/6 0/6 2/6 6/6 0/6 0/6 0/6 
Score 0 1.8 ± 0.4 0 1 ± 0 1.5 ± 0.5 0 0 0 
Tmax (min) 0 4.5 ± 3.1 0 6.0 ± 1.4 4.3 ± 2.1 0 0 0 
H3  
(1.0 mg/mL) 
Dogs 
affected 2/6 6/6 0/6 1/6 6/6 0/6 0/6 2/6 
Score 1.0 ± 0 2.0 ± 0 0 1  2.0 ± 0 0 0 1.0 ± 0 
Tmax (min) 5.0 ± 0 4.0 ± 2.1 0 25 6.8 ± 3.5 0 0 1.0 ± 0 
H4  
(10 mg/mL) 
Dogs 
affected 6/6 6/6 0/6 6/6 5/6 0/6 0/6 4/6 
Score 1.0 ± 0 2.0 ± 0 0 1.5 ± 0.5 2.0 ± 0 0 0 1.3 ± 0.5 
Tmax (min) 5.2 ± 2.6 2.0 ± 1.1 0 6.5 ± 2.0 3.2 ± 3.9 0 0 1.0 ± 0 
H5  
(375 
mg/mL) 
Dogs 
affected 6/6 6/6 0/6 6/6 6/6 0/6 1/6 6/6 
Score 2.2 ± 0.8 2.2 ± 0.4 0 2.5 ± 0.5 2.0 ± 0 0 1 2.5 ± 0.8 
Tmax (min) 6.3 ± 4.5 2.0 ± 2.4 0 10.7 ± 5.8 1.0 ± 0 0 15 1.0 ± 0 
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Table D2 Continued 
  Palpebral chemosis 
Palpebral 
hyperemia 
Palpebral 
follicles 
Bulbar 
chemosis 
Bulbar 
hyperemia 
Bulbar 
follicles 
Conjunctival 
discharge 
Ocular 
pruritus 
H6  
(500 
mg/mL) 
Dogs 
affected 6/6 6/6 0/6 6/6 6/6 0/6 0/6 6/6 
Score 2.7 ± 1.0 2.0 ± 0 0 2.3 ± 0.8 2.0 ± 0 0 0 2.8 ± 0.4 
Tmax (min) 9.2 ± 5.4 1.0 ± 0 0 11.2 ± 15.0 1.0 ± 0 0 0 1.0 ± 0 
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APPENDIX E.    PREPARATION OF SCHIRMER STRIPS FOR LC-MS ANALYSIS 
1) Transfer the Schirmer strip (wetted until 20-mm mark) to a 2-mL tubea using single-use 
tweezersb 
2) Spike 5 µL of 10 ng/µL prednisone internal standardc (10 ng/µL prepared in 1:1 
acetonitrile:water) on the dry portion of the strip (i.e. 25 to 35 mm strip end) 
3) Place the Schirmer strip into a 0.2-mL tubed that was pre-punctured at its bottom with a 18-
gauge needle 
4) Secure the 0.2-mL tube into a 2-mL tube using adhesive tape 
5) Centrifugee the combination for 2 minutes at 3884 x g to extract tear fluid out of the Schirmer 
strip into the 2-mL tube 
6) Transfer the centrifuged strip to another 2-mL tube and cut it into multiple <5mm pieces 
7) Add 600 µL of methyl tert-butyl ether (MTBE) into the tube containing the cut Schirmer 
strip   
8) Grind for 1 min with a handheld pestlef 
9) Store in +4℃ fridge for 2 hours 
10) Ultrasonic agitationg for 30 min          
11) Centrifugeh for 1 min at 3824 g 
12) Transfer the fluid to a new 2-mL tube, leaving the cut/shredded Schirmer strip behind 
13) Dry solvent with nitrogeni for 6-8 min at 5-8 psi 
14) Add 75 µL of 25% acetonitrile 
15) Vortexj for 1 min 
16) Centrifugeh for 1 min at 3824 g 
17) Transfer the fluid to the 2-mL tube containing the centrifuged tear sample (step #5)  
18) Vortexj for 30 sec 
19) Centrifugeh for 30 sec at 3824 g 
20) Transfer into LC-MS vialk containing a glass insert and a snap cap 
21) Centrifugel at 1074 x g for 10 min 
22) Transfer the sample from the glass insert to a 2-mL tube 
23) Add 320 µL of iced cold 100% acetonitrile 
24) Centrifugeh for 10 min at 10621 g 
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25) Transfer to a new 2-mL tube, leaving the precipitated proteins behind 
26) Dry solvent with nitrogeni for 10-15 min 
27) Add 100 µL of 25% acetonitrile 
28) Vortexj for 5 seconds 
29) Transfer the sample to a new glass insert 
30) Centrifugel at 998 g for 15 min 
 
*** Steps 23-31 were added after the initial samples were deemed inappropriate for LC-MS 
analysis. The proteins contained in the centrifuged tear sample were clogging the LC columns, so 
further precipitation in acetonitrile was required. *** 
 
a. 2 mL cryogenic vial, Fisherbrand, Fisher Scientific, Pittsburgh, PA, USA  
b. Evident® disposable plastic tweezer, Evident, LLC, Union Hall, VA, USA  
c. Prednisone-d7, Toronto Research Chemicals Inc., North York, Canada  
d. Eppendorf® safe-lock micro test tubes, Eppendorf North America Inc., Westbury, NY, USA 
e. VWR® mini centrifuge, VWR International, Mississauga, Ontario, Canada 
f. Argos® pestle mixer and pestle, Argos Technologies Inc., Elgin, IL, USA 
g. Bransonic® ultrasonic cleaner, Branson Ultrasonics Corporation, Danbury, CT, USA 
h. Eppendorf® Centrifuge 5417C, Eppendorf North America, Inc., Hamburg, Germany 
i. Biotage® nitrogen evaporator, Biotage, LLC, Charlotte, NC, USA 
j. LP vortex mixer, Thermo scientific Inc., Waltham, MA, USA  
k. Xpertek® 2-mL12mm*32mm snap seal vial, P.J. Cobert Associates, Inc., St. Louis, MI, USA 
l. Sorvall ST40 centrifuge, Thermo scientific Inc., Waltham, MA, USA  
 
 
 
 
 
